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Abstract 
 
The haematopoietic growth factor Erythropoietin (EPO) is essential for the survival of 
erythroid progenitors to maturation and differentiation. It has been recognised that the EPO 
signalling pathway is also present in other tissues including the brain and vasculature, and is 
integral to the physiological response to ischaemia. Exogenous EPO was found to improve 
the outcome in animal models of stroke. The primary aim of this thesis was to examine 
whether erythropoietin was protective in a model of acute kidney injury, and to determine 
the mechanism by which EPO exerted this effect. In vitro experiments using HK-2 cells, a 
human tubular epithelial cell line, showed that EPO induced dose-dependent changes in cell 
number, and activated a number of intra-cellular signalling pathways. EPO reduced 
apoptotic cell death induced by nutrient starvation through the expression of anti-apoptotic 
proteins. A short-term model of ischaemia reperfusion was used to determine that EPO 
reduced the development of acute kidney injury, with a reduction in caspase activity and 
apoptosis. Longer models of ischaemia were then performed to confirm these findings, and 
showed that a pre-conditioning regime before the onset of the insult was also effective. In 
order to examine the mechanism of action, EPO was used in a model of cisplatin-induced 
kidney injury. EPO reduced apoptosis and caspase activation through the maintenance of 
mitochondrial membrane potential, inhibition of stress kinase signalling, and expression of 
XIAP and Bcl-XL. EPO also reduced the induction of oxidative stress and PARP-1 activity. 
EPO was then given to animals exposed to cisplatin and confirmed the finding that pre-
treatment with EPO significantly reduced cisplatin nephrotoxicity. Finally, EPO was used in 
a model of myocardial infarction and heart cells in culture to confirm that EPO plays a 
significant physiological role in cellular protection in multiple tissues. 
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1.1   Acute Kidney Injury 
 
Acute kidney injury (AKI), also known as acute renal failure, is a clinical syndrome 
characterised by the rapid deterioration of kidney function over a period of hours or days, 
resulting in the failure of the kidney to excrete nitrogenous waste products, and to maintain 
fluid and electrolyte homeostasis. AKI can result from multiple types of insult, including 
decreased renal perfusion without cellular injury; an ischaemic, toxic, or obstructive insult to 
the renal tubular epithelium; a tubulo-interstitial process with inflammation; or a primary 
reduction in the filtering capacity of the glomerulus [Lameire N, 2005]. 
 
1.1.1  Epidemiology of AKI 
 
The incidence of AKI varies greatly depending on the clinical setting, the demographics of 
the patient population, and, in particular, the definition of renal insufficiency utilised. It is 
difficult to directly compare the many studies of the epidemiology and management of AKI 
due to the wide variation in definition used. This weakness has recently been addressed with 
the universal adoption of the term acute kidney injury (AKI) in preference to acute renal 
failure or acute tubular necrosis (ATN), indicating that kidney damage may occur in the 
absence of complete loss of function, and with the consensus development of the RIFLE 
classification (Risk, Injury and Failure) based on the degree of change in biochemical 
parameters, observed urine output, and two clinical outcome scores (Loss, End-stage), 
through the work of the Acute Kidney Injury Network [Kellum JA, 2002]. 
 
Hou et al demonstrated an overall incidence of AKI of 5 % in a hospitalised population (109 
of 2216 medical and surgical patients) using an increase in serum creatinine of > 44 µmol/L 
(0.5 mg/dl) above the measured baseline as the definition of AKI. AKI was associated with 
decreased renal perfusion (42 %) or major surgery (18 %) in the majority of cases. Predictors 
 21 
of poor prognosis included a reduced urine output (<400 mL/ 24 hr) and relatively modest 
elevation in serum creatinine concentration [Hou SH, 1983]. In the late 1990s an updated 
study, using identical diagnostic criteria, observed that the frequency of hospital acquired 
AKI had increased to 7.2 % [Nash K, 2002]. In comparison, community acquired AKI 
present at the time of admission to hospital was identified in only 0.9 % of patients 
[Kaufman J, 1991]. 
 
In the modern era, the use of more stringent RIFLE classification has reduced the observed 
incidence of AKI. Liangos et al analysed data from the National Hospital Discharge survey, 
a nationally collected sample of approximately 330,000 inpatient admissions from 500 
hospitals in the USA, and demonstrated a 1.9 % incidence of AKI in hospitalized patients. 
Patients with AKI were more likely to have the sepsis syndrome or other non-renal acute 
organ system dysfunction [Liangos O, 2006]. 
 
Sustained impairment of renal perfusion is the most common factor that predisposes patients 
to ischaemia-induced tubular injury, and is implicated in approximately 70 % of community 
acquired AKI, and 40 % of hospital-related events [Mehta RL, 2004]. Hospital acquired 
cases are more often multi-factorial, with an accumulation of multiple acute insults, 
including exposure to nephrotoxic agents such as radio-contrast agents, treatment with non-
steroidal anti-inflammatory drugs (NSAIDs), and infection, often in the presence of cardiac 
dysfunction and reduced tissue perfusion. Mortality rates in AKI range from 7 % among 
patients admitted to a hospital with hypotension-related AKI, to more than 80 % in patients 
with post-surgical AKI [Nash K, 2002; Thakker CV, 2003]. 
 
The severity of kidney injury may determine the natural history and patient outcome in AKI. 
Few epidemiology studies have examined the association between small changes in serum 
creatinine and patient outcome. These population studies can only show an association 
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between AKI and mortality, especially in intensive therapy unit-based studies, because it is 
often part of the spectrum of multi-organ failure. However, published studies have 
demonstrated a consistently elevated relative risk associated with AKI despite adjustment for 
co-morbid conditions and severity of illness. Levy et al. compared 183 patients with 
radiocontrast-associated AKI and 174 age-matched patients who received similar 
radiocontrast loads without developing AKI. The mortality rate was 34% in patients with 
AKI versus 7% in those patients without AKI. Adjusting for differences in co-morbidity, the 
odds of death were increased 5.5-fold in the AKI group [Levy EM, 1996]. This increased 
relative risk of death was confirmed in a more heterogeneous cohort of patients, which may 
be a truer representation of the general population, from a study of 19201 admissions to a 
large urban hospital. This demonstrated that even a 50 % increase in serum creatinine above 
baseline was associated with an increased mortality adjusted odds ratio of 5.8 (4.6-7.5), with 
similar increases (odds ratio 4.1 (3.1-5.5) in mortality observed with only a 28 µmol/L (0.3 
mg/dl) increase in serum creatinine [Chertow GM, 2005].  
 
This increase in mortality associated with even quite small changes in renal function may 
directly be related to the distant effects of renal ischaemia on other organ systems. Models of 
AKI have shown induction of a more general systemic inflammatory response, with 
apoptotic cell death in the myocardium and changes in cardiac function [Grigiryev DN, 
2008], vascular dysfunction [Kelly KJ, 2003], and neutrophil aggregation in the lungs with 
associated inflammation [Awad AS, 2009]. The observed increase in mortality may, 
however, be indirectly related to AKI, however, as the risk factors for AKI are also risk 
factors for cardiovascular disease and mortality, and AKI occurs much more commonly in 
those with higher co-morbidity, including pre-existing renal impairment. Patients with 
relatively early stage CKD (eGFR 30-45 mL/min) have a 5-fold increased odds ratio of AKI 
when compared to matched controls [Hsu Y, 2008]. 
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1.2  The Pathophysiology of Ischaemic AKI 
 
In health, the kidneys receive 25% of cardiac output, but renal blood flow is not uniformly 
distributed within the renal parenchyma, so that tissue perfusion and oxygen consumption 
are highly heterogeneous - resulting in areas susceptible to reduced oxygen tension 
[O’Connor PM, 2006]. Tissue oxygen tension varies between 60 -100 mm Hg (6.6 – 13.3 
kPa), obtained close to the cortical surface in micro-puncture studies, and 10-20 mm Hg 
(1.3-2.9 kPa) in the S3 segment of the proximal tubule [Welsh WJ, 2001]. The anatomical 
arrangement of pre-glomerular arterial and corresponding post-capillary venous vessels 
suggests a structural basis for this low medullary oxygen tension. This is confirmed by 
studies demonstrating the large anaerobic capacity of the outer-medullary region, chronic 
up-regulation of hypoxia-induced gene expression, and an increased susceptibility to 
hypoxic insult [Brezis M, 1989]. 
 
The kidney responds to alterations in renal perfusion pressure by a feedback loop to auto-
regulate pre-glomerular blood flow and hence maintain glomerular filtration rate (GFR) 
within fairly narrow limits, even with mean arterial pressure as low as 80 mm Hg [Dworkin 
LD, 2003]. When the blood pressure falls, gradual dilatation of the pre-glomerular arterioles 
occurs, mediated by the angiotensin stimulated generation of vasodilating products of 
arachidonic acid (prostaglandin I2) and nitric oxide [Baylis C, 1978]. As perfusion pressure 
falls further, concomitant vasoconstriction of the postglomerular arterioles, mainly under the 
influence of angiotensin II, maintains a constant glomerular capillary hydrostatic pressure.  
The postglomerular capillary bed, which perfuses the tubules, has diminished blood flow and 
pressure, but the tubules remain intact. Drugs which act on the prostaglandin system, such as 
non-steroidal anti-inflammatory drugs, or inhibit the angiotensin pathway, can interfere with 
the normal autoregulatory responses and increase the risk of impaired perfusion pressure and 
subsequent AKI [Abuelo JG, 2007]. 
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Figure 1.1 Perfusion Pressure and mechanisms to maintain GFR 
Several pathways interact to maintain the relationship between systemic blood pressure and 
renal perfusion. Vasoconstriction of the efferent arteriole increases transglomerular 
resistance and hence GFR, but contributes to tubular hypo-perfusion.  
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Prolonged ischaemic insults, alone or in synergistic combination with nephrotoxins, 
overcome the autoregulatory systems in the kidney, and initiate epithelial and vascular cell 
injury, resulting in an extremely rapid decrease in glomerular filtration rate (GFR), 
appropriately referred to as the initiation phase of AKI [Sutton TA, 2002].  
 
The initiation phase is immediately followed by the extension phase [Sutton TA, 2002], in 
which multiple interrelated events dependent on altered vascular function lead to worsening 
of epithelial and endothelial cell injury and subsequent cell death, primarily in the cortico-
medullary region of the kidney. Established ischaemic AKI is associated with a reduction in 
renal perfusion by 30-50%, and there is evidence of selective reduction in blood supply to 
the outer medulla [Yamamoto T, 2002].  
 
The maintenance phase represents a phase of stabilization of injury, and subsequent 
correcting events leading to cellular repair, division, and re-differentiation. This sets the 
stage for improved epithelial and endothelial cell function and recovery of GFR during the 
recovery phase. Correction of the initiating insult with appropriate therapy during the early 
initiation and extension phases of AKI may limit the degree of cellular injury and hence the 
duration of the maintenance phase, allowing more rapid onset of the recovery phase and 
hence preservation of kidney function. 
 
 
1.2.1  Vascular dysfunction  
 
Under physiological conditions, the oxygen tension of the kidney decreases from the outer 
cortex to the inner medulla [Brezis M, 1995]. After an ischaemic insult, total renal blood 
flow returns to normal, but marked, regional alterations occur, playing an important role in 
the extension phase of renal ischaemic injury [Yamamoto T, 2002]. Blood flow to the outer 
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medullary or cortico-medullary junction regions remains approximately 10 % of normal 
during early reperfusion, leading to congestion due to interstitial oedema, red blood cell 
trapping, leukocyte adherence and extravasation. 
 
Several lines of evidence indicate that endothelial dysfunction is a feature of the initiation 
phase of ischaemic renal injury. Firstly, ischaemia results in profound loss of the 
vasorelaxing effect of acetylcholine [Lieberthal W, 1989]. Vasorelaxation in response to 
stimuli generating endothelium-derived relaxing factor was also inhibited [Conger JD, 
1995]. In addition, nitric oxide production in response to bradykinin was found to be 
suppressed in ischaemic kidneys [Noiri E, 1996]. Loss of normal endothelial function and 
altered NO homeostasis alters vascular homeostasis, leading to an increased thrombotic 
potential and reduced response to local and systemically derived vaso-active substances. 
 
Intra-vital video-microscopy has proved useful for the study of blood flow in peri-tubular 
capillaries [Yamamoto T, 2002]. Reperfusion initiates an immediate partial recovery of 
blood flow after release of renal artery occlusion, followed by a profound and sustained flow 
reduction. There is evidence of retrograde flow in some vessels, and temporary loss of vessel 
patency. The pattern of glomerular microcirculation is similar to that of the peri-tubular 
capillaries; initial brief recovery of flow is followed by ‘no flow’. Restoration of flow in 
these capillary beds, however, is different. Glomerular circulation is re-established initially, 
while return of blood flow to peri-tubular capillaries is significantly delayed. So, endothelial 
injury and dysfunction have major roles in the ‘no-flow–reflow’ phenomenon in the early 
stages of ischaemic injury. This injury manifests structurally as loss of endothelial integrity, 
and functionally as defective endothelium-dependent vasorelaxation.  
 
Inflammatory activation of the endothelial cell with upregulation of adhesion molecules, as 
well as injury to the endothelial cells leading to cell swelling and loss of patency of the 
 27 
endothelial barrier, potentiates the interaction with leukocytes and platelets causing 
mechanical obstruction to the small vessels [Bonventre J, 2003]. Leukocytes are activated by 
a number of local factors, including cytokines, chemokines, eicosanoids and reactive oxygen 
species, which result in further upregulation of adhesion molecules, leukocyte recruitment 
and inflammation [Suwa T, 2001]. Leukocyte trafficking and the differential role of 
lymphocytes and mono-nuclear cells in the generation of reperfusion injury remains a 
controversial subject [De Greef KE, 1998; Park P, 2002]. Recent studies have suggested an 
important role of T-lymphocytes in the development of reperfusion injury, and in particular, 
the systemic inflammatory response [Ascon DB, 2006; Grigoryev DN, 2008].  
 
The reduced perfusion and hypoxic conditions lead to deprivation of nutrients and loss of 
ATP in the endothelium. Injection of cultured endothelial cells that constitutively express 
high levels of endothelial nitric oxide synthase (eNOS) into rats subjected to renal ischaemia 
resulted in implantation of these cells into the vasculature and reduction in ischaemic kidney 
injury, highlighting the important role of endothelial cells and the vasculature in the 
protection from renal ischaemic injury [Brodsky SV, 2002]. Permanent damage to the 
peritubular capillaries occurs in rats subjected to prolonged renal ischaemia, and this may be 
associated with the development of tubulo-interstitial fibrosis, poor urine concentrating 
ability, and impaired recovery in the post-ischaemic kidney [Basile DP, 2001]. 
 
 
1.2.2  Tubular changes 
 
In the commonly studied vascular clamp small animal models of renal artery occlusion, the 
S3 segment of the proximal tubule that traverses the outer-medullary region is extremely 
susceptible to ischaemic injury when compared to S1 and S2 segments or distal tubule 
[Ventatachalam M, 1978]. The sensitivity of the outer medulla derives from a combination 
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of its microvascular architecture, and a relatively low glycolytic capacity to generate ATP in 
the setting of rapid ATP depletion resulting from impaired oxidative phosphorylation. The 
medullary thick ascending limb of the loop of Henle, although situated in the same region, 
does not undergo the same extent of cell death because there is a greater glycolytic capacity 
to generate ATP under ischaemic conditions [Bonventre JV, 2002].  
 
During the maintenance phase of AKI, large areas of severe local ischaemia may no longer 
be present, but cell injury continues due to surrounding acute inflammation and the effects of 
prior insults on intrinsic cellular responses such as apoptosis. The tubular cell is also a major 
contributor to the local inflammatory response. Tubular epithelial cells produce a number of 
pro-inflammatory cytokines, including TNF    and interleukin-6, chemotactic cytokines such 
as RANTES and monocyte chemoattractant protein (MCP-1) in response to an ischaemic 
insult [Rice J, 2002]. Tubular epithelial cells also contribute to leukocyte migration through 
the local production of the CX3-family chemokine fractalkine (CX3CL1) [Chakravorty SJ, 
2002].  
 
The structural response to the tubular epithelium to ischaemic injury is multifaceted, and 
includes loss of cell polarity and brush border, cell death, de-differentiation of surviving 
cells, proliferation and restitution of a normal epithelium.  Cellular ATP depletion leads to a 
rapid disruption of the apical actin cytoskeleton and redistribution from the apical domain 
and microvilli into the cytoplasm [Molitoris B, 1992]. The ensuing alterations in microvillar 
structure leads to formation of membrane-bound, free floating extracellular vesicles, or 
“blebs,” that are either internalised or lost into the tubular lumen. Brush border membrane 
components that are released into the lumen contribute to the formation of casts and tubular 
obstruction. These casts and vesicles that contain actin and actin depolymerising factor have 
been detected in the urine in animal and human acute renal failure. Disruption of the actin 
cytoskeleton also results in the loss of tight junctions and adherens junctions. Reduced 
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expression, re-distribution and abnormal aggregation of a number of key proteins that 
constitute these junctions have been documented after ischaemic injury, and this loss of tight 
junction may magnify the transtubular backleak of glomerular filtrate that is induced by 
tubular obstruction. 
 
Ischaemia results in the early disruption of two basolateral polarised proteins, Na, K ATPase 
and adhesion molecule family of 
 
1-integrins. The Na, K, ATPase is normally tethered to 
the spectrin-based basolateral cytoskeleton at the basolateral domain via the adapter protein 
ankyrin. The mislocated Na, K, ATPase remains bound to ankyrin but is devoid of spectrin, 
possibly due to either phosphorylation of spectrin or cleavage of spectrin by proteases such 
as calpain [Woroniecki, 2003]. The   1 integrins are normally polarised to the basal domain, 
where they mediate cell-substrate adhesions. Ischaemic injury leads to a redistribution of 
integrins to the apical membrane, with consequent detachment of viable cells from the 
basement membrane. There is good evidence for abnormal adhesion between these 
exfoliated cells within the tubular lumen, mediated by an interaction between apical integrin 
and the Arg-Gly-Asp (RGD) motif of integrin receptors. Administration of synthetic RGD 
compounds attenuates tubular obstruction and renal impairment in an animal model of renal 
ischaemia [Molina A, 2005].  
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Figure 1.2 Alterations in tubular cell structure after ischaemic acute renal failure. 
The initiation phase leads to sub-lethal injury, with loss of brush border and disruption of 
cell polarity and the cytoskeleton. If the injury is alleviated at this stage, then complete 
recovery ensues. If not, cell death, desquamation, luminal obstruction and an inflammatory 
response occurs.  
 
 
 
Normal 
 
Loss brush border 
and polarity 
Necrosis and apoptosis 
Slough viable and apoptotic cells 
and luminal obstruction 
De-differentiation and spreading 
Proliferation
 
Brush-border 
Integrins 
 31 
1.3  Cellular Mechanisms of Tubular cellular injury following ischaemia-
reperfusion 
 
1.3.1   ATP and GTP depletion 
 
In the absence of normal mitochondrial oxidative phosphorylation, prolonged ischaemia 
leads to a rapid decrease in the level of available adenine nucleotide pool (ATP, ADP and 
AMP). Dephosphorylation of ATP and ADP lead to further catabolism of AMP to 
hypoxanthine and xanthine, which contribute to the generation of reactive oxygen species.  
Functional recovery in rabbits after ischaemic injury was correlated to the degree of ATP 
depletion and xanthine accumulation [Buhl MR, 1979]. Zager et al demonstrated regional 
differences in ATP depletion after 15 minutes of ischaemia, with the outer medulla most 
affected, but after 45 minutes these regional differences were no longer significant due to 
global reduction [Zager RA, 1990]. In vitro studies of chemical induced ATP depletion, 
using inhibitors of mitochondrial oxidative phosphorylation pathway such as antimycin A, 
have demonstrated an association between ATP depletion and activation of pro-
inflammatory and cell death pathways, including Fas and Fas ligand up-regulation and 
caspase-8 activation [Feldenberg, 1999]. Partial ATP depletion leads to apoptotic cell death 
whereas more severe or total ATP depletion causes necrosis [Leiberthal W, 1998]. 
 
GTP depletion also occurs in association with ATP depletion in both in vitro and in vivo 
models of ischaemic injury [Daugher P, 2000]. Preferential depletion of GTP with 
maintained ATP induces apoptosis in cultured renal tubular cells. Administration of 
guanosine before the inducement of ischaemic renal injury maintains GTP regenerative 
capacity, leading to a significant reduction in the number of apoptotic tubular cells, and 
hence improved renal function [Kelly KJ, 2001]. GTP depletion may induce apoptosis via 
the activation of p53, and there is in vivo evidence that inhibition of p53 pathway also 
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protects the kidney from ischaemia reperfusion injury [Kelly KJ, 2003; reviewed by Dagher 
PC, 2004]. 
 
1.3.2 Increased cytosolic Ca2+ concentrations 
 
Renal proximal tubular cells undergo a significant increase in free cytosolic ionised calcium 
concentration during the initial five minutes of hypoxia. The increase in Ca2+ precedes 
hypoxic membrane damage, and is reversible if re-oxygenation occurred before the cell 
underwent lethal injury [Wetzels JF, 1993]. ATP depletion leads to impaired calcium 
sequestration in the endoplasmic reticulum, as well as diminished extrusion into the 
extracellular space [Edelstein CL, 1997]. Increased cytosolic Ca2+ leads to uptake of Ca2+ 
into the mitochondria via the Ca2+ uniporter. In the presence of ATP depletion, 
mitochondrial Ca2+ overload leads to opening of mitochondrial permeability transition pore 
(mPTP) and permeabilization of the inner mitochondrial membrane, and the release of pro-
apoptotic mitochondrial proteins, including cytochrome c. 
 
Prolonged increases in cytosolic Ca2+ activate the Ca2+-dependent cysteine protease calpain. 
Calpain activity is tightly regulated by its ubiquitously expressed endogenous inhibitor 
calpastatin. Calpains result in the proteolysis of a broad spectrum of cellular proteins and a 
distinguishing feature of their activity is their ability to confer limited cleavage of protein 
substrates into stable fragments rather than complete proteolytic digestion. Thus, calpain-
mediated proteolysis represents a major pathway of post-translational modification that 
influences various aspects of cell physiology, including apoptosis, cell migration and cell 
proliferation [Sato M, 2001]. 
 
Renal proximal tubule epithelial cells constitutively express calpains, which are activated in 
response to toxic and hypoxic injuries. Inhibition of calpain activity using various 
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pharmacological inhibitors ameliorated necrotic cell death in proximal tubule cells subjected 
to hypoxic injury [Harriman JF, 2000], ATP depletion [Liu X, 2001] and reduced tubular 
dysfunction in rats subjected to ischaemia reperfusion injury [Chatterjee PK, 2001]. 
 
 
1.3.3 Poly (ADP-ribose) polymerase-1 (PARP-1) 
 
PARP-1 plays a primary role in the process of poly (ADP)-ribosylation, in which 
posttranslational modification of nuclear proteins is activated in response to DNA damage. 
Activation of PARP-1 by DNA strand breaks results in the synthesis of poly (ADP-ribose) at 
the expense of NAD+ that is cleaved into ADP-ribose and nicotinamide. PARP-1 catalyzes 
the binding of the first ADP-ribose on acceptor proteins, primarily at glutamic residues, and 
subsequently catalyzes the elongation and branching reactions with additional ADP-ribose 
units. Decreased NAD+ levels cause an unbalanced NAD/NADH ratio, which, in turn, 
affects the activation of enzymes involved in glycolysis, the pentose shunt, and the Krebs 
cycle. Decreased NAD+ levels also drastically alter the redox state of cells. Because the cell 
attempts to restore NAD+ pools by recycling nicotinamide with 2 ATP molecules, excessive 
activation of PARP-1 depletes pools of intracellular NAD+ and ATP and, consequently, 
interferes with most, if not all, energy-dependent cellular processes [De Murcia J, 1997]. 
 
The switch between necrosis and apoptotic cell death may also be modulated by the degree 
of activation of PARP-1 since this decision seems to be determined by the cellular ATP 
levels. PARP-1 overactivation and poly(ADP-ribose) synthesis result in the heavy use of 
NAD+ and a reduced activity of NAD+-dependent cellular processes, including ATP 
synthesis. Moreover, because NAD+ re-synthesis is done at the expense of ATP, the 
resulting ATP depletion is believed to induce cell death by necrosis. In apoptosis, PARP-1 is 
cleaved into two fragments of 89 kDa and 24 kDa (p89 and p24) by caspases-3 and -7 at the 
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DEVD site located in the NLS of PARP-1. The p89 fragment contains the catalytic site and 
the auto-modification domain, and p24 contains the DBD and zinc finger domains. The 
motive for PARP-1 cleavage is not yet defined, but it seems to be a key event in the 
execution phase of apoptosis, possibly by allowing preservation of the cellular ATP required 
to accomplish apoptosis, because this process is energy dependent, and therefore allows 
completion of apoptosis rather than necrosis.  
 
In the kidney, PARP-1 activity contributes to ischaemia reperfusion injury in transplanted 
kidneys [O’Valle F, 2005], and inhibition of PARP-1 has been shown to reduce tubular cell 
death in vitro [Chatterjee PK, 1999], and in animal models of haemorrhagic shock 
[McDonald MC, 1999] and acute renal ischaemia [Chatterjee PK, 2000]. 
 
 
1.3.4 Oxidant Injury 
 
There is now substantial evidence for the role of reactive oxygen species in the pathogenesis 
of AKI. During reperfusion, the conversion of accumulated hypoxanthine to xanthine, 
catalysed by xanthine oxidase, generates hydrogen peroxide and superoxide. In the presence 
of iron, hydrogen peroxide forms the highly reactive hydroxyl radical. Concomittantly, 
ischaemia induces nitric oxide synthase (iNOS) in tubular cells, and the NO that is generated 
interacts with superoxide to form peroxynitrite, which contributes to cellular injury via 
oxygen toxicity and nitrosative stress [Devarajan P, 2005]. Collectively, reactive oxygen 
species cause renal tubular epithelial cell death by oxidation of proteins, peroxidation of 
lipids, damage to DNA and induction of apoptosis via redox activation of the transcription 
factor NF-  B and the mitogen-activated stress kinase family [Finkel T, 1998].  
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In vitro studies have confirmed that reactive oxygen species are important mediators of 
necrotic cell death following ischaemic and toxic injury to tubular epithelial cells [Beckman 
JS, 1996]. Mitochondrial injury leads to uncoupling of oxidative phosphorylation which has 
two sequelae: impaired ATP production and increased superoxide generation. Lipid 
peroxidation of the membrane phospholipid bilayers and subcellular organelles is a major 
contributor to necrotic cell death.  Several scavengers of reactive oxygen species, including 
superoxide dismutase, catalase, N-acetylcysteine) have been effective in animal models of 
ischaemic injury [Chatterjee PK, 2004], but human studies have failed to show similar 
benefit [Macedo E, 2006].  
 
 
1.4 Alterations in Cell Viability and Mechanisms of cell death 
 
Both experimental and human studies indicate that tubular epithelial cells can suffer one of 
three distinct fates after ischaemia. The majority of cells remain viable, suggesting that they 
escape injury, or are only sub-lethally injured and can undergo recovery. The remaining 
tubular epithelial cells display patchy, non-continuous areas of cell death that results from at 
least two pathological mechanisms – necrosis and apoptosis. These two forms of cell death 
co-exist, and the mode of individual cell death depends primarily on the severity of the insult 
and the resistance of the cell type.  
 
Necrotic cell death is characterised by progressive loss of cytoplasmic membrane integrity, 
rapid influx of sodium and calcium ions and water, resulting in nuclear degeneration and 
cytoplasmic swelling. The latter feature leads to cellular fragmentation and release of 
lysosomal and granular contents into the extracellular space, with subsequent development 
of acute inflammation. 
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A distinction between these changes of necrotic cell death and the morphology of cells 
undergoing controlled non-inflammatory cell death was observed more than 50 years ago. 
The term apoptosis was applied to the characteristic morphological changes associated with 
programmed cell death [Kerr JF, 1972]. It is defined by cytoplasmic and nuclear shrinkage, 
chromatin margination and fragmentation, and division of the cell into multiple spherical 
bodies that retain membrane integrity. These apoptotic bodies are rapidly phagocytosed and 
degraded by macrophages and by surrounding epithelial cells [Lieberthal W, 1996]. 
Phagocytosis provides an efficient mechanism for the removal of dead cells without 
incurring any of the surrounding tissue inflammation and injury associated with necrotic cell 
death [Kerr JF, 1972] although in some circumstances apoptotic cells may undergo a process 
of secondary necrosis. 
 
Recently, a third process resulting in cell death has also been described, and is termed 
autophagy [Tsujimoto Y, 2005]. Autophagy plays a role in normal tissue homeostasis and 
growth, but is also activated in certain circumstances, such as nutrient starvation, hypoxia 
and high temperatures. The cells undergo partial autodigestion that prolongs survival for a 
short time, but if these adverse conditions persist, the cell dies [Ohsumi Y, 2001]. 
Autophagosomes are double-membrane cyctoplasmic vesicles that are designed to engulf 
various cellular constituents, including cytoplasmic organelles. These fuse with lysosomes to 
become autolysosomes, where sequestered cellular components are digested. Autophagy is 
now recognized to play an important role in ischaemia reperfusion injury in the kidney and 
heart [Suzuki C, 2008; Matsui Y, 2008] 
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1.4.1 Apoptotic cell death in Acute Kidney Injury 
 
There is now increasing evidence indicating that apoptosis is a major mechanism of early 
tubular cell death in ischaemic AKI. Several animal models have demonstrated the presence 
of apoptotic tubular cells [Schumer M, 1992], and this was subsequently confirmed in 
human studies in kidney transplantation [Oberbauer R, 1999; Castaneda MP, 2003]. 
Nevertheless, the mechanistic role of apoptosis in the degree of renal dysfunction observed 
is not fully understood.  
 
First, most estimates place the peak incidence of apoptosis at only approximately 3-5% of 
tubular cells after ischaemic injury, which arguably is insufficient to explain the degree of 
renal insufficiency. It is likely, however, that the degree of apoptotic cell death is 
underestimated, because it is a rapidly occurring event that is heterogenous in distribution, 
and both tissue preparation and techniques to demonstrate apoptosis have limited specificity. 
The terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick end labeling 
(TUNEL) assay, which adds labelled dUTP to multiple free DNA ends generated by 
activated endonucleases during cell death, has been widely used to determine the extent and 
localisation of apoptotic cell death, but can be criticized for its lack of sensitivity and 
specificity in discriminating among apoptotic and necrotic mechanisms of cell death [Kelly 
KJ, 2003]. 
 
Secondly, apoptosis is commonly encountered in the distal tubule, whereas loss of viable 
cells occurs in the proximal tubule. Distal tubular cells are more resistant to cell death, with 
some evidence that this resistance may be determined by persistent Akt phosphorylation and 
activation, possibly as a protective mechanism against the osmotic and hypoxic 
environment, and apoptosis may appear to be the dominant cause of cell death as necrosis is 
therefore prevented [Kroning R, 1999]. 
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Thirdly, apoptosis is crucial to the physiological repair processes that remove damaged cells 
after injury, and therefore may be beneficial to the organ and the organism. This can be 
reconciled by the observation that apoptosis occurs in two-waves in animal models. The first 
wave is detectable by six hours, peaks at 24-36 hrs and rapidly diminishes. The second wave 
becomes apparent after 4 days, removing hyperplastic and unwanted cells, and is likely to 
play a role in the remodelling of the regenerating tubule.  
 
 
1.4.2 The Caspase cascade 
 
Apoptosis is characterised by the activation of a family of cysteine proteases called caspases, 
which participate in enzymatic cascades that terminate in cellular disassembly. This action 
can be initiated through mitochondrial-dependent and -independent pathways. 
 
The genetic analyses of apoptosis in the nematode flatworm Caenorhabditis elegans led to the 
elucidation of genes that control this cellular suicide mechanism [Driscoll M, 1992]. The 
central components of apoptosis machinery in C. elegans are a troika of ced genes: ced-3, 
ced-4 and ced-9, where ced-3 protein is a cysteine protease responsible for the execution of 
the apoptotic program, ced-4 protein is a pro-apoptotic adaptor molecule, and ced-9 protein 
is an inhibitor of apoptosis [Hengartner 1992; Miura M, 1993]. Homologues of these genes 
have been clearly shown to regulate apoptosis in higher eukaryotes, albeit utilizing much 
more evolved and complex mechanisms. The mammalian homologues of the inhibitor of 
apoptosis ced-9, the B cell lymphoma-2 (Bcl-2) family members, are critical regulators of 
the mitochondrial step in apoptosis [Gross A, 1999]. 
 
All caspases are synthesized as inactive zymogens containing an N-terminal prodomain 
followed by a large 20 kDa subunit, p20, and a small 10 kDa subunit, p10. Depending on the 
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structure of the pro-domain and their function, caspases are typically divided into three 
major groups. The caspases with large prodomains are referred to as inflammatory caspases 
(group 1: caspase-1, -4,-5, -11, -12, -13, -14), initiator caspases (Group 2: caspases-2, -8, -9, 
-10), while caspases with a short prodomain of 20-30 amino acids are named effector 
caspases (Group 3: caspase-3, -6, -7). Cleavage of a procaspase at the specific Asp-X bonds 
results in the formation of the mature caspase, which comprises the heterotetramer p202-
p102 and causes release of the prodomain. Each heterodimer is formed by hydrophobic 
interactions resulting in the formation of parallel 
 
-sheets, composed of 6 anti-parallel 
 
-
strands [Stennicke HR, 1999].  
 
All caspases share a number of distinct features. These include the catalytic triad residues, 
consisting of the active site Cys285, which is a part of the conserved QACXG pentapeptide 
sequence, His237 and the backbone carbonyl of residue -177 [Stennicke HR, 1999]. The 
striking feature of the caspases is their specificity for substrate cleavage after an asparate 
residue, which is unique among mammalian proteases, except for the serine protease 
granzyme B. 
 
The initiator caspases form active catalytic dimers via association of their long prodomains 
with adapter molecules with selectivity for individual caspases. In contrast, executioner 
caspases become catalytically active only after cleavage by the active initiator caspases. 
Once activated, executioner caspases can cleave initiator caspases, which may not lead to 
their activation, but may serve to stabilize active initiator caspase dimers, or render them 
subject to regulation via cellular inhibitors of apoptosis. This hieracrchy of caspase 
activation generates a cascade culminating in executioner mediated cleavage of multiple 
substrates including PARP-1, cytoskeleton proteins such as fodrin, actin and focal adhesion 
kinase, an array of phenotypic characteristics including cell blebbing, condensation and 
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fragmentation of chromatin, and re-distribution of lipids in the outer plasma membrane, 
ending in controlled cell death [Lavrik IN, 2005]. 
 
 
1.4.3 Caspase Activation in AKI 
 
Several studies have documented activation of caspase molecules after ischaemia 
reperfusion in the kidney and post-hypoxic injury in renal proximal tubule epithelium. The 
expression of caspases-1, -2, -3, -6, -7, -8, and -9 has been characterized in rat kidneys at the 
mRNA level [Kaushal GP, 1998; Singh AB, 2002]. The expression and activity of caspases-
1, -2, and -6 are altered in kidneys post-I/R. LLC-PK1 and Madin-Darby canine kidney 
(MDCK) cells subjected to chemical hypoxia underwent apoptosis with a marked increase in 
activation of caspases-3 and -8. The activation of caspase-3 is accompanied by Bax 
translocation from cytosol to mitochondria and cytochrome c release from mitochondria.  
Inhibition of caspases using a pancaspase inhibitor is shown to protect kidneys from 
ischaemic injury. The pancaspase inhibitor Z-Val-Ala-Asp(OMe)-CH2F protected against 
ischaemic AKI in mice by inhibition of apoptosis and subsequent inflammation [Daemen M, 
2001]. Inhibitors of specific caspases have also been demonstrated to alter the natural history 
of renal injury in a short-term model of I/R in the rat, although there is controversy over 
exact specificities [Chatterjee PK, 2005]. The results from these studies clearly demonstrate 
a role for caspases in I/R. However, the role of individual caspases contributing to the injury 
and inflammation post-renal injury cannot be discriminated from these studies because non-
specific caspase inhibitors were utilized. The availability of more specific inhibitors of 
individual caspases will provide better clues as to the functions of individual caspases in 
renal I/R. RNA interference techniques have also been used to inhibit the expression and 
activity of specific caspases during ischaemia reperfusion injury in a murine model. RNA 
interference inhibition of caspase-3 and caspase-8 has been shown to reduce both 
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histological and biochemical markers of ischaemic injury, and significantly improved rates 
of animal survival [Zhang X, 2006]. 
Caspase-1 does not appear to play a direct role in the induction of apoptosis, but rather, is 
integral to the development of the acute inflammatory response and removal of pathogens 
[Scott AM, 2007]. The role of caspase-1 in ischaemia reperfusion injury has not been 
determined, as induction of injury in mice deficient for caspase-1 has furnished contrasting 
results. Results from one study indicated that caspase-deficient mice underwent less severe 
injury than their wild-type counterparts and that this was due to impaired interleukin-18 
activation [Melnikov V, 2001], whereas a second group found no changes in the severity of 
the injury between control groups and caspase-1-deficient mice [Daemen MA, 2001].   
 
1.4.4 Mechanism of Caspase activation: Extrinsic Pathway 
 
Apoptosis can be initiated through several separate but interacting pathways. Extracellular 
signals are transmitted to the cell via the TNF superfamily of death receptors, the members 
of which are characterised by a conserved extracellular cysteine-rich motif, and include Fas, 
TNFR1, TNF-related apoptosis-inducing ligand (TRAIL). These receptors, generally 
composed of 3 identical polypeptide chains, have binding and signalling features in common 
as well as unique, individual characteristics. These death receptors have an intracellular 
death domain (DD) that activates cytosolic cysteine proteases by proteolysis, recruiting 
adapter proteins that also have death domains, including FADD and TRADD. The death 
effector domain of FADD binds to the prodomain of caspase-8, forming a complex termed 
the death-inducing signalling complex (DISC). The auto-catalytic activation of caspase-8 
then activates a series of downstream caspases that result in cleavage of structural and 
regulatory intracellular proteins [Jin Z, 2005]. C-FLIP is a naturally occurring dominant 
negative antagonist of death receptor mediated caspase-8 activation, and contains two DED 
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and a defective caspase-like domain. C-FLIP can associate with DEDs of FADD and 
caspase-8, interfering with the recruitment of caspase-8. 
 
The extrinsic pathway is activated by ischaemia reperfusion injury in the kidney. Mice 
treated with siRNA knockdown of caspase 8 expression were protected from ischaemic 
injury and had improved survival when compared to untreated animals [Zhang X, 2006]. 
 
1.4.5  Mechanism of Caspase activation: Intrinsic (mitochondrial) pathway 
 
The apoptotic signal transduction pathways that are undertaken in response to an intrinsic 
signal such as DNA damage, oxidative stress and growth factor deprivation involve 
mitochondrial release of pro-apoptotic molecules. A critical regulatory role for the 
maintenance of mitochondrial membrane permeability has been suggested for proteins of the 
Bcl-2 family, which includes anti-apoptotic proteins Bcl-2 and Bcl-XL [Walensky LD, 
2006]. 
 
Permeabilization of the outer mitochondrial membrane is followed by release of pro-
apoptotic proteins, usually present in the intermembrane space of these organelles, into the 
cytosol. Such effectors include cytochrome c, smac/DIABLO, HtrA2/ OMI, the flavoprotein 
apoptosis-inducing factor (AIF) and endonuclease G. In the cytosol, cytochrome c interacts 
with the adapter protein Apaf-1 and induces a conformational change that allows stable 
binding of dATP/ ATP, an event that drives the formation of a heptamer Apaf-1/ cytochrome 
c complex, the apoptosome [Acehan D, 2002], which binds procaspase-9 via their 
homologous caspase recruitment domains (CARDs). Caspase-9 is activated by allosteric 
change and dimerisation, rather than cleavage [Rodriguez J, 1999], which in turn activates 
the downstream effector caspase-3,-6 and -7 by proteolytic cleavage of inactive precursors. 
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The vital role of mitochondrial release of cytochrome c in stress induced apoptosis has been 
questioned. Initial reports on mice lacking either Apaf-1 [Cecconi 1998], or caspase-9 
[Hakem 1998] supported the importance of cytochrome c in the intrinsic pathway: mice died 
near birth with enlarged brains, as do mice lacking caspase-3. Recent findings, however, rule 
out the essential role for Apaf-1 and caspase-9 in stress induced apoptosis in certain cell 
lines [Marsden VS, 2002]. Unlike Bcl-2 overexpression or loss of Bim, the absence of Apaf-
1 or caspase-9 did not interfere with the development of mature lymphocytes, where 
programmed cell death is essential. Thus, in many cells, the apoptosome is dispensible for 
the initiation of stress induced apoptosis. Since the level of caspase activity is lower in Apaf-
1 knockouts, the apoptosome must be an amplifier of the caspase cascade rather than a 
critical initiator of it [Marsden VS, 2002]. This amplification may be more important in 
some cell types than others, and in certain types of cellular stress leading to activation of the 
programmed cell death machinery. 
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Figure 1.3 Apoptotic signalling cascade via Activation of Caspase pathways.  
Apoptotic cell death is initiated by activation of a caspase cascade via two distinct but 
communicating pathways: receptor mediated activation of caspase-8 and mitochondrial 
depolarisation causing release of cytochrome c which activates caspase-9. These 
intermediate caspases causes activation of the effector caspases-3, -6 and -7 which causes 
nuclear vacuolation and shrinking, disruption to cellular membrane, and ultimately cell 
death. 
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Mitochondria participate in inducing apoptosis after I/R through multiple changes, including 
generation of oxygen free radicals, calcium translocations, altered permeability transitions, 
and release of cytochrome c, apoptogenic factors, and Bcl-2 family members. Renal I/R in 
rats can induce mitochondrial swelling, rupture of inner and outer membranes, and release of 
Bcl-2 post-injury. A recent study investigated the proximate events that lead to 
mitochondrial permeability transition and release of cytochrome c after 
hypoxia/reoxygenation injury in kidney proximal tubular cells. A persistent respiratory 
defect occurs in complex I-dependent substrates during reoxygenation after hypoxia, and this 
defect is associated with condensed mitochondrial configuration and incomplete recovery of 
mitochondrial membrane potential. Amelioration of impaired substrate flux through 
mitochondrial complex I and ATP generation by   -ketoglutarate plus greatly improved 
mitochondrial function and cellular recovery. The identification of these upstream pathways 
of anaerobic metabolism and the possibility of metabolic manipulations to improve 
mitochondrial functions at an early stage may help to prevent irreversible mitochondrial 
damage in renal ischemia [Plotnikov EY, 2007].  
Ischaemic renal injury is associated with a marked increase in the expression of the 
antiapoptotic Bcl-2 family of proteins, Bcl-2, Bcl-XL and the apoptotic protein Bax, in distal 
tubules and moderate increases in the proximal tubules [Chien CT, 2001]. The marked 
upregulation of the antiapoptotic proteins in the distal tubules may tip the balance in favour 
of cell survival, and this imbalance may be involved in its adaptive resistance to ischaemic 
injury. It can be hypothesised that this survival mechanism may allow the cells to produce 
growth factors that may aid in the protection and/or regeneration of the distal tubules by an 
autocrine mechanism and of the more vulnerable proximal tubules by a paracrine 
mechanism.  
The relative expression of the Bcl-2 family of proteins in distal and proximal tubules 
subjected to oxidant injury in culture is similar to that seen in vivo. However, the expression 
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of Bcl-XL is decreased in proximal tubular cells and a translocation of Bcl-XL from the 
cytosol to the mitochondria is observed in the surviving distal tubule cells. No change in the 
sub-cellular distribution of Bax was observed in the surviving distal tubule cells, and it 
remained widely distributed in the cytosol. The expression of Bcl-2 or Bax was also 
unchanged in PTC post-oxidant injury [Chien CT, 2001]. It is unclear if the translocation of 
Bcl-XL plays a role in its protection from the oxidative injury. In a separate study, proximal 
tubules subjected to ATP depletion induced by hypoxic injury or impaired oxidative 
phosphorylation are shown to translocate Bax from the cytosol to the mitochondria. It is 
suggested that Bax may form pores in the mitochondrial outer membrane causing the release 
of cytochrome c from the mitochondrial intermembrane space and may activate apoptotic 
pathways [Wei Q, 2004].  
 
1.4.6 Cellular inhibitors of apoptosis 
 
The inhibitors of apoptosis (IAPs) family proteins includes eight mammalian family 
members, including X-linked inhibitor of apoptosis (XIAP), c-IAP1, c-IAP2, and ML-
IAP/livin [Deveraux QL, 1999]. They act as a last line of defence to prevent cellular 
disassembly by binding to caspases by their BIR (Baculovirus IAP repeat) motif, which 
contains a conserved cysteine and histidine core sequence Cx2Cx6Wx3Dx5Hx6C [Dereraux 
QL, 1997; 1999] which may lead to ubiquitination of the caspases. XIAP, X-linked inhibitor 
of apoptosis, contains three BIR domains and has been shown to directly inhibit caspase-3, -
7 and -9, but not caspase-1, -6, -8 or -10. This caspase selectivity could be due to the 
presence of conserved amino acid residues found in the BIR domains and the linker regions 
that separate them [Sun C, 1999]. Severe hypoxia up-regulates these endogenous inhibitors 
of apoptosis, particularly c-IAP2, and hypoxia-resistant epithelial cells which express 
increased c-IAP2 and Bcl-XL are more resistant to a second ischaemic or toxic insult [Dong 
Z, 2001; Dong Z, 2003].  
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The activity of IAPs is regulated by Smac/DIABLO, a structural homologue of the 
Drosophila proteins Reaper, Hid, and Grim [Du C, 2000]. Smac/DIABLO is released from 
mitochondria and inhibits IAPs, which facilitates caspase activation during apoptosis. Omi/ 
HtrA2 has been recently identified as another modulator of IAP function. Omi/HtrA2 is a 
mitochondrial-located serine protease, which is released in the cytosol and inhibits IAPs by a 
mechanism similar to Smac [Suzuki Y, 2001]. 
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1.5  Erythropoietin 
 
1.5.1   The cell biology of erythropoietin 
 
Erythropoietin (EPO) is a glycoprotein hormone with a molecular weight of 30.4 kDa. The 
gene for EPO, situated on chromosome 7q11-22, consists of five exons and four introns, 
encodes a protein precursor of 193 amino acids. During post-translational modification,  
which consists of cleavage of a 27 amino acid sequence, glycosylation of 3 N-linked (at Asn-
24, Asn-38 and Asn-83) and one O-linked (ser-126) amino acids, the removal of Arginine 
residue (Arg-166) from the C-terminal end yields the final circulating EPO molecule 
comprising of 165 amino acids. The tertiary structure of erythropoietin is defined by four 
anti-parallel   -helices. EPO was successfully purified from the urine of patients with aplastic 
anaemia [Miyake T, 1977]. From tryptic fragments of this urinary EPO, DNA probes were 
synthesized for the isolation and cloning of the human EPO gene [Jacobs K, 1985]. The 
manufacture and application of recombinant human EPO molecule (rhEPO) to treat the 
anaemia of chronic renal failure followed shortly thereafter [Winearls CG, 1986; Eschbach 
JW, 1987]. 
 
In the healthy adult, EPO secretion is primarily from the kidney, in response to hypoxia, in 
order to maintain an optimal red cell mass to cope with normal tissue oxygen demand. The 
basal level of EPO secretion in the picomolar range maintains a plasma concentration 
equivalent to 15-25 mU/ L, although during periods of hypoxic stimulation plasma levels 
may increase by 50 -100 fold [Al-Huniti NH, 2004].  In the kidney, EPO production is 
restricted to a population of cells in the interstitium of the cortex and outer medulla. 
Immunohistochemical characterization utilizing SV40 labelled erythropoietin-producing 
transgenic mice demonstrated that EPO is produced in a population of fibroblast-like type I 
interstitial cells using light and electron microscopy [Maxwell PH, 1993].  
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Figure 1.4  Primary structure of erythropoietin, demonstrating cysteine sulphide 
cross-bridges 
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Recently, it has been discovered that EPO is additionally produced at several other sites, 
including the brain [Masuda S, 1994], the endometrium [Yokomizo R, 2002] and the 
epididymis [Kobayashi T, 2002]. The physiological role of EPO produced in these locations 
remains uncertain, but foetal production at multiple sites may be essential for normal 
development [Juul SE, 2004]. 
 
 
1.5.2  Regulation of EPO production 
 
EPO gene expression is under the control of the oxygen-sensitive transcription factor 
hypoxia-inducible factor (HIF), which consists of a regulatory   -sub-unit (HIF-1   , -2   , and -
3   ) and the constitutively expressed sub-unit HIF-1β [Wang GI, 1993]. Both subunits are 
members of multi-protein families and belong to the extended family of basic helix-loop-
helix PAS domain transcription factors. Low oxygen tension averts enzymatic prolyl-residue 
hydroxylation within a region of HIF-    called the oxygen-dependent degradation domain 
(ODD), by a family of prolyl-4-hydroxylases (PHD 1-3). In normoxia, the hydroxyl residue 
serves as a target for von-Hippel-Lindau (VHL)-dependent polyubiquitination and 
subsequent proteosomal degradation. Hypoxia prevents HIF degradation by inhibition of this 
oxygen-dependent pathway, leading to nuclear accumulation of HIF and DNA binding. The 
VHL gene product is the recognition component of a multiprotein E3 ubiquitin-ligase 
complex that captures HIF-    chains that have undergone enzymatic prolyl hydroxylation 
[Jaakkola P, 2001].  
 
The HIF isoform that hypoxically regulates EPO production remains controversial. Although 
HIF-1 was initially purified from human hepatoma (HepB3) cells as the HIF molecule that 
bound to the 18-nucleotide fragment of the 3’ regulatory element containing the HRE, the 
regulation was found to be largely dependent on HIF-2, and not HIF-1, in studies utilizing a 
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siRNA knockdown approach [Warnecke C, 2004]. Hepatic production of EPO is suppressed 
in the livers from animals with Cre-LoxP-mediated inactivation of HIF-2, and complete 
absence of HIF-2 further suppressed physiological EPO concentrations [Rankin EB, 2007]. 
This may be due to preferential binding of HIF-2 to the HRE, although the expression of 
HIF-2 is variable, and this observed dominance may be cell type specific [Racliffe PJ, 2007]. 
 
In addition, prolyl hydroxylation requires 2-oxoglutarate as a co-factor because the 
hydroxylation reaction is coupled to the decarboxylation of 2-oxoglutarate to succinate, 
which accepts the remaining oxygen atom [Kivirikko K, 1998]. The prolyl-4-hydroxylase 
requires iron as a cofactor, and cobalt administration mimics the effect of hypoxia on HIF-1    
activation. Cobalt administration to rats, via up-regulation of HIF-dependent proteins 
including EPO, VEGF and haem-oxygenase-1 (HO-1), diminished the degree of renal injury 
caused by ischemia-reperfusion [Matsumoto M, 2003], suggesting the HIF-dependent 
production of EPO may play an important role in ischaemic pre-conditioning. Evidence 
supporting the importance of EPO in ischaemic pre-conditioning comes from work in 
transgenic heterozygotic HIF -/+ mice, which express only small amounts of constitutively 
expressed HIF-1, and are resistant to an ischaemic pre-conditioning protocol [Cai Z, 2003]. 
These animals showed increased renal production of EPO which was significantly greater 
than the increase in other HIF-dependent hormones VEGF and HO-1. 
 
HIF activation leads to the altered expression of a diverse range of cytokines and mediators 
that mediate the adaptive response to stress and ischaemia, including pro-angiogenesis 
hormone vascular endothelial growth factor (VEGF), glucose transporters (GLUT1) and 
glycolytic enzymes, iron metabolism (transferrin), and a variety of genes involved in cellular 
proliferation, differentiation and viability (IGF binding proteins, p21, cyclin G2 and caspase-
9) [Iyer N, 1998]. 
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Figure 1.5 Oxygen Sensing and EPO gene transcription. 
Low oxygen tension averts enzymatic prolyl-residue hydroxylation within a region of HIF-
1    called the oxygen-dependent degradation domain (ODD), by a family of prolyl-4-
hydroxylases (PHD 1-3), which, in normoxia, serves as a target for von-Hippel-Lindau 
(VHL)-dependent polyubiquitination and subsequent proteosomal degradation, thereby 
preventing HIF degradation, leading to nuclear accumulation of HIF-1. In the presence of c-
factor p300, HIF binds to the hypoxia response element (HRE) in the EPO promoter 
sequence and increases gene transcription. 
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1.5.3 EPO in Haematopoietic Tissues 
 
Due to the natural destruction of aging erythrocytes in the reticuloendothelial system there is 
a need for continual production of new red blood cells throughout life. There are several 
stages of erythroid cell maturation and each step is dependent on the presence of numerous 
growth factors for survival, proliferation and differentiation [Kaushansky K, 2006]. The 
effects of erythropoietin on the erythroid components of bone marrow are mediated by 
binding to specific EPO receptors on erythroid precursors (intermediate-stage erythroid 
burst-forming units (BFU-E) and the erythroid colony-forming units (CFU-E), which have 
already differentiated from pluri-potent stem cells. Differentiation to this stage is not 
dependent on EPO, as EPO-R knock-out mice are incapable of erythropoiesis but have 
committed BFU-E and CFU-E in foetal liver tissue [Wu H, 1995]. Thus the expression of 
the EPO receptor is itself an essential part of the mechanism by which erythropoiesis is 
controlled. The expression of the erythropoietin receptor is dependent on the specific phase 
of differentiation, and in the absence of EPO, the erythroid progenitors undergo apoptotic 
cell death [Boyer SH, 1992]. 
 
EPO can efficiently support the proliferation of murine erythroid progenitor cells ex vivo, 
and induce entry into the cell cycle in dormant cells [Miller CP, 1999]. Using the EPO-
dependent human erythroid progenitor cell line HCD-57, Silva et al showed that 
erythropoietin maintained their viability via repressing apoptosis by upregulating Bcl-XL, an 
anti-apoptotic protein of the Bcl-2 family [Silva M, 1996]. To further highlight the 
importance of this pathway, Bcl-XL null mice exhibit fetal liver haematopoietic defects and 
severe anaemia during embryogenesis [Wagner KU, 2000]. 
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1.5.4  Erythropoietin Receptor and Intracellular Signalling 
 
Before the cloning of the EPO receptor cDNA, investigators had used radiolabelled EPO to 
demonstrate specific binding to cells derived from the erythroid lineage [D’Andrea D, 1990]. 
These studies showed that approximately 200 EPO receptors were present on the cell surface 
of purified normal erythroid progenitors. This relatively low expression of cell surface 
receptors is characteristic of other receptors of haematopoietic cytokines such as G-CSF, 
GM-CSF and interleukin-3 [Groopman JE, 1989]. Affinity cross-linking experiments using 
radiolabelled EPO revealed two cross-linked EPO receptor complexes, and subsequent 
crystallization studies have confirmed receptor dimerisation [Matthews DJ, 1996]. 
 
The murine EPO receptor was cloned by transfecting pools of recombinant plasmids from a 
MEL cDNA library in to COS cells and screening for uptake of radiolabelled EPO by 
transfected cells [D’Andreau AD, 1989]. The cloned EPO receptor was a 507-amino acid 
polypeptide with a single membrane spanning domain, with extensive homology with the 
interleukin 2 receptor 
 
 chain [D’Andreau AD, 1990]. The extracellular domain of the 
receptor possesses a conserved domain of ~200 amino acids, which derives from the 
duplication of a 100 amino acid subdomain with a type III fibronectin structure [Bazan JF, 
1990]. The EPO receptor exhibits a WSXWS sequence in the membrane-proximal 
subdomain and two pairs of cysteines in the first subdomain. The two pairs of cysteine are 
held by disulphide bonds. The WSXWS sequence is thought to be necessary for the correct 
folding and cell membrane stability [Yoshimura A, 1992].  
 
Like all the receptors in the cytokine receptor superfamily, the EPO receptor does not 
possess endogenous tyrosine kinase activity, but binding of EPO to the extracellular portion 
of the receptor induces a conformational change, which brings JAK2 kinase into proximity, 
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allowing autophosphorylation and activation of JAK2 kinase domain (Figure 1.5). This 
induces rapid tyrosine phosphorylation of a number of proteins [Witthuhn B, 1993]. Eight 
tyrosine residues located on the cytoplasmic domain of the EPO receptor are phosphorylated 
by JAK2, upon EPO stimulation, and these phosphorylated tyrosine residues are docking 
sites for proteins containing src-homology 2 (SH2) domains [Dusanter-Fourt I, 1992]. 
 
The STAT (signal transducer and activator of transcription) pathway plays a major role in 
cytokine-induced signalling. EPO activates both STAT5A and STAT5B [Damen JE, 1993; 
Wakeo H, 1995]. The two first tyrosine residues in the intracellular domain of the EPO 
receptor (Y343 and Y401) are responsible for STAT5 binding and activation [Chin H, 
1996].  The precise role of STAT5 activation induced by EPO is the subject of controversy. 
A correlation between STAT5 activation and cellular proliferation has been observed, but 
STAT5 activation may also play a role in erythroid differentiation [Chretien S, 1996]. 
 
A direct association between phosphatidylinositol 3-kinase (PI 3-kinase) and the EPO 
receptor has been shown, which involves the SH2 domains of the p85 subunit of the PI 3-
kinase and tyrosine-479 of the EPO receptor [Damen J, 1995]. An alternative pathway for 
the activation of PI 3-kinase has been described, which involves the tyrosine 
phosphorylation of the adaptor protein IRS2 and its subsequent association with PI 3-kinase, 
which allows for the previous finding that cells expressing a truncated EPO receptor had PI 
3-kinase activity [Verdier F, 1997]. PI 3-kinase leads to phosphorylation and activation of its 
downstream target, the serine/ threonine kinase AKT, which in turn phosphorylates multiple 
targets including FKHRL1, and P70S6-kinase [Downward J, 1998]. Several studies have 
suggested that the PI 3-kinase/AKT pathway is the major pathway involved in the anti-
apoptotic effects of EPO in erythroid progenitors [Haseyama Y, 1999] and also has a role in 
the proliferation and differentiation of endothelial progenitor cells [Bahlmann FH, 2003].  
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AKT is an important molecule in mammalian signalling to promote cell survival by 
inhibiting apoptotic cell death pathways. AKT is also able to induce protein synthesis 
pathways, and therefore is a key signalling step in general tissue growth. AKT regulates the 
cellular survival and metabolism pathways by binding and regulating many downstream 
effectors both directly and indirectly, including BAD, a pro-apoptotic protein of the Bcl-2 
family. AKT phosphorylates BAD on Ser136, which makes BAD dissociate from the Bcl-2/ 
Bcl-XL complex and lose the pro-apoptotic function [Chong Z, 2005]. AKT also activates 
NF-  B via regulating I  B kinase (IKK), thus result in transcription of pro-survival genes 
which are up-regulated by NF-kB [Terrangi J, 2008].  
 
Erythropoietin receptor signalling is terminated through receptor internalisation and 
proteosomal degradation [Verdier F, 2000], after 30-60 minutes of stimulation. Receptor 
activation and signalling causes the activation of protein tyrosine phosphatases, which de-
phosphorylates JAK2 and inactivates its kinase function, with inactivation of STAT 
pathways [Klingmuller U, 1995]. Mutations in the EPO receptor that lead to decreased or 
absent de-phosphorylase activity, prolonging the stimulation signal produced by ligand 
binder are associated with familial erythrocytosis syndromes [Arcisoy MO, 1999]. 
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Figure 1.6 Conformational change on ligand binding allows activation  
EPO binds to the extracellular portion of the receptor, leading to structural rearrangement 
which allows proximity-dependent autophosphorylation of receptor associated JAK2 
kinases, which phosphorylate tyrosine residues on the intracellular portion of the receptor, 
allowing SH-2 domain containing mediators, activating STAT5. The activated STAT5 
homodimer translocates to the nucleus. 
 
 
 
 
 
P 
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P 
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Studies of the tissue distribution of EPO and the EPO receptor in the developing human 
foetus have demonstrated the presence of mRNA for EPO and the receptor in virtually all 
major organs in the first two trimesters [Juul SE, 1998]. This leads to speculation that EPO 
acts in concert with somatic growth and developmental factors during early foetal life. 
Although mice with EPO gene knock-down were found to be neurologically normal 
[Maxwell PH, 1994], subsequent studies have demonstrated defects in cardiac structure and 
reduction in the expression of neuronal stem cells [Chen ZY 2007] in these animals. Latent 
expression in adult tissues may be up-regulated in disease states, particularly in the 
development of cancer. Indeed, an increasing number of cancer cell types have been shown 
to express a functional EPO receptor [Westenfelder C, 2000; Kumar SM, 2005], which may 
have implications for the therapeutic use of erythropoietin in certain clinical situations. 
Further work is required to fully answer the questions raised by these observations. 
 
Mature endothelial cells also express EPO receptors (Epo-Rs) and EPO induces a 
proangiogenic response in cultivated mature endothelial cells, as evidenced by stimulation of 
endothelial cell proliferation, migration, endothelin-1 release, and increase in cytosolic-free 
calcium concentration [Chong Z, 2002]. A physiologic significance for the EPO-EPO-R 
signaling pathway has been demonstrated for the oestrogen-dependent cyclical angiogenesis 
in the uterus [Yasuda Y, 1998]. 
 
 
1.5.5 Use of EPO in Anaemia associated with end-stage renal failure 
 
Anaemia develops in most patients with CKD because less erythropoietin is produced by the 
diseased kidneys [Erslev AJ, 1997]. The decline in haemoglobin (Hb) concentration may 
start at levels of creatinine clearance of around 70 mL/min among men and 50 mL/min 
among women, and progresses relentlessly. The management of anaemia before the 
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introduction of recombinant human erythropoietin was a struggle, with a combination of 
“good dialysis”, minimizing blood loss, parenteral iron and androgens, together with 
avoidance of excess blood tests, achieving average haemoglobins of approximately 8 g/ dl. 
This left about 10% of patients dependent on blood transfusions and susceptible to the 
complications of iron overload. Following successful cloning of EPO, pilot studies followed 
very rapidly [Winearls C, 1986], leading to a number of successful multi-centre trials 
[Eschback JW 1989]. The doses required to reverse anaemia and maintain haemoglobin 
were found to be similar in American and UK studies [Bommer J, 1988; Eschbach JW, 
1989]. 
 
The erythrokinetic studies performed on the first dialysis patients treated with r-HuEPO 
showed that the total red cell volume was below normal before treatment and increased after 
treatment. These increases in red cell volume were accompanied by reciprocal changes in 
plasma volume, so that total blood volume was not altered by treatment. Red cell survival in 
non-transfused patients was only modestly shortened before treatment and was not altered by 
treatment. Studies of the response of bone marrow erythroid progenitors to r-HuEPO 
treatment showed that after treatment, the number of bone marrow BFU-E had fallen to a 
mean of 24% of pre-treatment values, but there was no significant change in the number of 
CFU-E. The failure to change the number of CFU-E would have to be explained by self-
renewal and replenishment from the BFU-E, keeping the size of this compartment constant 
[Reid CDL, 1988].  
 
The best marker of benefit of the introduction of erythropoietin to clinical practice is the 
reduction in the need for regular blood transfusions [Sundal E, 1991]. The improvement in 
symptoms attributable to anaemia, and hence quality of life, is unequivocal, and confirmed 
in several randomised, placebo controlled trials [Auer J, 1990]. Associated improvements in 
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haemodynamic status due to correction of anaemia lead to reduction in progression of left 
ventricular hypertrophy, with a concomitant reduction in mortality. 
 
The therapeutic use of EPO in these patients led to the identification of systemic and 
vascular effects that caused significant complications. EPO administration results in an 
increase in diastolic blood pressure of up to 10 mmHg in 10-20% of patients [Smith KJ, 
2003]. The underlying mechanism of this effect is unclear, but a number of possibilities have 
been studied, including the induction of the vaso-constrictor endothelin-1 [Carlini RG, 
1993], altered intracellular calcium concentration and a diminished response to NO [Marrero 
MB, 1998].  
 
 
1.5.6 The novel role of Erythropoietin in the Nervous System 
 
Both erythropoietin and the EPO receptor are functionally expressed in the nervous system 
of rodents, primates and humans. In the mouse, EPO is present in the hippocampus, capsula 
interna, cortex and mid-brain areas [Digicaylioglu, 1995]. In cultured rat cortical neurones, 
the expression of the EPO receptor has been demonstrated by immunostaining and RT-PCR 
[Morishita, 1997]. In humans, EPO and the EPO receptor are present in both astrocytes and 
neurones, although the level of expression varies according to gestation age, with reduced 
production after birth [Juul, 1999]. 
 
Hypoxia results in the induction of EPO in brain tissues. Accumulation of EPO mRNA and 
the EPO protein in response to hypoxia has been observed in cultured astrocytes [Marti HH, 
1996]. EPO and the EPO receptor are also inducible in the hippocampal neurones, although 
in vivo models demonstrate a broader up-regulation during hypoxia [Bernaudin M, 1999]. 
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Initial experiments have therefore examined the potential role of EPO in the nervous system 
during cerebral ischaemia. Infusion of EPO into the lateral ventricle of gerbils subjected to 
the occlusion of the common carotid arteries prevented ischaemia-induced learning disability 
and resuced hippocampal neurones from degeneration [Sakanaka M, 1998]. Multiple studies 
have now confirmed the beneficial effects of EPO administration in the course of ischaemic 
brain injury in vivo, using systemic administration to overcome the impracticalities of 
ventricular delivery systems [Sadamoto Y, 1998; Matsushita H, 2003; Grasso G, 2002].  
 
Ischaemia-related investigations examining the potential of erythropoietin to prevent 
neuronal injury have also been extended to the spinal cord, peripheral nervous system and 
visual system, summarized in table 1.1.  
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Animal studies 
Focal and global cerebral ischemia 
 
 
Sakanaka M, 1998 
25–100 U i.p. or 0.2–25 U 
day-1 i.c.v. applied either 
pretreatment or post-
treatment with injury in rats, 
mice or gerbils 
Infarct volume, brain edema and 
neuronal apoptosis decreased; 
neuronal survival increased 
Retinal ischemia 
 
Junk AK, 2002 
5000 U kg i.p. or 2 ml 
intravitreal applied imm. or 
posttreatment  
Photoreceptor and retinal 
ganglion cell apoptosis decreased 
Neonatal hypoxic–ischemic brain 
injury 
 
Aydin A, 2003 
1000–5000 U/Kg i.p. applied 
pre-treatment with injury in 
mice 
Infarct volume and neuronal 
apoptosis decreased; caspase-3 
activity decreased 
Spinal cord injury 
 
Gorio A, 2002; Celik M, 2002 
100–5000 U/kg i.p. with injury 
in rats  
Motor neuron apoptosis, 
inflammation and lipid 
peroxidation decreased; 
functional recovery improved 
Subarachnoid hemorrhage 
 
Buemi M, 2000 
1000 U/kg i.p. applied 5 min 
after injury in rabbits 
Neuronal death decreased; 
functional recovery and blood flow 
autoregulation improved 
Peripheral nerve injury 
 
Campana W, 2003 
1000–5000 U/kg s.c. applied 
pre-treatment with injury in 
rats 
Dorsal and ventral root ganglion 
cell injury decreased; recovery 
from mechanical allodynia 
improved 
Tissue culture studies 
Anoxic injury 
 
Chong ZZ, 2003 
10 ng/mL applied pre-
treatment with injury in ECs or 
hippocampal neurons 
DNA fragmentation and PtdSer 
exposure decreased; cell survival 
increased 
NO injury 
 
Yamasaki M, 2005; Sakanaka M, 
1998 
10 ng/ml or 20 U/ml applied 
pre-treatment or imm. with 
injury in ECs or hippocampal 
neurons 
DNA fragmentation, PtdSer 
exposure and NO production 
decreased; cell survival increased 
Glutamate toxicity 
 
Yamasaki M, 2005 
50 ng/ml or 3–300 pM/ml pre-
treatment with injury in 
hippocampal, cortical and 
cerebellar neurons 
Glutamate release decreased; 
neuronal survival increased 
 
 
 
Table 1.1 Therapeutic use of EPO in experimental models of brain injury 
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1.6 Aims 
 
The evidence presented in the introduction has led to the hypothesis that the haematopoietic 
growth hormone Erythropoietin is functional in tissues outside the bone marrow, and that it 
exerts physiological effects to lessen injury induce by exposure to ischaemia, and to inititate 
the tissue healing process. 
 
In order to test this hypothesis, the primary aim of this thesis is to establish the role and 
effects of the haematopoietic growth factor erythropoietin (EPO) on the course of ischaemia 
reperfusion injury in the kidney. In order to fully achieve this, it is essential to study the 
direct in vitro effects of EPO on proximal tubular epithelial cells, and examine the 
intracellular mechanisms which underpin the protective effects of EPO in these models. 
Finally this thesis will aim to extend the examination of the effects of EPO into different 
types of injury model, including other in vivo organ systems.  
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Chapter Two:  
In vitro effects of Erythropoietin in a Human Proximal tubular 
epithelial cell line 
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2.1 Introduction 
 
In erythroid precursor cells at the CFU-E stage, EPO activates a number of signalling 
pathways via engagement of its cell surface receptor, which reduce growth factor 
withdrawal-induced cell death, and hence allow proliferation and differentiation, as 
discussed in detail in section 1.5.4. 
 
A direct effect of EPO on the viability and resistance to cell death of tubular epithelial cells 
would require cell surface expression of a functional EPO-R on this cell population. The 
identification of a functional EPO/ EPO-R system in the nervous system led to a range of 
studies demonstrating signalling effects and beneficial responses in a range of injury models, 
including hypoxia and toxic insults, described in section 1.5.7. At the time of starting the 
body of work described in this thesis, experiments utilizing both polyermase chain reaction 
mRNA expression and immunoblotting techniques had demonstrated that the EPO-R is 
present on human, mouse and rat proximal tubular epithelial cells, and that, in cultured 
proximal tubular epithelial cells, EPO binds to its cell surface receptor, and exerts effects on 
cellular proliferation in culture [Westenfelder C, 1999]. 
 
 
2.2 Aims 
 
The aim of the experiments in this chapter was to examine the signalling pathways activated 
by EPO in a human proximal tubular epithelial cell line, concentrating on the pathways 
known to be EPO-responsive in erythroid progenitor cells, and determine the effects of EPO 
on cell survival in a basic in vitro injury model. 
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2.3 Materials and Methods 
 
2.3.1 Proximal Tubule epithelial cell lines 
 
HK-2 cells, a proximal tubule epithelial cell line (PTEC) derived from normal human 
kidney, were obtained from the ECACC (European collection of cell cultures). HK-2 cells 
were immortalised by transduction with human papilloma virus 16 (HPV-16) E6/E7 genes. 
The recombinant retrovirus vector pLXSN 16 E6/E7 containing these genes was used to 
transfect the ectotropic packaging cell line Psi-2. Subsequent viruses produced by the Psi-2 
cells were used to transfect the amphotropic packaging cell line PA317. Viruses obtained 
from the PA317 cells were used to transduce primary proximal tubule epithelial cells. The 
pLXSN 16 E6/E7 confers resistance to neomycin. The cells retain a phenotype indicative of 
well differentiated proximal tubular epithelium, and express alkaline phosphatase, gamma 
glutyltranspeptidase, leucine aminopeptidase,   3, 
 
1-integrins and fibronectin [Ryan MJ, 
1994]. 
 
 
2.3.2 Cell Culture 
 
HK-2 cells were cultured in Dulbecco’s Modified Eagles Medium Ham’s F12 with 10% v/v 
fetal calf serum (FCS) and antibiotics (benzylpencillin 100 U/ mL, streptomycin 10   g/ mL, 
amphotericin 2.5   g/ mL (all Sigma-Aldrich Chemical Co., UK) [hereafter called standard 
medium] in sterile T753 culture flasks (VWR, UK) and incubated at 37˚C in a humidified 
atmosphere comprising of 95% air and 5% CO2. When confluent, the cells were sub-
cultured; the medium was removed and the cells washed with 10 mL of Phosphate Buffered 
Saline pH 7.4 (PBS). PBS was removed before the addition of 10 mL of 0.05% Trypsin 
(Sigma), which was then incubated at 37˚ for approximately 10 minutes until the cells had 
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detached from the culture flask. The cells were then harvested by centrifugation at 800rpm 
for 5 minutes. The supernatant was removed with care to avoid disturbing the pelleted cells, 
which were re-suspended in 10 mL culture medium for a wash step. The cells were again 
harvested by centrifugation at 800 rpm for 5 minutes. The supernatant was removed and the 
pellet was resuspended in culture medium and aliquoted into fresh culture flasks at a cell to 
medium ratio of 1: 3. Cells were used for all experiments between passage three and six, and 
fresh batches of cultured cells were developed at all times to maintain optimum cell 
conditions for experiments. Foetal calf serum contains a variety of growth hormones, at very 
small concentrations, and may include EPO, although the amount is not specified in the 
manfacturer’s information. 
 
 
2.3.3 Cell Count 
 
After being harvested, an aliquot of pelleted cells was resuspended in 10 mL of culture 
medium and a 1:1 dilution of the cell suspension made with 0.1% v/v of Trypan Blue. 100 
  L of cell suspension-trypan blue mixture was transferred to a haemocytometer chamber 
over which a cover slip was placed. Using one chamber of the haemocytometer, the numbers 
of dead and viable cells were counted in the middle 1mm2 square and at least two of the four 
corner squares. Each square on the haemocytometer (with the cover slip in place) represents 
a total volume of 0.1mm3 (10-4 mm3). Therefore, 
 
Live cells per mL = mean number of unstained cells per square x 104 x 2 
Total cells  = cells per mL x volume 
Cell viability   = number of unstained cells x 100 
     Total number of cells  
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2.3.4 Cell freezing 
 
After being harvested by centrifugation, pelleted cells were resuspended in 100   L of cell 
culture medium, and then aliquots were added to cell culture freezing medium ( 10 % 
DMSO, 90% culture medium) and transferred to a cryovial, which was placed in a 
polystyrene container at -80˚ C for 2 hours before being transferred to liquid nitrogen for 
long term storage. 
 
 
2.3.5 Quantification of protein by BCA assay 
 
The BCA assay is a detergent-compatible formulation, based on bicinchoninic acid (BCA), 
for the colorimetric detection and quantification of total protein. This method combines the 
well-known reduction of Cu2+ to Cu1+ by protein in an alkaline medium (the biuret reaction) 
with the highly sensitive and selective colorimetric detection of the cuprous cation (Cu1+) 
using a reagent containing bicinchoninic acid [Smith PK, 1985]. The purple colour reaction 
product of this assay is formed by the chelation of two molecules of BCA with one cuprous 
cation. This water-soluble complex exhibits a strong absorbance at 562 nm that is nearly 
linear with increasing protein concentrations over a broad working range (20-2,000   g/ ml). 
 
Protein concentrations are determined with reference to a standard curve of known protein 
concentrations made up with bovine serum albumin. 100 µL of each known dilution of the 
standard curve was added to duplicate wells on a 96 well plate (8 wells). 100 µL from each 
protein sample was added to the plate. The assay reagent buffer was added to each well (200 
µL), and the plate incubated at 37 ˚C for 30 minutes. Absorbance at 562 nm was measured in 
a plate reader and corrected for a blank well measurement. 
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2.3.6 Western Immunoblotting 
 
Sub-confluent cells were incubated in culture medium with and without experimental factors 
for varying time points. At the end of the experiment, the incubation was stopped by 
washing the cells with ice-cold PBS. Cells were removed after scraping the flasks with a 
Teflon coated cell scraper, followed by centrifugation for 5 minutes at 1200 x g. Cell pellets 
were then lysed by the addition of ice-cold lysis buffer: 
  
 Standard Lysis buffer 
 20 nM Tris (pH 7.4) 
 150 mM NaCl 
 1% NP-40 
 0.5 % w/v Na deoxycholate 
 0.1 % SDS (Promega) 
 
Protease inhibitors were added immediately prior to cell lysis at the following 
concentrations: 
 
 1 mM PMSF (10 mg/mL stock solution  in isopropanol) 
 1 mM Na orthovanadate (100 mM stock solution) 
 30   L of a 5-19 U/mL solution of aprotinin from bovine lung 
 
For 1-5 x 106 cells, 100   L of lysis buffer was typically used. This was left on ice for 15-20 
minutes with regular vortexing and then centrifuged at 15000 x g for 15 minutes at 4˚C. The 
protein content of the supernatant was measured using the bicinchoninic acid (BCA) protein 
quantification assay (Pierce) in a 96-well plate format, described in 2.3.5. 
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2.3.7 SDS-PAGE 
 
For each individual gel, 20 - 40   g of protein from each sample was electrophoresed on a 
polyacrylamide gel in the presence of SDS. The composition of the solutions for SDS-PAGE 
is shown below: 
 
Stacking gel 
 Protogel (30 % w/v acrylamide; 0.8% w/v bis-acrylamide) 0.33 mL 
 Resolving buffer (1.44 M Tris-HCl; 0.384% SDS, pH 8.8) 0.63 mL 
 10 % Ammonium persulfate (APS)    12.5   L 
 H20         1.54 mL 
 TEMED        2.5   L 
  
 Resolving gel 
 Protogel        1.67 mL 
 Resolving buffer (0.5M Tris-HCl; 0.4% SDS, pH 6.8)  1.30 mL 
 10 % APS       50   L 
 H20         1.98 mL 
 TEMED        5   L 
 
Samples were mixed with sample buffer (0.125M Tris-HCl (pH 6.8), 4% SDS, 20 % 
glycerol, 10% 2-mercaptoethanol), heated to 95˚C for 5 minutes and placed on ice. 20 - 40 
  L (corresponding to 20 - 40   g of protein, equalised for the lowest protein content) per well 
was loaded onto the gel. Electrophoresis was carried out at 25 mA per gel for approximately 
45 minutes at room temperature in a buffer containing 0.025 M Tris (pH 8.3), 0.192 M 
glycine, 0.1 % SDS. 
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In later experiments, the Invitrogen XCell mini-cell electrophoresis system was used for all 
immunoblotting. Pre-cast NuPAGE Bis-Tris gels were used (10% or graduated 4-12%), and 
gels were run at 200 V constant, in running buffer (MOPS 50 mM, Tris-HCl 50 mM, 0.1% 
SDS, EDTA 1mM (pH 7.7). 
 
 
2.3.8 Immunoblotting and detection of target proteins 
  
Acrylamide gels were carefully removed from the electrophoresis apparatus and laid on top 
of a piece of polyvinyldifluoride (PVDF) membrane (Immobilon P; Millipore, Sigma) which 
had been cut to size and pre-soaked in 100% methanol and dH20. Air bubbles were 
smoothed out with a sterile glass rod and the gel and membrane sandwiched between two 
sponges soaked in transfer buffer (10 mM CAPS, pH 11.0; 10% methanol in dH20). The 
sandwich was then placed in the transfer apparatus with the membrane facing the anode and 
electroblotting carried out at 400 mA for 1 hour at room temperature. Following 
electroblotting, the membrane was separated from the gel and any residual acrylamide 
washed off by soaking in TBS-T for 2 minutes. Non-specific sites on the membrane were 
blocked by incubation with 5% BSA in TBS-T overnight at 4˚C. After washing in TBS-T for 
5 minutes at room temperature, the membrane was probed with specific primary antibody 
(1:400- 1:2000 v/v in TBS-T + 1% BSA) for 2 hours at room temperature with constant 
agitation. 
 
The membrane was then washed in TBS-T 3 times for 5 minutes each. The membrane was 
then incubated with polyclonal secondary IgG antibody conjugated to horse-radish 
peroxidase (1:2000 in TBS-T + 1% BSA) for 1 hour at room temperature with constant 
agitation. The membrane was washed as before. The protein band of interest was visualised 
by chemiluminescence (ECL chemiluminescence Detection system, Amersham, UK). Equal 
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volumes (~2 mL) of ECL solutions (A+B) were mixed and gently pipetted onto the 
membrane and left for 30 seconds without agitation. The solutions were then drained off and 
the membrane placed on a lint-free tissue to remove any excess solution. The membrane was 
immediately covered in cling-film and exposed to light-sensitive film (Kodak Biomax Light) 
for various times in the dark room. The film was developed using an X-ray developer. 
 
 
2.3.9 Quantification of cell viability and proliferation with MTS assay 
 
Cell viability and proliferation experiments were performed utilizing the novel tetrazolium 
compound (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt; MTS) and the electron coupling reagent, phenazine methosulfate 
(PMS). In the presence of PMS, MTS is chemically reduced by live cells into formazan, 
which is soluble in tissue culture medium, and the formation of formazan is directly 
proportional to the number of viable, metabolizing cells. Experiments were carried out in 
clear 96-well microplates, using 100   L of phenol-red free standard culture medium per 
well. At the end of the experiment, 20   L of the MTS reagent (CellTiter 96® Assay, 
Promega) was added to each well and gently mixed. The plate was returned to the incubator 
for 30 minutes at 37˚C.   
 
The absorbance of the formazan at was read at 492nm, and expressed as a percentage of 
absorbance from control cells. Values over 100 % were taken as to be a measure of 
increased cell proliferation over control, although this could be confounded by experimental 
conditions that alter cellular metabolism. 
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2.3.10 Quantification of cell death by DNA fragmentation assay 
 
Cell death was detected by a DNA fragmentation enzyme linked immunosorbent assay 
(ELISA), which quantifies the mono- and oligo-nucleosomes in the cytoplasmic fraction of 
cell lysates (Cell Death Detection ELISA PLUS; Roche Diagnostics, Lewes, UK). Cytosolic 
lysates extracted using digitonin buffer (10   M Digitonin in PBS (pH 7.4)) were diluted 6- 
fold in kit lysate buffer. 20   L of the diluted cell lysate per well was added to a streptavidin 
coated microplate. 80   L of a mixture of anti-histone-biotin and anti-DNA-POD were added 
and the plate incubated for 2 hours at room temperature with gentle mixing on a microplate 
stirrer (300 rpm). During the incubation period, the anti-histone antibody binds to the histone 
component of the nucleosomes and simultaneously captures the immunocomplex to the 
streptavidin coated microplate via its biotinylation. Additionally, the anti-DNA-POD 
antibody reacts with the DNA content of the nucleosomes. The plate is then washed 3 times 
with incubation buffer (250   L/ well) before 100   L of 2, 2'-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid (ABTS) solution is added to each well and the plate 
incubated at room temperature for 5-10 minutes on a plate-shaker (300 rpm).  
 
The plate is read at 405 nm on a Dynex MRX II plate reader. DNA fragmentation is 
expressed as an enrichment factor from a time 0 control sample per mg of total cell lysate 
protein. 
 
 
2.3.11  Transcription factor DNA- binding Assay by ELISA  
 
Families of closely related homo- and hetero-dimer complexes that bind to DNA 
(transcription factors) regulate many of the global signalling pathways and are widely 
studied as disease targets. Traditionally, translocation of transcription factors was 
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determined by electrophoretic mobility shift assay (EMSA) using labeled specific 
oligonucleotides, but this technique is time-consuming and only semi-quantitative in nature. 
The DNA binding ELISA uses binding of a specific antibody and labeled secondary 
antibody to give more sensitive, highly quantitative data. 
 
10   g of nuclear protein extract was added to each well on a 96-well plate coated with an 
immobilized oligonucleotide containing a transcription factor-specific consensus sequence, 
 
STAT family  (5’-TTCCCGGAA-3’) 
 
with 30   L buffer, and the plate was incubated at room temperature with gentle agitation for 
one hr. After washing, buffer containing a transcription factor-specific primary antibody 
(1/10000 dilution) was added to each well, and the plate incubated without agitation for one 
hour. The plate was washed 3 times, and then a HRP-conjugated secondary antibody was 
added. The plate was incubated for one hour, and then washed four times. 100   L of 
developing buffer was then added to each well for up to 10 min, and absorbance read on a 
Dynax MRX II (450 nm with reference 650 nm). Values were expressed as optical density 
(n=3 for 3 independent experiments). 
 
 
2.3.12  Cell Transfection and transfection of siRNA 
 
RNA-mediated interference (RNAi) is a well-recognised pathway employed by most 
eukaryotes as a cellular line of defence directed against invading viral genomes or as a 
method to clear a cell of aberrant transcription products [Hamilton AJ, 1999]. Whilst the 
exact mechanism of successful RNAi-mediated gene silencing remains to be fully 
elucidated, this method has become an invaluable tool for analysis of gene function and 
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target validation. Cellular uptake of long double stranded RNA (dsRNA) has been shown to 
induce RNA interference in a diverse group of lower eukaryotic organisms. In 2001, Dr 
Tuschl et al showed that when short RNA duplexes (21-23 bases in length) were introduced 
into mammalian cells in vitro, sequence-specific inhibition of target mRNA was effected 
without inducing an interferon response [Elbashir SM, 2001]. 
 
 
2.3.13  Optimisation of siRNA transfection protocol for HK-2 cells 
 
In order to determine the most effective protocol for siRNA transfection in HK-2 cells, a 
series of optimization experiments were performed. HK-2 cells were seeded in low density 
(50% confluence) into 6-well plates 24 hours before transfection. Control non-targeted 
siRNA labelled with fluorescein was used to assess transfection by fluorescent microscopy. 
Standard medium was removed from each well and replaced by 800   L standard media 
without antibiotics. Three   L control siRNA (final concentration 100 nM) was mixed with 
serum-free medium and incubated at room temperature for 7 minutes. 3   L Oligofectamine 
(Invitrogen), GeneJuice, Dimrie-C, RNAifect, and NEB reagent were mixed with serum-free 
medium and kept. The two reagents were then gently mixed by inversion and incubated at 
room temperature for 20 minutes. The volume was made up to 1200   L with medium, and 
200   L per well was added gently and mixed by swirling. 
 
The plate was incubated in the incubator overnight. The medium was removed and 2 drops 
of antifade reagent (plus DAPI nuclear stain) was added dropwise to each well and placed in 
a dark box. Fluorescence was examined under a microscope, and percentage of cells 
showing green fluorescence was calculated by counting total cell number by positive nuclear 
DAPI staining on two random high powered fields. The highest efficiency of transfection 
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achieved over a number of experiments was with the transfection reagent oligofectamine, 
illustrated in Figure 2.1, and this was adopted for all subsequent transfection experiments. 
 
 
2.3.14  Statistical Analysis of Experiments 
 
All experiments were performed in identical passaged cells in triplicate unless stated in the 
methods.  All values described in the text and figures are expressed as the mean ± standard 
error for n (number of) observations. Each data point representing biochemical 
measurements was obtained from up to 10-12 separate animals. For histological scoring, 
caspase activity assays and apoptosis scoring, each data point represents analysis of kidneys 
taken from six individual animals.   
 
All statistical analysis was performed using GraphPad Prism 3.01/ Instat 1.1 (GraphPad 
Software, San Diego, USA). Data for multiple group comparisons were analysed using one-
way ANOVA followed by Dunnett post-hoc test, or Kruskal-Wallis ANOVA for non-
parametric data. A P value of less than 0.05 was considered significant. 
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Figure 2.1  Quantification of siRNA transfection rate by fluororescent microscopy 
for labelled non-targeted control siRNA. Comparison was made with DAPI nuclear 
staining to calculate percentage transfection and amount of expression by fluorescence. 
All slides were analysed in a single session without adjustment of microscope settings. 
Images were downloaded from the PC and have not been altered. 
 
  Oligofectamine 
 GeneJuice 6 
Dimrie-C 
DAPI
 
 
 
siRNA - GFP 
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2.4 Results 
 
2.4.1 Expression of EPO receptor on HK-2 cells 
 
The detection of the EPO-R in whole cell lysates was performed by immunoblotting with a 
validated specific polyclonal rabbit antibody to the C-terminal (Santa Cruz C-20) of the 
EPO-R, the specificity of which is not affected by ligand binding. Lysates were prepared 
from serum-starved UT-7 cells, a growth-factor dependent human erythroleukaemic cell 
line, known to widely express the EPO-R, to act as a positive control for immunoblotting 
[Dusanter-Fourt I, 1992].  
 
Figure 2.2 shows a representative western blot, from three individual experiments, of whole 
cell lysates from HK-2 cells, showing two bands at approximately 68 and 55 kDa, 
corresponding to the EPO-R, with similarly sized bands identified in the UT-7 cell lane.   
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Figure 2.2 Immunoblot of EPO-R in Two cell lines shows similar bands sized 
approximately 65-69 kDa. Representative images are shown from 3 separate 
experiments. Protein loading was confirmed by reprobing membrane for actin. 
 
 
 
 
 
 
 
 
 
IB: 
EPO-R 
       70 KDa 
   HK-2          UT-7 
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2.4.2 EPO induces proliferation in HK-2 cells which is dependent on presence of 
EPO receptor 
 
HK-cells were seeded at 1 x 105/ mL in a 96 well plate in standard medium containing 10% 
FCS and incubated overnight. The medium was removed and stimulated with phenol-red 
free standard medium containing different concentrations of EPO (1-100 U/ mL), and an 
MTS assay was performed after 24 hrs incubation. Experiments were repeated on three 
individual occasions, with 12 wells per experimental group. 
 
At 24 hrs, administration of EPO caused a dose-dependent increase in cell number over 
control levels in the range of concentrations 1 - 50 U/ mL (when compared to control cell, 
EPO 1 U/mL + 19 % ± 0.5, EPO 10 U/mL + 33 % ± 1, EPO 50 U/mL + 45 % ± 1, P<0.01), 
shown in Figure 2.3. 
 
To confirm that these effects of EPO on cellular proliferation were dependent on receptor-
mediated cell signalling, expression of the EPO-R was inhibited by transfection of an EPO-R 
specific siRNA (Dharmacon). Cells were seeded in 96 well plates and transfected with EPO-
R siRNA or a control, non-targeted siRNA using the established protocol described in 4.2.3. 
The medium was removed 24 hrs after addition of the transfection solution or control, and 
then refreshed with phenol-red free standard medium with and without EPO at maximal 
effective concentration determined from the previous experiment (50 U/ mL). The plate was 
then incubated for 24 hrs, followed by a MTS assay. Control cells unstimulated by EPO 
demonstrated that there was no significant effect of the transfection process on cell viability 
(P=ns), and normal response to 24 hr incubation with EPO (when compared to un-stimulated 
cells, EPO 50 U/mL +17 % ± 7; P<0.01). However, cells transfected with EPO-R siRNA 
showed a significant reduction in the response to EPO at 24 hrs when compared to non-
transfected cells (P<0.01), shown in Figure 2.4.  
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Figure 2.3 MTS value for n=12 wells expressed as relative value to control cells. 
EPO induced proliferation in HK-2 cells is dose-dependent (P<0.001). 
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Figure 2.4 Loss of proliferation response to EPO in the absence of EPO-R 
following siRNA knockdown. MTS calculated for n=8 wells (3 separate experiments) 
and expressed as relative to control cells (P<0.01 EPO treatment in control cells). 
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2.4.3 EPO induces STAT activation and DNA binding 
 
HK-2 cells were seeded at 50-75 % confluence in standard medium in 6-well plates and 
placed in an incubator overnight. The medium was removed, and the cells re-fed with 
standard medium without FCS. The cells were incubated for 6 hours, and then the medium 
was removed. Cells were stimulated with 1mL standard medium without FCS containing 
EPO (50 U/ mL) for 10 minutes. At the end of each experiment (n=6 wells for three separate 
experiments), cells were washed with ice-cold PBS, scraped with a Teflon cell scraper, and 
centrifuged at 600g at 4˚C for 5 minutes. The supernatant was discarded and the cell pellet 
was snap-frozen in liquid nitrogen.  
 
Protein extraction was performed, and 10 µg of fractional lysates, corrected by volume for 
assay determined protein concentration, were used to determine STAT activation in a 
commercial transcription factor DNA binding ELISA assay (TransAM, Active Motif, 
France). The activation for STAT3 and STAT5A was determined. All results were expressed 
as increase in DNA binding over the value obtained for control un-stimulated cells for three 
experiments. 
 
After stimulation with EPO (50 U/ mL) for ten minutes, there was significant increase in 
activation of STAT3 and STAT5A (STAT3 expression + 47 ± 3 % P<0.01, STAT5A + 52 ± 
2 % P<0.01 when compared to time zero controls), shown in Figure 2.5 and 2.6. 
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Figure 2.5 STAT3 activation by EPO at 10 minutes in HK-2 cells was measured by 
ELISA. DNA binding was expressed as multiple of control cells for n=3 experiments. 
EPO caused increase in STAT3 DNA binding (P<0.01). 
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Figure 2.6 STAT5A activation at ten minutes by EPO in HK-2 cells was measured 
by ELISA. DNA binding was expressed as multiple of control cells for n=3 
experiments. EPO caused increase in STAT5A DNA binding (P<0.01). 
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2.4.4 EPO Phosphorylates key Intracellular Pathways
 
 
HK-2 cells were incubated overnight in serum free medium followed by stimulation with 
EPO (50 U/mL) for varying lengths of time, or EPO plus either UO126 (10   M), AG490 (10  
  M), or LY294002 (10   M). Following lysis with Phospho-safe lysis buffer (Pearce Inc), 
equal amounts of protein were run on a 4-12% graduated SDS gel.  
 
Membranes were probed with specific polyclonal antibodies for phosphorylated ERK1/2. 
Incubation with EPO caused increased phosphorylation of ERK 1/2 which was maximal at 
15 minutes. The observed phosphorylation of ERK by EPO was completed abrogated by co-
incubation with the MEKK1 inhibitor UO126. 
 
Membranes were also probed with specific polyclonal antibodies for serine-473 
phosphorylated AKT. Membranes were stripped and re-probed for total AKT. Incubation 
with EPO caused increased serine phosphorylation of AKT which was maximal at 60 
minutes. The observed phosphorylation of AKT by EPO was completed abrogated by co-
incubation with LY294002, confirming the role of PI-3 Kinase. AG490, a JAK2 inhibitor, 
also reduced the phosphorylation of AKT by EPO at 60 minutes. This confirms the 
dependence of EPO signalling pathways on JAK2 activity. 
 
The previous experiment demonstrated that AG490, an inhibitor of JAK2 kinase activity, 
reduced the phosphorylation of AKT in response to EPO stimulation in HK-2 cells. In order 
to confirm this finding was due to the inhibition of EPO-R / JAK2 interaction, a similar 
experiment was performed 24 hours following transfection of JAK2 siRNA, according to 
established protocol described in 3.3.2.2. Inhibition of JAK2 expression completely 
abrogated the phosphorylation of AKT following EPO stimulation (Figure 2.9) 
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Figure 2.7 Immunoblot for Phospho-ERK 1/2 
Serum-starved cells were stimulated with EPO for 5-15 minutes and then scraped on ice and 
underwent protein extraction. Immunoblots with a specific primary antibody for phospho-
ERK were performed. (Figure is presentative of three separate experiments). Inhibiting 
MEK1 with pre-administration of UO126 markedly reduced ERK phosphorylation by EPO.  
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Figure 2.8 AKT activation by EPO 
Immunoblots for phospho-AKT (serine 478) in HK-2 cells stimulated with EPO for 30-60 
minutes. Maximum band density was observed in cells stimulated for 60 minutes. This 
increase in phosphorylation was reduced by the addition of a JAK2 inhibitor, confirming the 
dependence of EPO-R signalling on JAK2 activity, and completely prevented by LY294002, 
a reversible inhibitor of PI3-kinase.
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Figure 2.9  Loss of AKT activation following inhibition of JAK2 expression  
AKT phosphorylation (serine 473) in response to EPO stimulation is prevented in cells 
transfected with JAK2 siRNA. All groups exposed to EPO 50 U/mL for 30 minutes. 
Representative blot shown from three separate experiments. 
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2.4.6 EPO attenuates Apoptosis following Serum Starvation 
 
Deprivation of FCS from the standard medium causes a progressive loss of cell viability 
over time in HK-2 cells. HK-2 cells were plated out in standard medium in 96-well plate. 
After 24 hr, the standard medium was removed, and 100 µL of phenol-red free medium was 
replaced without FCS except in control wells. EPO was added in a range of final 
concentrations to experimental groups. The cells were incubated in normal conditions for 30 
hrs and an MTS assay was performed. Serum deprivation caused a significant reduction in 
cell viability (P< 0.01). Dose-response experiments (EPO 1 -100 U/ mL) reversed the 
reduction in cell viability caused by 30 hrs incubation in serum-deprived conditions (EPO 1 
U/L P<0.01; EPO 10 P< 0.01; EPO 20 U/mL P< 0.001; EPO 50 U/mL, P< 0.001), shown in 
Figure 2.10.  
 
In parallel, extracted cell pellets from the end of experimental procedures were lysed in 
digitonin buffer and a DNA fragmentation ELISA was performed. Serum starvation induced 
a significant increase in DNA fragmentation (control 1.0 ± 0.1; starvation 1.93 ± 0.48, 
P<0.01). EPO treatment reduced the increase in DNA fragmentation (+ EPO 1.13 ± 0.33, 
P<0.05), shown in Figure 2.11.  The lysates in which DNA fragmentation was measured 
were also used to examine the expression of proteins that regulate apoptotic signalling by 
immunoblotting. Serum starvation for 24 hrs was associated with a reduction in the 
expression of anti-apoptotic proteins XIAP and Bcl-XL. EPO treatment was associated with 
increased expression of XIAP and Bcl-XL. Representative blots from these experiments are 
shown in Figure 2.12. 
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Figure 2.10    Cell viability following serum starvation with different concentrations of 
EPO was measured by MTS assay. At 30 hours, MTS values for treatment groups were 
expressed relative to cells exposed to serum starvation. Groups were compared by 
ANOVA. 
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Figure 2.11 EPO reduces serum deprivation induced DNA fragmentation, 
measured by ELISA. Values for three experiments were expressed relative to control 
cells cultured with standard FCS. EPO significantly reduced DNA fragmentation 
(P<0.01 by ANOVA). 
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Figure 2.12 EPO maintains expression of XIAP and Bcl-XL 
Western blots on lysates from cells deprived of serum for 24 hours and cells deprived of 
serum for 24 hrs treated with EPO (50 IU/mL) were probed with primary antibodies for 
XIAP and Bcl-XL. Serum starvation reduced the expression of both anti-apoptotic proteins, 
but administration of EPO caused maintenance of expression associated with a reduction in 
apoptotic cell death. 
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2.5 Discussion 
 
The data presented in this chapter demonstrate the signalling processes initiated by the 
engagement of EPO with its cell surface receptor in human proximal tubular epithelial cells. 
The presence of the receptor on the particular cell line studied in these experiments was 
confirmed by the presence of an appropriately-sized strong band by immunoblotting, and 
also, independently, by the observation that knockdown of EPO-R expression by RNA 
interference completely abrogated the cellular response previously observed upon EPO 
stimulation. 
  
Two bands were observed in the western blot for the EPO-R, at 59 and 68 kDA 
approximately. The 68-kDa band was similar in size to that observed from the erythroblastic 
cell line UT-7, known to highly express the EPO-R. There has been some debate concerning 
the size of the human EPO-R protein, which undergoes post-translational modification. 
Westenfelder et al, using the same commercial antibody, detected two EPO-R 
immunoreactive proteins in murine proximal tubular cells of approximately 68 and 90 kDa, 
respectively, and the 68 kDa protein was not observed in non-anaemic murine spleen 
suggesting that this represented the EPO-R [Westenfelder C, 1999]. The cloned murine 
EPO-R cDNA encodes a 55 kDa polypeptide, and the EPO-R is post-translationally 
modified by N-linked glycosylayion and phosphorylation, increasing its mass to 
approximately 76 kDa [Sawyer ST, 1993]. 
 
The ability of EPO-R siRNA to reduce intracellular signalling molecules and abrogate cell 
proliferation in the experiments described is strong evidence that these cells express a 
functional EPO-R. Recently, the specificity of the EPO-R antibody used in these 
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experiments has been questioned [Elliot S, 2006], as a dominant band at approximately 70 
kDa was observed in cells which do not express the EPO-R, and the observed band could be 
abrogated by knockdown of HSP70 expression by RNA interference. Further studies have 
confirmed that the C-20 antibody does identify the EPO-R, but may show cross-reactivity 
with other proteins. EPO-R expression should be confirmed by either mRNA studies or 
functional studies with RNA interference, as was performed in these experiments [Verdner 
F, 2005]. The development of more specific commercial antibodies against the EPO-R is 
urgently required. 
 
The described experiments demonstrated that EPO did have direct effects on the 
proliferation and survival of tubular cells in a cellular injury model. The protection from 
injury afforded by EPO in proximal tubule epithelial cells was dependent on the activation of 
EPO-receptor induced signalling. In neuronal cells, studies utilizing soluble EPO receptors 
and anti-EPO antibodies as competitive inhibitors of EPO receptor activation have 
confirmed that the effects of EPO in vitro are mediated via the EPO receptor [Ruscher K, 
2002]. However, the recent development of a carbamylated erythropoietin molecule, CEPO, 
that does not stimulate erythropoiesis but retain a neuronal protective capacity, has 
questioned the uniqueness of the erythropoietin/ erythropoietin receptor interaction [Leist M, 
2004]. These authors have suggested that EPO signalling in neuronal cells may be mediated 
through the interaction between the EPO receptor and a common 
 
-subunit heteroreceptor 
[Brines M, 2004], although this observation has yet to be confirmed, and EPO retains its 
anti-apoptotic properties in cell lines that do not express the common 
 
-subunit 
heteroreceptor [Um M, 2007]. 
 
Activation of JAK2 by EPO has been shown, in endothelial cells and neuronal cells, to lead 
to the activation of phosphatidylinositol-3 kinase (PI 3-kinase) and Akt phosphorylation. 
Once activated, Akt activates multiple targets with anti-apoptotic effects, including 
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phosphorylation of Bad, Bax, caspase-9 and GSK-3
 
, maintenance of mitochondrial 
membrane potential and preservation of glycolysis and ATP synthesis. Inhibition of PI 3-
kinase inhibited the specific serine-473 phosphorylation of AKT induced by EPO. 
Therefore, one major mechanism by which EPO protects proximal tubule cells against injury 
is through the induction the EPO receptor-dependent activation of PI 3-kinase leading to 
phosphorylation and activation of its target Akt, and subsequent downstream pathways. 
 
EPO inhibits apoptotic cell death in proximal tubule epithelial cells (as determined by DNA-
fragmentation assay), and in higher doses, causes significant proliferation even in serum-free 
conditions. EPO administration was associated with the up-regulation of Bcl-XL and XIAP. 
Bcl-XL, a member of the B cell lymphoma-2 family, has been shown to determine resistance 
to hypoxic insults in vitro [Dong Z, 2003]. Taken together, these in vitro findings support the 
conclusion that EPO directly protects proximal tubule epithelial cells by (i) binding to the  
EPO receptor and inducing JAK-2 kinase activity, (ii) with PI3K leading to phosphorylation 
of Akt and its downstream mediators, and (iii) up-regulation of a series of anti-apoptotic 
proteins including Bcl-XL and XIAP. These experiments have demonstrated that EPO is 
functional in human proximal tubule cells, and led to the hypothesis that EPO would reduce 
tubular cell death in an animal model of kidney injury. 
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Chapter Three: 
 Effect of Erythropoietin Administration on a  
Short term model of ischaemia reperfusion in the rat 
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3.1  Introduction  
 
 
As discussed in section 1.2, the outcome of AKI is a function of the interaction of multiple 
cell types in the tubular and vascular compartments of the kidney that must ultimately be 
understood at the whole tissue level, and is not predictable from the study of the behaviour of 
a single cell type. 
This complexity necessitates an approach utilizing whole animal studies to unravel the 
mechanisms of injury and develop therapeutic modalities. This has led to the development of 
"single insult" models of renal injury induced by ischaemia, toxins and radiocontrast agents. 
An established animal model of ischaemia-reperfusion injury, which as far as possible 
mimics the type of renal injury observed in clinical medicine, in particular kidney 
transplantation, has been developed in the laboratory. This short-term model of ischaemia-
reperfusion injury in the rat has been intimately characterised and is highly reproducible 
[Williams P, 1997; Chatterjee PK, 2003]. 
This model of bilateral renal artery occlusion in the rat is characterized histologically by 
widespread necrosis of proximal tubules, the distribution and extent of which vary with the 
ischaemic interval. The distal nephron is less affected, with mild damage in thick limbs of 
the loops of Henle and focal apoptosis rather than widespread necrosis in the distal 
convoluted tubules and collecting ducts. The S3 segment of the proximal tubule, which has 
the lowest oxygen tension in health, is most severely affected with between 20-90% of these 
segments showing lethal injury [Shanley PF, 1985]. In human AKI, morphological injury is 
usually more subtle and focal, affecting both proximal and distal tubules, although 
comprehensive biopsy series from patients with ischaemic AKI are lacking [Rosen S, 2008].  
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However, there are some important similarities between the rat model of ischemia and 
human AKI, with loss of the brush border, a predilection for the most severe injury to occur 
in the proximal straight tubules (S3 segments), prominent apoptotic cell death in the early 
phase, and the presence of luminal cast formation. Functional similarities between human 
ischaemic AKI and the renal artery occlusion model of AKI include the severe reduction in 
GFR and the reversibility, in most cases, of tubular injury with recovery of renal function.  
 
3.2 Aims 
 
The aim of this study was to determine whether EPO would have a protective effect in a 
model of ischaemia reperfusion injury in the kidney, an organ which is prone to ischaemic 
damage, and which expresses the EPO-receptor [Westenfelder C, 1999]. EPO had been used 
in a study in the management of anaemia in AKI in rats. Although there was no benefit in 
that study with regard renal function, mortality was significantly lower in the EPO treated 
animals [Nemato T, 2001]. 
 
A protocol of bolus administration of a single dose of EPO was devised from the design of 
studies of EPO cellular protection in models of cerebral ischaemic injury [Sakanaka S, 
1998]. The aims of the experiment were to discover the biochemical and histological effects 
of EPO in an in vivo setting, and whether EPO was effective if administered at different 
timings relative to the initiation of tissue reperfusion. 
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3.3 Methods 
 
 
3.3.1 In vivo rat model of ischaemia reperfusion (Short term)  
 
Male Wistar rats (200-300g) were used in this procedure. Rats were kept in normal day/ 
night conditions and receive standard chow and water ad libitum. The protocol described has 
been approved by the U.K. Home Office and the care and use of animals is in accordance 
with the Guidelines in the Operation of the Animals (Scientific Procedures) Act 1986. 
 
All rats were anesthetised with sodium thiopentone (Intraval Sodium, 85 mg/kg i.p; Rhone 
Merieux Ltd., Essex, U.K.) and anaesthesia was maintained by supplementary infusions of 
sodium thiopentone. The fully anaesthetised rat is placed, on its back, onto a thermostatically 
controlled heating mat (Harvard Apparatus Ltd, Kent, UK) and body temperature was 
maintained at 38±1oC by means of a rectal probe attached to a homeothermic blanket. A 
tracheotomy was performed to maintain airway patency and to facilitate spontaneous 
respiration. The right carotid artery was cannulated (PP50, I.D. 0.58mm, Portex, Kent, U.K.) 
and connected to a pressure transducer (Senso-Nor 840, Horten, Norway) for the 
measurement of mean arterial blood pressure (MAP) and derivation of the heart rate (HR) 
from the pulse waveform. The right jugular vein was cannulated (PP25, I.D. 0.40mm; 
Portex) for the administration of drugs. A midline laparotomy was performed and the 
bladder was cannulated (PP90, I.D. 0.76mm; Portex). 0.5 mL of normal saline was 
administered via the venous line to replace lost fluid. The venous line was connected to a 
constant-rate infuser pump and saline administered at a rate of 8 mL/Kg/ hr throughout the 
experimental period. 
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Animals were allowed to stabilize for 30 minutes after completion of preparatory surgery. 
Using a cotton bud to carefully move away the spleen and small intestine on the right hand 
side of the abdomen, the right kidney and the pedicle (containing renal artery and vein) was 
exposed. The pedicle was isolated and clamped using a Differenbach’s bulldog artery clip. 
The intestine is replaced and the left kidney isolated and the pedicle clamped in the same 
way. Occlusion was verified visually by a change in the colour of the kidney to a paler shade 
and then to a darker (cyanotic) colour within minutes. The intestine was replaced into the 
peritoneum and the peritoneum closed with a small clip and covered with saline-soaked 
gauze. A total ischaemia time of 45 minutes was used for all experiments. The kidneys were 
carefully exposed, and the artery clamps removed with the aid of forceps to prevent tearing 
or localised injury to the renal pedicle. Reperfusion was confirmed by an immediate colour 
change in the kidney. The peritoneum was closed with a small clip and covered with saline-
soaked gauze.  
 
 
3.3.2 Biochemical analysis 
 
At the end of the reperfusion period (6 hrs in all groups unless stated), blood (1 mL) samples 
were collected via the carotid artery into tubes containing serum gel. The samples were 
centrifuged (6000 g for 3 minutes) to separate the serum from which biochemical 
parameters, including creatinine, sodium and asparate transaminase (AST), a marker of 
tubular injury, were measured. All serum samples were analyzed within 24 hours of 
collection (Vetlab Services, Sussex, UK). Urine was collected throughout the reperfusion 
period and the volume recorded. Activity of urinary N-acetyl-β-D-glucosaminidase (NAG), 
a specific indicator of tubular damage [Bosomworth MP, 1999; Kotanko P, 2000] was also 
measured on snap frozen urine aliquots, performed by Dr Joaquim Chaves at the Clinica 
Medica e Diagnostico, Lisbon, Portugal. 
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3.3.3 Histological Evaluation 
 
Kidneys were removed from rats at the end of the experimental period and were cut in 
sagittal section into two halves, which were fixed in immersion in 10% (wt/ vol) 
formaldehyde in phosphate buffered saline (PBS; 0.01M; pH 7.4) at room temperature for 24 
hours. After dehydration using graded ethanol, pieces of kidney were embedded in Paraplast 
(Sherwood Medical, Mahwah, NJ) and cut in fine (8 µm) sections and mounted on glass 
slides. Sections were then deparaffinized with xylene, counterstained with hematoxylin and 
eosin, and viewed under a light microscope (Dialux 22, Leitz, Milan, Italy).  
 
100 intersections were examined for each kidney and score from 0-3 was given for each 
tubular profile: 0 normal histology; 1, tubular cell swelling, brush border loss and nuclear 
condensation with up to 1/3 nuclear loss; 2, as for score 1, but greater than 1/3 and less than 
2/3 tubular profiles showing nuclear loss; and 3, greater than 2/3 tubular profile shows 
nuclear loss. The histological score for each kidney was calculated by addition of all scores 
with a maximum score of 300, by two blinded histopathologists [Chatterjee PK, 2000]. 
Deparaffinized sections were also used for immunohistochemical analysis. Sections were 
incubated overnight with primary anti-caspase-3 antibody (1 in 10,000) in blocking buffer. 
After washing, secondary antibody was added for 30 minutes at 25˚C, followed by washing. 
A HRP containing buffer was added for a further 30 minute incubation before the slides 
were counterstained with haematoxylin, dehydrated and mounted for review by a blinded 
pathologist and the author. 
 
In addition randomly picked sections were quantitatively assessed for apoptotic nuclei, and 
graded for severity, extent of nuclear changes, and the presence of nuclear debris and 
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apoptotic blobs. These were scored by a blinded pathologist and the author for three high-
powered fields per animal. 
3.3.4 Preparation of tissue Homeogenate for protein Analysis 
 
Sections of experimental kidneys that had been snap-frozen in liquid nitrogen immediately 
after dissection, were weighed and approximately equal tissue samples by weight were used 
for homogenisation. The tissue block was cut into small pieces and placed in a sterile glass 
tissue homogeniser. 
 
Buffer containing 25 mmol/L EDTA,  20 mmol/L EGTA, 10 mmol/L sodium hydroxide (pH 
7.3) and Imidazole: HCl buffer containing 10 mmol/L mercaptoethanol (pH 7.3) was added 
according to dry tissue weight (1 mL / 250 mg tissue) and the tissue was homogenised with 
twenty equal strokes of the glass rod over 2 minutes. The suspension was aspirated by 
pipette into an eppendorff tube and then the samples were centrifuged at 14000g for 15 min 
at 4˚C. The resulting supernatant was aspirated into pre-chilled 1 mL Eppendorff tubes. Each 
sample was aliquotted into several tubes to avoid repeated thaw/ freeze cycles, and samples 
were kept on ice throughout the procedure. 
 
3.3.5 End-point Caspase Activity Assay 
 
The activity of caspase-3 was measured using the substrate Ac-DEVD linked to a 
fluorogenic 7-amino, 4-methylcoumarin (AMC) molecule. For in vivo experiments, frozen 
samples of harvested kidneys were washed in ice-cold PBS, and homogenized in ice-cold 
buffer containing 25 mmol/L EDTA, 20 mmol/L EGTA, 63.2 mmol/ L imadazole-HCl, 10 
mmol/L 2-mercaptoethanol (pH 7.3). After centrifugation at 16000g for 15 minutes at 4˚C, 
the supernatant was aspirated and the amount of protein quantified using the BCA assay. 
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50   g cellular protein was incubated with 50 µM substrate in caspase assay buffer (213.5 
mM HEPES, pH 7.5, 31.25% sucrose, and 0.3125% CHAPS) for 1 hour, and fluorescence 
was measured on a microplate reader (Fluostar Galaxy, BMG Laboratory Technologies, 
Aylesbury, UK), with excitation at 380 nm and emission set at 460 nm. For each sample, 
four replicates were assayed, with two replicates containing 50 µM of the caspase-3 inhibitor 
(Ac-DEVD-CHO), and the remaining pair of replicates containing similar volume of vehicle 
(DMSO).  
 
The activities of caspase-8 and caspase-9 were determined in the same way, using  
 
Caspase 8: substrate Ac-IETD-AMC   inhibitor: Ac-IETD-CHO 
Caspase 9: substrate Ac-LEHD-AFC     inhibitor: Ac-LEHD-CHO 
 
Fluorescence readings from wells containing inhibitor were subtracted from total 
fluorescence, and results calculated as nmol AMC/ min/ per mg protein. 
 
 
 
3.3.6 Experimental Design 
 
 
The short term model of ischaemia reperfusion injury in the anaesthetised rat was used for 
all experiments described in this chapter. Experimental design was as below: 
 
(1) Sham-operated rats (n=8) 
(2) Sham-operated rats, EPO 300 U/Kg administered 30 minutes prior to sham clipping 
(n=8) 
(3) Ischaemia-reperfusion (I/R) , animals subjected to 45 minutes bilateral renal pedicle 
clamping, followed by 6 hours reperfusion. (n=12) 
(4) I/R, EPO administered 30 minutes prior to bilateral renal pedicle clamping. (n=12) 
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(5) I/R, EPO administered 5 minutes prior to reperfusion. (n=13) 
(6) I/R, EPO administered 30 minutes into the reperfusion period. (n=12). 
3.4 Results 
 
3.4.1  Effect of Ischaemia reperfusion and EPO on Haemodynamic Parameters  
 
Continuous arterial blood pressure was recorded throughout the experimental process in all 
animals. Hourly mean blood pressure was calculated for all experimental groups to 
determine whether EPO had any adverse or beneficial effect on haemodynamic parameters. 
 
Resting mean arterial blood pressure in all experimental groups after stabilization was 130-
140 mm Hg (P=ns). There was no significant effect on EPO administration on mean arterial 
blood pressure in sham operated animals. Ischemia reperfusion was associated with a non-
significant fall in blood pressure in early reperfusion (Figure 3.1). When comparing each 
group as a series of BP measurements, there was no significant difference between I/R and 
EPO treated animals (ANOVA with bonferrari). 
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Figure 3.1 Mean arterial Blood Pressure during the Experimental Period in all 
experiments groups. Mean BP was calculated from the arterial pressure trasducer 
measurements and recorded every 30 minutes. Mean BP over the whole experimental 
period was similar in all groups (P=ns, ANOVA). 
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3.4.2 Effect of EPO on Renal Dysfunction caused by I/R 
 
Routine biochemical parameters of kidney function were analysed in all experimental 
groups, including serum and urine creatinine and sodium. In comparison with sham animals, 
45 minutes of ischaemia led to significant increases in serum, urinary and histological 
markers of renal dysfunction and injury after 6 hours reperfusion. 
 
Administration of EPO to sham-operated animals did not have any effect on markers of renal 
function despite an increase in urine flow rate (Figure 3.4). Rats that underwent renal I/R 
exhibited significant increases in the serum concentrations of creatinine compared with 
sham-operated animals (serum creatinine: sham 53 ± 2 µmol/L; I/R 217 ± 7, P<0.001) 
(figure 3.2) and decreases in urine flow (sham animals 0.01 ± 0.0001 mL/hr; I/R 0.006 ± 
0.001, P<0.001) (figure 3.3) and creatinine clearance (sham animals 1.3 ± 0.1 mL/min; I/R 
0.053 ± 0.016, P<0.001) (figure 3.4), suggesting a significant degree of glomerular 
dysfunction. 
 
In comparison with I/R animals, the administration of a single intravenous bolus of EPO 
(300 U/ kg), either pre-ischemia or just prior to the onset of reperfusion, produced a 
significant reduction in serum levels of creatinine (EPO pre I 144 ± 6; EPO post R 143 ± 7; 
EPO late 183 ± 8; P<0.01) associated with maintenance of improved urine flow rate (EPO 
pre 0.022 ± 0.002; EPO post R 0.02 ± 0.002; EPO late 0.01 ± 0.007, P<0.01) and creatinine 
clearance (EPO pre I 0.28 ± 0.05, EPO post-R 0.31 ± 0.05, P<0.01). EPO administration 30 
minutes after the onset of reperfusion still afforded renoprotection by attenuating the fall in 
glomerular filtration rate, and hence calculated creatinine clearance (figure 3.4). 
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Figure 3.2 Serum Creatinine after six hours Reperfusion in all experimental 
groups. Creatinine in the I/R group was compared with all treatment groups by 
ANOVA. 
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Figure 3.3 Urine Flow rates following Ischaemia-Reperfusion were measured in all 
experimental groups. When compared with I/R injury, urine flow was significantly 
maintained in EPO treated animals (P<0.01 by ANOVA). 
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Figure 3.4 Calculated Creatinine Clearance following Reperfusion was calculated 
from urinary creatinine and urine flow in all experimental groups. Effect of treatment 
with EPO was compared against I/R by ANOVA. Pre-treatment and Pre-reperfusion 
treatment significantly maintained creatinine clearance (P>0.05 by ANOVA). 
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3.4.3 Effect of EPO on Biomarkers of Ischaemia-Reperfusion induced Tubular Injury 
 
In comparison with values obtained from sham-operated animals, renal I/R produced a 
significant increase in urinary N-acetyl-
 
-D-glucosaminidase (NAG) activity (sham 8 ±2, 
I/R 22.7 ± 5.6, P<0.05), a specific marker of tubular dysfunction, corrected for urine 
volume.  Serum concentrations of the enzyme asparate transamininase (AST) was analysed 
as a marker of tubular injury induced by reperfusion [Chatterjee PK, 2000]. Fractional 
excretion of sodium, as a quantitative marker of tubular function was calculated from the 
formula:  
 
 FENa (%) = uNa [   mol/ L] x urine flow [mL/ min]/ CCL [mL/min] x sNa [   mol/ L] x 100), 
 
I/R injury significantly increased sodium excretion (sham 1.3 ± 0.18 %; I/R 19.9 ± 5.9, 
P<0.01), demonstrating a reduction in tubular conservation of sodium. EPO administration 
was associated with a significant reduction in urinary NAG activity (sham 8 ± 2, I/R 22 ± 
5.6, EPO pre 9.9 ± 3.0, EPO post 7.9 ± 0.8, P<0.01), shown in Figure 3.5, and preservation 
of tubular function, measured by maintenance of sodium excretion (EPO pre-reperfusion 7 ± 
0.5 %, P<0.05) shown in figure 3.6. There was insufficient sample to measure sodium 
excretin in the EPO late (30 mins) group. 
 
Renal I/R also produced a significant increase in serum AST (sham 200 ± 30, I/R 1864 ± 
232, P<0.01). Administration of EPO caused a significant reduction in serum AST levels 
(EPO pre 522 ± 40, EPO post 607 ± 64, EPO late 1130 ± 177, P<0.01), shown in Figure 3.7, 
suggesting a marked reduction in tubular injury and hence preserved tubular function post 
reperfusion-injury. 
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Figure 3.5 Tubular injury measured by urinary NAG concentration following 
renal I/R injury in the rat. Measurements were corrected to urine volume. Treatment 
groups were compared to I/R by ANOVA. EPO treatment was associated with 
significantly lower urine NAG (P<0.001 by ANOVA). 
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Figure 3.6 Tubular Functional reserve by Fractional Sodium Excretion following 
Reperfusion Injury. When compared with I/R injury, there was a significant decrease 
in the change in sodium excretion in EPO treated animals (P<0.05 by ANOVA).
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Figure 3.7 AST, a marker of Tubular Reperfusion Injury at Six Hours in all 
Experimental Groups. Comparision with I/R injury, by ANOVA, showed a significant 
reduction in tubular injury with early EPO treatment (P<0.01 by ANOVA). 
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3.4.4 Effects of EPO on Histological Alterations Caused by Renal I/R 
 
Renal I/R caused marked alterations in renal histology when compared with kidneys taken 
from sham-operated animals. Specifically, this included widespread degeneration of tubular 
architecture, tubular dilatation, cell swelling and necrosis, luminal congestion with loss of 
brush border and infiltration of polymorphonuclear neutrophils (PMNs) (Figure 3.7 A and 
B). In contrast, renal sections obtained from animals treated with EPO pre ischaemia, or pre-
reperfusion, demonstrated marked reduction of the histological features of renal injury. EPO 
administration 30 minutes after the onset of reperfusion was still associated with a 
significant reduction in injury, but this reduction was less marked than in the other treatment 
groups (Figure 3.7 C and D). Scoring of histological changes is shown in Figure 3.9. 
 
Initially, TUNEL staining was attempted to gain a qualitative score for apoptotic cell death. 
Unfortunately, there was very high background staining which did not allow adequate 
discrimination of positive staining. In view of this, proximal tubular cell apoptosis was 
examined on serial sections under high power field, randomly selected by a blinded 
pathologist and then scored by the author and the pathologist and scores combined. 
 
Kidneys from animals subjected to renal I/R showed extensive nuclear changes consistent 
with apoptotic cell death (Figure 3.10). In comparison, kidneys from sham-operated animals 
had no evidence of apoptosis. EPO administration prior to ischaemia, and pre-reperfusion 
significantly reduced the extent of apoptotic cell death (p<0.05). EPO administration 30 
minutes after the onset of reperfusion caused only a small reduction in the number of 
apoptotic cells, but there was a reduction in the incidence of necrotic cell death.  
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Figure 4.8 Histological Assessment of Renal Injury 
 
Kidney sections taken from:  
 
(A) sham operated rat  
(B) renal ischemia-reperfusion. Renal sections from a rat subjected to renal I/R after 
administration of  
(C) EPO pre-ischemia (30 min), and  
(D) EPO post reperfusion (30 min)  
Haematoxylin and eosin-stained kidney sections (magnification x150). 
Figures are representative of at least three animals (n=5 for all groups).  
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Figure 3.9 Histological assessment of Renal Injury following Reperfusion (method 
described in section 3.3.3). Scores for treatment groups were compared with I/R by 
ANOVA. 
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Figure 3.10. Quantitative scoring of apoptotic nuclei in high-powered fields was used to 
determine the extent of apoptotic cell death. Measurements were combined from the 
author and a blinded pathologist. Four fields were examined for each specimen, and an 
average score taken. Scores were analysed by ANOVA. 
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3.4.5 Effect of EPO on Caspase-3 activity in vivo 
 
Animals subjected to ischaemia reperfusion were sacrificed during the reperfusion period 
after two, four and six hours respectively. Kidney tissue was harvested and then snap-frozen 
in liquid nitrogen. Tissue samples (n=6) for each group were homogenised and caspase 
activity measured. When compared to immediately pre-reperfusion, there was a significant 
time-dependent increase in caspase-3 activity (0hr 118 ± 28, 4 hr 239 ± 21 P<0.01, 6 hr 282 
± 40 P<0.001), shown in figure 3.11.  
 
Caspase-3 activity (nmol/ min/ mg total protein at 37ºC) was significantly increased in the 
homogenates of kidneys at 6 hours in kidneys subjected to renal I/R, when compared with 
sham-operated animals (p<0.01). The elevation in caspase-3 activity was significantly 
reduced by EPO administration, both pre-ischaemia (p<0.05) or just prior to reperfusion 
(p<0.05). EPO treatment 30 min after reperfusion was associated with a non-significant 
reduction in caspase-3 activity, consistent with the higher levels of apoptosis observed in 
these kidneys (figure 3.12).  
 
Immunohistochemical staining, described in 3.3.3, using a specific antibody to the cleaved 
active fragment of caspase-3 confirmed these observations. There was widespread positive 
cytoplasmic and perinuclear staining in both cortical and medullary tubules following I/R 
(Figure 3.13 B, representative image (n=4 for all groups)), when compared to sham animals 
(Figure 3.13 A). The severity and distribution of staining was greatly reduced in animals 
receiving EPO either pre-ischemia (Figure 3.13 C) or pre-reperfusion, but only partially 
when EPO was administered later in reperfusion (Figure 3.13 D).  
 
 
 
 120 
 
 
 
 
 
Re
pe
rfu
sio
n
+ 
2 h
rs
+ 
4 h
ou
rs
+ 
6 H
ou
rs
0
100
200
300
400
Ca
sp
as
e 
3 
ac
tiv
ity
/ m
g 
pr
o
te
in
P<0.01
P<0.01
 
 
Figure 3.11 Time course of Caspase-3 activity following reperfusion from kidneys 
snap-frozen at time points after reperfusion. Six kidneys were analysed for caspase 
activity for each time point. There was a significant increase in caspase-3 activity in 
later time points (P<0.01 by ANOVA). 
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Figure 3.12 Tissue Caspase Activity following Six hours reperfusion in all 
Experimental groups. Kidneys from each group (n=6) were homogenised and caspase-3 
activity measured. EPO treatment caused a significant decrease in caspase-3 activity at 
six hours (P<0.01 by ANOVA).  
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Figure 3.13 Immunohistochemistry for active caspase-3 in Representative 
Specimens in Experimental Groups – a. Sham, b. I/R, c. EPO pre-ischaemia, and d. 
EPO re-reperfusion (representative image from n=5 kidneys each group). Arrow shows 
cytoplasmic positive caspase-3 fragments in proximal tubule. 
 
a
b
c
d
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3.4.6 Effect of EPO on Caspase-9 and Caspase-8 activity in vivo 
 
Having demonstrated that apoptotic cell death was reduced, and that this was mirrored by a 
significant decrease in the activation of the executioner caspase-3, the relative contributions 
of the extrinsic and intrinsic (mitochondrial) pathways in the activation of caspases-3 were 
examined. Both pathways have been shown to participate in ischaemia-reperfusion injury. 
Caspase-8 and caspase-9 activity was assayed in tissue homogenates from all experimental 
groups. 
 
Following I/R, activity of caspase-9 was significantly increased when compared to sham-
operated animals (sham 218 ± 20, I/R 300 ± 21, P<0.01). The increase caspase-9 was 
attenuated by EPO treatment (EPO pre-reperfusion 230 ± 7, P<0.05), shown in Figure 3.14. 
 
When compared sham-operated animals, ischaemia reperfusion caused an increase in the 
activity of caspase-8 at six hours (sham 38 ± 5, I/R 144 ± 48, P<0.01). Treatment with EPO 
as a pre-treatment, or just prior to reperfusion significantly reduced the increase observed 
(EPO pre-ischaemia 48 ± 17, P<0.01; EPO pre-reperfusion 56 ± 38, P<0.01), shown in 
Figure 3.15. 
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Figure 3.14 Caspase 9 Activity in kidney tissue homogenates following I/R injury 
was analysed as described in 3.3.5. EPO treatment was associated with significantly 
lower caspase-9 activity following I/R (P<0.05 by ANOVA). 
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Figure 3.15 Caspase-8 Activity in kidney tissue homogenates following I/R injury 
showed a reduction in activity in EPO treated animals when compared to I/R (P<0.05 
by ANOVA). 
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3.5 Discussion 
 
Following from the results in chapter two, which showed direct effects of EPO on tubular 
epithelial cells in culture, the studies described in this chapter demonstrate that recombinant 
human EPO is able to reduce the degree of injury in the kidney following ischaemia-
reperfusion (I/R) injury.  
 
EPO reduced both the glomerular and tubular injury and dysfunction, assessed by both 
biochemical and histological parameters, caused by severe bilateral renal ischaemia and 
reperfusion in the rat. EPO reduced I/R injury when administered as a single intravenous 
bolus injection, either prior to the onset of ischaemia (30 min pre-treatment) or when given 
immediately before release of clamps (pre-reperfusion). Most notably for its potential use as 
a therapeutic agent in clinical settings, EPO even partially protected kidney function against 
I/R injury when given 30 min after the onset of reperfusion, although there was more severe 
histological damage and more apoptotic cells. 
 
The degree and extent of injury induced by ischaemia in control animals in this model was 
consistent with previously published work [Chatterjee PK, 2000]. Morphological studies 
have clearly demonstrated the existence of both necrosis and apoptosis in animal models of 
AKI [Rana A, 2001], and there is recognition of the importance of apoptosis in the initiation 
phase of renal injury, and the presence of apoptotic tubular epithelial cells has been 
demonstrated in kidneys of humans with ischaemic AKI [Castaneda MP, 2003]. Chemical 
inhibition of the caspase cascade has been shown to protect the kidney in a similar model of 
ischaemia-reperfusion in the mouse [Daemen MA, 1999]. The reduction in renal injury by 
EPO was associated with a significant decrease in the number of apoptotic tubular epithelial 
cells, and a reduction in caspase-3 activity, which suggest that EPO may partially mediate its 
effects by acting directly on tubular epithelial cell resistance to cell death through the up-
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regulation of anti-apoptotic mechanisms. The use of immunohistochemical techniques to 
determine tubular localisation of the active fragment of caspase-3 was good specific 
evidence to confirm the quantitative assessment of tubular apoptosis used in the absence of 
TUNEL staining. There was also a reduction in the activities of caspase-8 and caspase-9 at 
six hours post-reperfusion. I/R causes the upregulation of inflammatory cytokines including 
TNF-   which lead to cell death through the receptor-mediated caspase-8 pathway. A 
reduction in cell death and hence a reduction in inflammation and cytokine release following 
EPO treatment may limit the pathways that induce further apoptosis by preventing cytokine-
dependent amphification of cellular injury. 
 
A number of potential beneficial effects of EPO in the kidney may account for the organ 
protection observed, which may not require direct effects on tubular cell death. An increase 
in renal blood flow might contribute to or even account for the observed protective effects of 
EPO. This is, however, unlikely, as there was no significant haemodynamic effect of acute 
administration of EPO on the systemic circulation. Although EPO increased urine flow rate 
in sham-operated rats, suggestive of a possible effect on cortical perfusion and intra-
glomerular pressure, creatinine clearances were similar between the sham operated groups, 
and there was no difference in tubular function measured by fractional sodium excretion 
induced by EPO in sham animals. This observation is consistent with the study by Huang et 
al, which demonstrated no immediate effect on isolated cortical and papillary perfusion in 
normal rats following acute EPO administration [Huang C, 1992]. 
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Chapter Four: 
 Effect of Erythropoietin Administration on Recovery Models of 
Ischaemia-Reperfusion Injury 
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4.1  Introduction  
 
 
The experiments described in chapter three showed that EPO given at the time of 
reperfusion, or as an immediate pre-treatment 30 minutes before ischaemia, was effective in 
attenuating the degree of renal injury observed at six hours. In this model, the extent of 
injury at six hours is predictive of the maximum renal dysfunction at 24 hours, and the 
natural history of the model shows progressive recovery of function after 24 hours, although 
histological recovery occurs more slowly with the development of fibrosis [Williams P, 
1997].  
 
It was recognized in 1986 that brief periods of ischaemia render an organ resistant to 
subsequent more prolonged ischaemic period, known as ischaemic preconditioning. Four 
cycles of five minutes of coronary artery occlusion prior to 40 minutes occlusion reduced 
infarction size by 75% [Murry CE, 1986]. This protective effect was lost when three hours 
occlusion was applied, reinforcing the vital need for timely reperfusion to limit damage. 
Ischaemic preconditioning offers two “windows” of protection in time - “early” or 
“classical” providing protection immediately after the preconditioning stimulus, and “late” 
or “delayed” preconditioning being effective for up to 24 hours. Activation of HIF-
dependent signaling pathways, including EPO, has been shown to play an important role in 
ischaemic preconditioning in the heart and kidney [Cai Z, 2003; Hill P, 2008]. Cobalt 
administration to rats, via up-regulation of HIF-dependent proteins including EPO, VEGF 
and haem-oxygenase-1 (HO-1), diminished the degree of renal injury caused by ischemia-
reperfusion [Matsumoto M, 2003].  
 
A pre-conditioning therapy would be attractive in clinical scenarios where renal dysfunction 
is predictable, such as cardiac surgery, repair of aortic aneurysm or organ transplantation. 
The mechanism of renal protection from pre-conditioning therapy is potentially different 
from that observed in the short term model with EPO administered at the time of 
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reperfusion. Preconditioning may allow the synthesis of new anti-apoptotic signalling 
molecules which mediate organ protection, and there is evidence that endogenous nitric 
oxide (NO), possibly derived from endothelial NO synthase, plays an important role in 
delayed conditioning [Bolli R, 1997]. When renal tubular epithelial cells are exposed to 
repeated hypoxic insults, a clone of more resistant cells are selected, which show increased 
expression of anti-apoptotic proteins, including Bcl-2 and particularly Bcl-XL [Brooks C, 
2007]. Induced Bcl-XL overexpression reduces apoptosis in animal model of ischaemia-
reperfusion [Chien CT, 2007], and the pre-conditioning expression of this anti-apoptotic 
pattern might be HIF-dependent [Chen N, 2008].  
 
 
4.2 Aims 
 
The aim of this study was to determine whether EPO would also have a protective effect in a 
longer, recovery model of ischaemia reperfusion injury in the kidney. The aims of the 
experiments were to confirm that the biochemical and histological effects of EPO observed 
in the early phase post-reperfusion, as described in chapter three, were still present during 
the maintenance and recovery phase of AKI. The recovery model also was used to determine 
the relative effects of a pre-conditioning regime during which EPO was administered for 3 
days before ischaemic injury. 
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4.3 Methods and Materials 
 
4.3.1 Recovery Model of Ischaemia Reperfusion in the anaethetised Rat 
 
When compared to the short-term model used in chapter three, the recovery model requires 
that the incision is closed and the animal recovers and survives during the period of 
experimentation. Experience in the laboratory had previously shown that the large 
abdominal wound used in the short term model was associated with wound breakdown and 
infection leading to reduced animal survival. A dorsal approach leaves a sutured wound that 
is virtually impossible for the animal to disrupt with its teeth or claws. Metallic surgical 
staples were used rather than sutures for closure of the skin incision to avoid any potential 
for loosening or cutting. 
 
Male Wistar rats (200-300g) were used in this procedure. Rats were kept in normal night/ 
day conditions and receive standard chow and water ad libitum. The protocol described has 
been approved by the U.K. Home Office and the care and use of animals is in accordance 
with the Guidelines in the Operation of the Animals (Scientific Procedures) Act 1986. 
Animals were anaesthetised with halothane, and placed on a sterile mat headed by an 
overhead lamp. Fur was shaved over the dorsal spine bilaterally, and an incision in the skin 
and fascia was made. The abdominal wall was identified and opened with a small (< 1.0 cm 
incision). Each kidney was identified and mobilised on its pedicle by blunt dissection of the 
peri-renal fat and connective tissue. Once fully mobilised, the renal pedicle was clamped 
with a Differenbach’s bulldog artery clip. Cessation of renal perfusion was confirmed by the 
development of colour change in the kidney. The kidney was replaced in the abdominal 
cavity, and the incision temporarily closed with a clamp. At 45 minutes, the kidney was 
mobilized and the clamp removed. Immediate “pinking-up” of the kidney confirmed 
adequate reperfusion. Animals were given 5 mls intrabdominal saline and subcutaneous 
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analgesia (pethidine). The abdominal wall incision was closed with interrupted sutures and 
the skin was closed with staples. Animals were placed in a cage under a heating lamp and 
observed until anaesthetic had worn completely off. Animals were anaethetized for terminal 
venesection, and then sacrificed at 24 hrs, 48 hrs and 72 hrs after the onset of reperfusion. 
 
4.3.2 Murine Model of ischaemia-reperfusion Injury 
 
Male C57BL/6J mice (Charles River, Milan, Italy) weighing 25 to 30 g were used to assess 
the role of EPO in the pathogenesis of renal I/R in the mouse. Mice were allowed access to 
food and water ad libitum and were cared for in compliance with Italian regulations on 
protection of animals used for experimental and other scientific purposes (D.M. 116192), as 
well as with the European Economic Community regulations (O.J. of E.C. L358/1 
12/18/1986). These experiments were performed with the technical assistance of Dr. N. 
Patel. 
 
Mice were anesthetized using chloral hydrate (125 mg/kg, intraperitoneally) and core body 
temperature maintained at 37°C using a homoeothermic blanket. Mice were maintained 
under anaesthesia for the duration of ischaemia (i.e., 30 minutes). After performing a 
midline laparotomy, mice in I/R groups were subjected to bilateral renal ischemia for 30 
minutes, during which the renal arteries and veins were occluded using microaneurysm 
clamps. The time of ischaemia chosen was based on that found to maximize reproducibility 
of renal functional impairment, while minimizing mortality in these animals. After the renal 
clamps were removed, the kidneys were observed for a further 5 minutes to ensure reflow 
after which 1 mL saline at 37°C was injected into the abdomen and the incision was sutured 
in two layers. Mice were then returned to their cages where they were allowed to recover 
from anaesthesia and observed for 24 hours. Sham-operated mice underwent identical 
surgical procedures to I/R mice except that microaneurysm clamps were not applied. 
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4.3.3  Experimental Design 
 
The recovery model of ischaemia reperfusion was performed in the following experimental 
groups: 
(1) Sham operated (n=8) 
(2) Ischaemia reperfusion (n=12) 
(3) Ischaemia reperfusion – administered EPO 1000 U/Kg at reperfusion (n=10) 
(4) Ischaemia reperfusion – administered EPO 1000U / Kg two hours post-reperfusion 
(n=8) 
 
Mice were divided into the following four groups in experiments involving the acute 
administration of EPO: 
(1) I/R group in which control mice underwent renal ischemia for 30 minutes followed by 
reperfusion for 24 hours (N = 11) 
(2) I/R EPO prereperfusion group included mice that were administered EPO (1000 IU/kg 
subcutaneously bolus) 5 minutes prior to reperfusion (N = 10) 
(3) sham group were sham-operated mice, which were subjected to the surgical procedures 
described above, but were not subjected to renal I/R (N = 4) 
(4) sham EPO prereperfusion group were mice that were treated identical to sham mice 
except for the administration of EPO (1000 IU/kg subcutaneously) 5 minutes prior to sham 
reperfusion (N = 4). 
 
In the above experiments, the route of administration and dose of EPO were based on that of 
a previously reported experiment in the mouse. Mice, which did not receive EPO, were 
administered 8 mL/kg saline (vehicle for EPO) at equivalent time points (5 minutes prior to 
reperfusion). In experiments involving the chronic administration of EPO, mice were 
divided into the following four groups: 
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 (1) I/R group included control mice, which underwent renal ischemia for 30 minutes 
followed by reperfusion for 24 hours (N = 6) 
(2) I/R EPO pretreatment group mice were administered EPO (1000 IU/kg/day 
subcutaneously) for 3 days prior to I/R (N = 6) 
(3) sham group were sham-operated mice, which were subjected to the surgical procedures 
described above, but were not subjected to renal I/R (N = 4) 
(4) sham EPO pretreatment-group were mice that were treated identical to sham mice except 
for the administration of EPO (1000 IU/kg/day subcutaneously) for 3 days prior to sham I/R 
(N = 4). 
 
Mice, which did not receive EPO, were administered 8 mL/kg/day saline (vehicle for EPO) 
at equivalent time points (72, 48, and 24 hours before operation). 
 
4.3.4 Measurement of Tissue Myeloperoxidase Activity 
 
Myeloperoxidase (MPO) activity in kidney samples was determined as an index of 
polymorphonuclear (PMN) leukocyte accmulation. Kidneys were homogenized in a solution 
containing 0.5% hexa-decyl-trimethyl-ammonium bromide and 10 mmol/L 3-(N-
morpholino)-propane-sulfonic acid dissolved in 80 mmol/L sodium phosphate buffer (pH 7), 
and centrifuged for 30 minutes at 20,000g at 4°C. An aliquot of the supernatant was then 
allowed to react with a solution of tetra-methyl-benzidine (16 mmol/L) and 1 mmol/L 
hydrogen peroxide.  
 
The rate of change in absorbance was measured by a spectrophotometer at 650 nm. MPO 
activity was defined as the quantity of enzyme degrading 1 mol peroxide/min at 37°C and 
was expressed in units per gram weight of wet tissue. 
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4.4  Results 
 
4.4.1 Effect of EPO administration in a recovery model of ischaemia reperfusion 
injury. 
 
Biochemical parameters were studied in animals subjected to I/R injury and groups were 
sacrificed at different time points between 24 – 72 hrs following recovery.  
 
The natural history of I/R in this model showed a peak in serum creatinine at 24 hrs (sham 
animals (n=8) creatinine 34 ± 3, I/R (n=12) 193 ± 74, P<0.01), which had returned to near 
normal levels by 96 hrs (Figure 4.1). EPO was administered as a single sub-cutaneous 
injection (1000 U/ Kg). EPO administered at the time of reperfusion significantly attenuated 
the rise in creatinine at 24 and 48 hrs (creatinine in EPO treated animals 24 hrs 65 ± 31, 
P<0.001). When administered two hours after reperfusion, EPO therapy was associated with 
a similar reduction in the rise in creatinine (creatinine at 24 hrs 90 ± 35, P<0.01), when 
compared to control animals. 
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Figure 4.1 Serum Creatinine following I/R injury in the Recovery Model was 
measured at 24, 48 and 72 hours. I/R caused a significant increase at 24 hours when 
compared to sham animals (P<0.01). EPO treatment prevented this increase (dashed 
line), and there was a significant reduction in creatinine at 24 hours even when EPO 
was administered 2 hours into reperfusion (P<0.05) 
 
 
0 12 24 36 48 60 72
0
50
100
150
200
250
300
I/R
EPO pre
EPO late
hrs
cr
ea
tin
in
e 
u
m
o
l/L
 137 
4.4.2 Effect of Administration of EPO on renal dysfunction in the Mouse 
 
When compared to sham-operated mice, I/R caused a significant increase in the plasma 
levels of creatinine in control mice (serum creatinine: sham 18 ± 7 µmol/L; I/R 170 ± 6, 
P<0.001), suggesting a significant degree of renal dysfunction. Administration of EPO, at 
reperfusion (1000 IU/kg) or, as pre-conditioning (1000 IU/kg/day for 3 days prior to I/R), 
attenuated the rise in serum creatinine observed by I/R in control mice (EPO at reperfusion 
128 ± 9; EPO pre-conditioning 70 ± 22, P<0.01) (Figure 4.2).  
 
Histological examination of kidneys obtained from control mice subjected to I/R 
demonstrated a significant degree of renal injury. Specifically, kidneys obtained from these 
animals exhibited degeneration of tubular structure, tubular dilatation, swelling and necrosis, 
luminal congestion, and eosinophil infiltration. In contrast, renal sections obtained from 
mice treated with EPO acutely (1000 IU/kg prior to reperfusion) and chronically (1000 
IU/kg/day prior to I/R) demonstrated a marked reduction in the severity of these histological 
features of renal injury, when compared with kidneys obtained from control mice subjected 
to I/R only (Figure 4.3). 
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Figure 4.2 Renal function at 24 hours in Mice subjected to I/R injury was 
significantly preserved in animals treated with EPO (P<0.05) at reperfusion, with 
greater protection with pre-conditioning regime (P<0.01, by ANOVA). 
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Figure 4.3 Histological Analysis of Mouse kidneys subjected to I/R Injury 
Representative sections of kidney tissue from mice sacrificed 24 hours following I/R injury.  
A  Sham operated animal 
B  I/R injury  
C  I/R injury with EPO administered at reperfusion 
D  I/R injury after 3 days pre-conditioning with EPO (1000 U/ Kg) 
 
 
 
 
A B 
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4.4.3 Effect of EPO on renal inflammation caused by Ischaemia-Reperfusion 
 
When compared to sham-operated mice, the kidneys obtained from control mice subjected to 
I/R demonstrated a significant increase in MPO activity (sham animals 3 ± 0.3; I/R 66 ± 9.8, 
P<0.001), suggesting increased PMN infiltration into renal tissues. The increase in the tissue 
level of MPO seen in mice administered EPO, either acutely (1000 IU/kg prior to 
reperfusion) or chronically (1000 IU/kg/day prior to I/R) was significantly smaller than 
those seen in control mice subjected to I/R (EPO pre-reperfusion 15.2 ± 8; EPO pre-
conditioning 5.5 ± 1.7, both P<0.01), which in the case of chronic EPO treatment were 
similar to values obtained from sham-operated mice (figure 3.5). It should be noted that the 
chronic administration of EPO reduced the MPO levels to levels which were not different 
from those observed in sham-operated animals. 
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Figure 4.4 Tissue Myeloperoxidase Concentration following I/R Injury in the 
Mouse was measured as a marker of inflammation. I/R induced a significant rise in 
tissue MPO (P<0.01). EPO treatment prevented the development of inflammation 
following I/R (P<0.01 by ANOVA). 
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4.5 Discussion 
 
In this series of experiments, EPO reduced the renal dysfunction and degree of injury caused 
by bilateral occlusion and reperfusion observed both at 24 and 48 hours after organ 
reperfusion. This beneficial response to EPO administration was observed in both rat and 
mouse models of ischaemia-reperfusion injury.
 
 
 
In mice subjected to renal I/R, EPO (1000 IU/kg given 5 minutes prior to reperfusion) 
significantly attenuated the renal dysfunction (increases in plasma creatinine) and 
characteristic histological signs of marked tubular injury. A significant reduction in 
polymorphonuclear neutrophil accumulation, measured by MPO assay was also observed. 
All this data confirmed a well-known pattern of renal dysfunction and injury caused by I/R 
of the kidney. Moreover, our findings are in agreement with the notion that renal ischaemia 
causes both renal and tubular dysfunction, as well as secondary inflammation. 
 
Pre-conditioning pre-treatment of mice with EPO (1000 IU/kg/day for 3 days) also reduced 
the renal injury, dysfunction, and inflammation caused by bilateral renal artery occlusion in 
the mouse. Interestingly, the degree of protection afforded by this regimen with EPO was 
greater than the one afforded by the acute administration of a single dose of EPO at the time 
of reperfusion. There are several potential explanations for this finding. First, one could 
argue that the pre-treatment protocol has resulted in favourable systemic or local renal 
hemodynamic effects. However, although acute administration of EPO (in the rat) has no 
effect on blood pressure or cortical and pyramidal perfusion, repetitive administration of 
EPO for up to 1 week caused a small reduction in cortical blood flow [Huang C, 2001]. This 
would argue against EPO induced haemodynamic changes in glomerular filtration rate, but 
might contribute to the induction of delayed pre-conditioning pathways. 
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Secondly, as the half-life of EPO is 10 hours in the rodent, it is possible and likely that the 
repetitive administration of 1000 IU/kg subcutaneously per day for 3 days (pre-treatment 
protocol) resulted in a higher steady-state plasma concentration, when compared to the peak 
concentration achieved from a single dose administration prior to reperfusion (1000 IU/kg 
prior to reperfusion). 
 
Thirdly, pre-treatment of mice with EPO for 3 days may well have resulted in the up-
regulation of protective genes, including endothelial nitric oxide synthase (eNOS), maganese 
superoxide dismutase (Mn-SOD) and heat shock protein 70 (HSP70), which in turn could 
have contributed to the observed protective effect, mimicking the effects of delayed 
ischaemic preconditioning, which is protective in animal models of ischaemic myocardial 
and brain injury, and is mediated by the up-regulation of multiple factors, including EPO, 
vascular endothelial growth factor and haem-oxygenase-1, which improve tissue 
performance in response to metabolic stress under the control of the oxygen sensor hypoxia-
inducible factor-1 (HIF-1). The effects of delayed preconditioning were lost in HIF-1+/- 
mice [Cai Z, 2003]. The crucial role of the down stream effects of EPO production in 
delayed preconditioning of brain injury has been demonstrated by the attenuation of 
protection observed with the use of a soluble EPO receptor, and in vitro, medium transfer 
from hypoxic and glucose-starved astrocytes to untreated neurons induced protection against 
hypoxia in neuronal cells, which was attenuated strongly by the application of a soluble EPO 
receptor and anti-EPO receptor antibodies [Ruscher K, 2002]. The main difference is that, 
unlike treatment at reperfusion, preconditioning with the pre-treatment protocol enables 
increased protein synthesis and not simply activation of existing protein messengers. 
 
Fourth, the recent findings that bone marrow–derived stem cells contribute to the 
regeneration of proximal tubule epithelial cells following I/R injury also creates an attractive 
hypothesis that the protection observed with EPO pretreatment is partially due to an increase 
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in the mobilization and circulation of endothelial progenitor cells and possibly bone 
marrow–derived stem cells. It has been shown in mice that EPO treatment caused a 
significant increase in the percentage of proliferating lin-/sca-1+ stem cells in the bone 
marrow and mobilization of endothelial progenitor cells [Heeschen C, 2003; Bahlmann FH, 
2003]. There is evidence that the pretreatment protocol of EPO used here results in enhanced 
levels of circulating endothelial progenitor cells. Most notably, it has been suggested that the 
increase in circulating endothelial progenitor cells by EPO contributes to the beneficial 
effects of EPO in animal models of I/R. It is, however, not known whether enhanced 
circulating levels of endothelial cell progenitors protect the kidney against I/R injury or 
improve endothelial repair and hence recovery of renal function after an acute ischaemic 
event. 
 
The effects of EPO in a mouse model of ischaemia reperfusion described in this chapter 
have demonstrated that the observed effects in the rat are confirmed in a different species, 
increasing the likelihood of these effects being applicable to human studies. This is an 
important observation, as other growth factors such as insulin-like growth factor-1 (IGF-1) 
that were effective in one animal model have subsequently been not shown similar results in 
studies in rats or human clinical trials [Hirschberg R, 1999].  
 
The beneficial effect of EPO on the course of ischaemic AKI has now been confirmed in 
several other studies [Yang CW, 2003; Vesey DA, 2004]. Yang et al administered high dose 
EPO (5000 U/ Kg IP) 24 hrs before the induction of ischaemia, and observed a significant 
degree of renal protection, and suggested that EPO caused the up-regulation of heat-shock 
protein 70 (HSP70). Vesey et al used a less severe animal model (nephrectomy and 
unilateral renal ischaemia), and demonstrated a significant reduction in both necrotic and 
apoptotic cell death, particularly in the region of the cortico-medullary junction 
. 
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Having demonstrated that EPO prevents the renal injury induced by ischaemia reperfusion in 
an animal model, associated particularly with a significant reduction in the degree of 
apoptotic cell death, the next step was to determine whether EPO would have a direct effect 
on proximal tubular cells in vitro, using a range of injury models that stimulate the 
mechanisms of cellular injury induced by ischaemia-reperfusion. 
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Chapter Five: 
Erythropoietin prevents Toxin-induced Apoptosis  
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5.1 Introduction 
 
Cisplatin is a highly effective chemotherapeutic agent used in the treatment of a wide variety 
of solid tumours, particularly ovarian, head and neck, and testicular germ cell tumours 
[Boulikas T, 2003]. However, 25-35% of patients experience a significant decline in renal 
function after administration [Lebwohl D, 1998]. The nephrotoxicity is a cumulative, dose-
dependent effect which may necessitate dose reduction or withdrawal of cisplatin treatment, 
and hence limiting its effectiveness in many patients. Despite this toxicity, cisplatin remains 
one of the most commonly used chemotherapy drugs due to its therapeutic efficacy. Several 
mechanisms have been proposed for cisplatin nephrotoxicity [Arany I, 2003].  
 
In animal models of cisplatin nephrotoxicity, analysis of proximal tubular injury reveals both 
necrotic and apoptotic mechanisms of cell death [Zhou H, 1999], which predominately 
affects the S3 segment of the proximal tubule. In vitro, the morphological changes of 
apoptosis have been demonstrated in low-dose cisplatin treated mouse isolated proximal 
tubules [Lieberthal W, 1996]. In culture, cisplatin induces apoptosis in a porcine renal 
proximal tubular epithelial cell line (LLC-PK1 cells) via Bax translocation to the 
mitochondrial membrane, cytochrome c release, and the activation of caspase-9 and caspase-
3 [Park MS, 2002].  
 
 In proximal tubule cells in culture, mitochondrial depolarisation leading to the release of 
mitochondrial pro-apoptotic molecules including cytochrome c, Omi/ HtrA2, 
Smac/DIABLO and apoptotic inducing factor (AIF) has been shown in response to cisplatin 
treatment [Seth R, 2005; Cilenti L, 2005]. Mitochondrial depolarisation may be induced 
through a number of pathways, including oxidative stress, activation of mitogen activated 
kinases including JNK, and DNA damage, leading to p53-dependent caspase-2 activation 
[Jiang M, 2004; Seth R, 2005]. However, the importance of DNA damage to cisplatin-
induced cell death has been questioned. Cisplatin has been shown to activate the caspase 
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cascade in enucleated cells (cytoplasts) via the generation of superoxide. Lower doses of 
cisplatin, insufficient to cause apoptosis, may lead to DNA damage, p53 activation and 
replicative senescence [Berndttson, 2007]. 
 
5.2 Aims 
 
The data presented in the previous chapter shows that EPO induces several signalling 
pathways, following ligand binding to its specific cell surface receptor, in proximal tubular 
epithelial cells in vitro, and that the activation of these pathways increased the resistance of 
the cell against apoptosis cell death induced by several different stimuli. The aim of the 
experiments in this chapter was study the particular mechanisms that mediated this anti-
apoptotic effect by utilizing cisplatin-induced apoptosis as a standard model of 
mitochondrial stress induced caspase-dependent cell death. A rat model of cisplatin 
nephrotoxicity was used to determine whether the effects observed in vitro were confirmed 
in an animal model. 
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5.3 Methods and Materials 
 
5.3.1 Fluorescent Microscopy and JC-1 staining of live cells 
 
Quantitative changes in mitochondrial membrane potential (  m) in cells at the early stages 
of apoptosis were measured using the fluorescent dye JC-1 [De Lisa F, 1995]. This dye 
exists as a monomer with emission at 530 nm (green fluorescence) at low concentrations but 
forms J-aggregates with emission at 590 nm (red fluorescence) at high concentrations. 
Therefore, the relative fluorescence of JC-1 at different wavelengths can be considered as an 
indicator of a change in mitochondrial membrane polarization. 
 
HK-2 cells were seeded at 1 x 105/ mL in 6 well plates in standard medium. Cells were 
stimulated with cisplatin for 16 hours overnight, in the presence or absence of EPO (50 U/ 
mL). Cells were washed with 1 mL PBS, and then 1 mL 4% paraformaldehyde was added to 
each well for 10 minutes. Cells were then washed twice with PBS, then 0.2% Triton-X was 
added. After a further wash step, 2 drops of signal enhancer was added, and the plate 
incubated for 30 minutes. The cells were washed in PBS, then the coverslip was transferred 
and placed in an inverted position on the centre of a microscope slide, and 2 drops of 
mounting buffer containing DAPI, a fluorescent dye which strongly binds nuclear DNA, was 
added, and the slides stored in the dark. Slides were examined on a Zeiss fluorescent 
microscope. Relative intensity of fluorescence was qualitatively determined by 2 
independent observers for 3 high-powered fields. Representative images were saved. 
 
5.3.2 JC-1 Quantitative Assay 
 
The medium was removed, and replaced with phenol-red free medium containing JC-1 (10 
 M), and incubated in the dark for 30 minutes. Fluorescence was measured at two 
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frequencies 530nm and 580 nm, and controlled for background reading in a blank (cell-free) 
well. Cisplatin induced a significant reduction in the ratio of fluorescence at 450/ 510 nm, 
when compared with control cells, demonstrating a decrease in red fluorescence due to loss 
of mitochondrial “j-aggregrates” following depolarisation of the mitochondrial membrane 
Briefly cells were seeded at 1 x 106/ mL. After different treatments, the cells were incubated 
with 10 µM JC-1 at 37 °C for 8 min, washed twice, and resuspended in 100µL PBS. Relative 
fluorescence intensities were monitored using the FluoroMax-2 fluorescence 
spectrofluorometer with 490 nm excitation/535 nm emission and 570 nm excitation/610 nm 
emission. The 
 
m was expressed as the ratio of the fluorescence of J-aggregate (570 nm 
excitation/610 nm emission) to monomer (490 nm excitation/535 nm emission) forms of JC-
1, controlled by substracting fluorescence detected from blank wells. 
 
 
5.3.3 PARP Activity Assay 
 
Poly (ADP-ribose) polymerase (PARP) is a nuclear enzyme with DNA nick sensor function. 
Upon binding to broken DNA, PARP becomes activated and cleaves NAD+ into 
nicotinamide and ADP-ribose. PARP then polymerises ADP-ribose on nuclear receptor 
proteins including histones, transcription factors and PARP itself. PARP has been implicated 
in DNA repair, cell cycle progression and transcriptional regulation. Excessive PARP 
activation, induced by oxidative stress, leads to the depletion of cellular NAD and ATP 
pools and results in cell dysfunction or necrotic cell death, discussed in section 1.3.3.  
 
In a cellular ELISA system, cells grown in 96-well plate are incubated with biotinylated-
NAD after permeabilization with digitonin. Activated PARP cleaves bio-NAD into 
nicotinamide and biotinylated ADP-ribose and hence poly-bio-ADP-ribose polymers that are 
detected by conjugation with a streptavidin-peroxidase and colorimetric peroxidase 
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substrate. 50 µL of Biotinylated-NAD+ with was added to all experimental wells of a 96-
well plate, and the plate was incubated at 37˚C for 30 minutes. The medium was aspirated 
and 200 µL of 95% ethanol, chilled to -20˚C, was added to each well and followed by 20 
min incubation at -20˚C. The ethanol was aspirated and each well was treated with 200 µl 
30% hydrogen peroxide solution in methanol. The plate was incubated for 15 minutes at 
room temperature. The plate was then washed and 200 µl of streptavidin-peroxidase 
conjugate added, and incubated for 25 minutes at room temperature. The plate was washed 
three times and 100 µl TMB substrate was added and incubated in the dark. The 
development of blue colour was measured on the Dynex II by absorbance at 605nm, 
compared to blank wells. 
 
 
5.3.4 Quantification of intracellular reactive oxygen species by FACS 
 
The cell permeable fluorogenic probe 2’7’-dichlordihydrofluorescin diacetate (DCF-DA) 
was used to detect oxidative stress. DCF-DA diffuses freely across cell membranes and is 
hydrolyzed by non-specific cellular esterases to the non-fluorescent compound 
dichlorofluorescin (DCFH), which is predominately trapped within the cell. In the presence 
of ROS, DCFH rapidly undergoes one-electron oxidation to the highly fluorescent 
compound dichlorofluorescein (DCF). Cell exposed to experimental conditions were washed 
once in PBS and then incubated with DCF-DA (20  M) for 30 minutes at 37 ˚C in the dark. 
The cells were then trypsinized in 0.25% trypsin and then pelleted by centrifugation at 2000 
rpm for 5 minutes. Pellets were washed once in PBS, and after a further centrifugation step, 
were re-suspended in 500  L PBS in FACS tubes. Samples were analysed on a Becton-
Dickenson flow cytometer. Side and forward scatter were controlled and the cell population 
was gated. Single dimension histogram at the appropriate wavelength was measured and 
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gated for 10000 cells per sample. For three individual experiments, samples (n=8) were 
analysed and median fluorescence shift was calculated and analysed. 
 
5.3.5 Rat Model of Cisplatin Nephrotoxicity 
This study was carried out using twenty-four male Wistar rats (Tuck, Rayleigh, Essex, UK) 
that weighed 250 to 300 g and received standard diet and water ad libitum. Animals were 
cared for in accordance with the Home Office Guidance in the Operation of the Animals 
(Scientific Procedures) Act 1986 (HMSO, London, UK). 
Animals were treated with a single intra-peritoneal bolus of cisplatin (7 mg/Kg) or an 
identical volume of carrier (DMSO) solution. On day 5, blood was taken from tail vein and 
the animal sacrificed under general anaesthesia using intraperitoneal injection of sinactin 
(Inactin®, Suzan Bennett, Natick, USA). The abdomen was opened and both kidneys were 
removed. They were promptly bisected and fixed in formaldehyde (15%) and then embedded 
in paraffin; sections were cut at 3 µm and stained with haematoxylin and eosin, PAS, and 
trichrome Masson with light green. 
A pathologist carried out a semiquantitative analysis of the kidney sections in a blinded 
fashion. Glomeruli and vessels were normal. Changes observed were limited to the tubules, 
especially to the proximal straight S3 portion, the main site of cisplatin toxicity. Tubular 
lesions were graded as follows: 0=no damage; 1+=area of tubular epithelial cell swelling, 
vacuolization, necrosis, desquamation less than 50%; 2+=lesion areas grater than 50% with 
or without focal involvement of the S3 segment in the medullary rays; 3+=lesion areas 100% 
with diffuse involvement of the medullary rays.  
 
 
 
 153 
5.4 Results 
 
5.4.1  Cisplatin induces dose dependent increase in proximal tubular epithelial cell 
death which is attenuated by pre-administration of EPO 
 
Cisplatin in DMSO was freshly prepared for each set of experiments. Human proximal 
tubule epithelial (HK-2) cells were incubated with increasing concentrations of cisplatin for 
24 hrs, and then DNA fragmentation (Cell Death ELISA) and cell viability assays (MTS 
assay) were examined.  
 
Cisplatin caused a reduction in cell viability (figure 5.1) which was associated with an 
increase in DNA fragmentation, as a marker of apoptosis (figure 5.2). These results indicate 
that the pro-apoptotic effects of cisplatin are dose-dependent, with the greatest amount of 
DNA fragmentation seen in cells treated with 50 µM cisplatin. Cells were pre-treated with 
varying concentrations of EPO (10-50 U/ mL) for one hr before being exposed to 25-50  M 
cisplatin for 24 hrs. EPO pre-treatment caused a dose-dependent increase in cell viability 
(when compared to control cells: CP 68% ± 5, CP with EPO 10 U/ml 81% ± 11, CP + EPO 
30 86 ± 10, CP + EPO 50 91 ± 11; P<0.01) which was associated with a significant decrease 
in DNA fragmentation (when compared to control cells: CP 7.6 ± 1.2 fold increase in DNA 
fragmentation, CP + EPO 4.8 ± 0.5; P < 0.01).  
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Figure 5.1 Cell Viability is preserved by EPO in dose dependent manner. An MTS 
assay was performed after 24 hours exposure to cisplatin. Cell viability was expressed 
relative to the MTS value of control cells (in 3 separate experiments). EPO maintained 
cell viability when compared to untreated cells (P<0.01 by ANOVA). 
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Figure 5.2 EPO pre-treatment reduces Cisplatin induced DNA fragmentation in 
an ELISA assay. Values for experimental groups were expressed relative to control 
cells for 3 experiments. EPO significantly abrogated the rise in apoptosis following 
cisplatin exposure (p<0.001 by ANOVA). 
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5.4.2 Cisplatin induces Apoptosis via the activation of multiple Caspases  
 
To elucidate whether the activation of capase-3 was necessary for cisplatin-induced cell 
death, HK-2 cells were plated out in a 96-well plate in 100µL phenol-red free standard 
medium, and a modified in situ assay for caspase-3 activation was used.  In this assay, total 
caspase activation at various time points during the experiment was determined by 
quantification of cumulative AMC fluorescence in small aliquots of experiment medium (see 
methods section 2.3.4). 
 
Cisplatin (50  M) induced a significant time-dependent increase in caspase-3 activity 
between 8 and 24 hrs (Figure 5.3). Pre-treatment with EPO (50 U/ mL) for one hr 
significantly reduced the increase in caspase-3 activity induced by cisplatin at 24 hours (CP 
4158 ± 532, CP + EPO 1789 ± 247; P<0.001). To determine whether caspase-3 activation 
was dependent on the mitochondrial stress pathway, lysates previously used to determine 
DNA fragmentation at 24 hrs were used to assay caspase-9 activity. There was a significant 
increase in caspase-9 activity induced by cisplatin at 24 hours (Figure 5.4), which was 
significantly reduced by pre-treatment with EPO (CP 314 ± 71, CP + EPO 165 ± 97, 
P<0.05). Park et al. have previously shown no activation of caspase-8 at 24 hours in 
cisplatin exposed proximal tubular epithelial cells [Park N, 2002] 
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Figure 5.3 Caspase-3 activity was measured at various time points up to 24 hours 
in cisplatin exposed cells (results from n=6 wells in 3 separate experiments). When 
compared to early time points, there was significant rise in caspase-3 activity at 24 
hours, which was reduced by EPO treatment (P<0.01).  
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Figure 5.4 EPO reduces caspase-9 activity induced by cisplatin when measured at 
24 hours following cisplatin exposure (P<0.01 by ANOVA). 
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5.4.3 EPO inhibits mitochondrial depolarisation induced by Cisplatin 
 
The activation of caspase-9 requires the release of cytochrome c from depolarised 
mitochondria. The mitochondrial probe JC-1 was used to study changes in relative 
mitochondrial membrane potential. Initially, fluorescent microscopy was utilized to examine 
JC-1 uptake and staining in cisplatin treated cells, as described in 5.3.1. Cells were fixed and 
stained with JC-1 before microscopy. In a series of experiments (n=3), there was a 
qualitative difference in JC-1 staining in cisplatin treated cells, with an increase in cells with 
orange fluorescence in EPO treated cells, indicting preservation of mitochondrial J 
aggregates (figure 5.5). 
 
In order to quantitatively assess the observed findings in these initial experiments, an in situ 
assay was developed, described in section 5.3.2. HK-2 cells, plated in a 96-well plate (16 
wells for each experimental group), were incubated with cisplatin (50 µM) with and without 
pre-treatment with EPO (50 U/ mL), for 24 hours. Pre-treatment with EPO caused 
significant preservation of JC-1 ratio (Figure 5.6), indicating preservation of mitochondrial 
membrane potential (control cells 11.4 ± 0.8, CP 10.3 ± 1.3, CP + EPO 9.0 ± 1.7; P <0.05).  
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Figure 5.5 JC-1 staining by microscopy in Cisplatin exposed HK-2 cells  
Cells incubated with Cisplatin demonstrated reduced orange fluorescence in polarised 
mitochondria with a predominance of green fluorescence indicating dimerised cytoplasmic 
JC-1. EPO pre-treatment was associated with preservation of orange fluorescence activity 
from monomeric JC-1 in mitochondria. 
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Figure 5.6 EPO pre-treatment was associated with preserved JC-1 ratio when 
compared to Cisplatin exposed cells. JC-1 was added to cells at the end of the 
experiment and fluorescence measured at two wavelengths. The ratio was calculated 
from the difference between intensity at different wavelengths for n=8 wells per 
experiment (P<0.05 by ANOVA). 
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5.4.4 Cisplatin induced apoptosis is dependent on the translocation of pro-apoptotic 
Bax to mitochondria with down-regulation of Bcl-XL 
 
Changes in mitochondrial membrane potential are dependent on the balance of pro- and anti-
apoptotic proteins.  HK-2 cells were exposed to cisplatin for 24 hours with and without pre-
treatment with EPO. Cells were lysed in RIPA buffer and 20  g cellular protein was 
electrophoresed on a pre-cast 4-12% graduated gel (Invitrogen, UK). After electroblotting, 
membranes were probed with specific antibody to Bcl-XL (Santa-Cruz). Cisplatin down-
regulated the expression of Bcl-XL, but pre-incubation with EPO prevented the reduction in 
expression (Figure 5.7a representative blot). Cell fractionation was also performed, and 
cytoplasmic and mitochondrial expression of Bax was examined by western blotting. 
Cisplatin induced the translocation of Bax to the mitochondrial fraction (Figure 5.7b). 
 
 
In order to confirm the role of Bax in cisplatin induced apoptosis, RNA interference was 
used to knock-down Bax expression in HK-2 cells before cisplatin exposure. HK-2 cells 
were plated at 1 x 105 cells/ mL in 6 well plates, and transfected with Bax and control non-
targeted siRNAs, as described in section 2.6. After 24 hrs, the medium was replaced with 
standard medium with cisplatin (50 µM) for a further 24 hrs. Western immunoblotting with a 
Bax polyclonal antibody was performed to determine total Bax levels and hence confirm 
reduced expression in siRNA knock-down.  
 
Knock-down of Bax expression by transfection with Bax siRNA abrogated DNA 
fragmentation induced by cisplatin (Figure 5.8) to a similar degree to the cellular protection 
observed with EPO treated cells (control 15 ± 6, CP 70 ± 16, CP + EPO 40 ± 14, CP in Bax 
siRNA treated cells 33 ± 11; P <0.01), confirming that Bax is a vital mediator of the 
mitochondrial mechanism of apoptotic cell death induced by cisplatin.  
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Figure 5.7 Immunoblotting for pro- and anti-apoptotic molecules.  
 
A Immunoblot with Bcl-XL antibody. Representative blot from n=3 experiments. 
Cisplatin exposure reduced expression of Bcl-XL, which was maintained in EPO 
treated cells. 
B Individual blots with specific Bax antibody from cellular fractions. Cisplatin 
induced Bax shift into mitochondrial fraction when compared to control cells. 
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Figure 5.8 Inhibition of Bax prevents cisplatin induced apoptosis. 
 
A Immunoblot with Bax antibody confirms reduction in expression with siRNA. 
 
B DNA fragmentation ELISA as measure of cell death shows significant increase 
in DNA fragmentation with cisplatin exposure, which was reduced by siRNA Bax 
knockdown and by EPO treatment (P<0.05, by ANOVA). 
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5.4.5 EPO maintains the expression of the inhibitor of apoptosis, XIAP 
 
The expression of XIAP by western blotting was decreased after 24 hours exposure to 
cisplatin. This reduction is expression was prevented in EPO treated cells, shown in Figure 
5.9, suggesting that maintenance of NF  B dependent anti-apoptotic signalling via XIAP is 
important to the anti-apoptotic effects of EPO in this model.  
 
To confirm this, we transfected cells with XIAP siRNA, and then examined the amount of 
DNA fragmentation induced by cisplatin (50  M) in three separate experiments. Compared 
to cells transfected with non-targeted control siRNA (control 23 ± 1.9, CP 50 ± 0.4, EPO + 
CP 34 ± 5, P<0.01), there was a small increase in DNA fragmentation in control cells 
transfected with XIAP siRNA (control 27 ± 4, P=ns). There was significantly more 
apoptosis in cells exposed to cisplatin in which XIAP had been knocked down (CP 61 ± 2.6) 
(Figure 5.10). The protective effects of EPO pre-treatment were abrogated by transfection 
with XIAP siRNA (57 ± 4, P=ns when compared to CP), confirming this pathway as vital to 
the anti-apoptotic effects of EPO in proximal tubular epithelial cells. 
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Figure 5.9 Immunoblot of XIAP from lysates of cells exposed to cisplatin and 
EPO. Representative image from n=3 experiments. Equal protein loading was 
confirmed by re-probing with housekeeper protein. 
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Figure 5.10 Inhibition of XIAP prevents the beneficial effect of EPO in cisplatin 
induced apoptosis. A DNA fragmentation ELISA assay was used to determine cell 
death relative to control cells. Transfection with XIAP siRNA induced an increase in 
DNA fragmentation in control cells when compared to controls. The protection 
observed with EPO treatment in control transfected cells (P<0.01, ANOVA) was lost in 
XIAP siRNA transfected cells. 
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5.4.6 EPO reduces cisplatin induced oxidative stress and PARP activation 
 
Incubation with cisplatin (10  M-50  M) caused a significant increase in DCF fluorescence, 
shown in Figure 5.11, indicating an increase in the generation of reactive oxygen species. 
Pre-incubation with EPO attenuated the mean increase in oxidative stress induced by 
cisplatin (control 26 ± 0.7 , 10  M cisplatin 47± 0.3, 10  M  + EPO 38 ± 3, 25  M cisplatin 
47.5 ± 0.2 , 25  M cisplatin + EPO 40.5 ±1.5, P< 0.01). 
 
DNA damage induces the activity of PARP-1, which contributes to ATP depletion and 
secondary necrosis cell death. PARP activity is increased in oxidative stress, and may 
contribute to the development of lethal cellular injury. PARP-1 activation in live cells was 
determined as described in 5.3.3. HK-2 cells were seeded in a 96-well plate in standard 
medium. Cells were pre-treated with EPO (50 U/ mL) for one hour, then the medium was 
removed and replaced by 100 µL standard medium containing cisplatin (50 µM). Cisplatin 
exposed cells showed marked activation of PARP-1 (control 0.24 ± 0.07, CP 0.84 ± 0.4; 
P<0.01), which was significantly reduced by EPO pre-treatment (CP + EPO 0.27 ± 0.04, 
P<0.01 when compared to CP), shown in Figure 5.12. 
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Figure 5.11 DCF staining in cisplatin treated HK-2 cells caused a right-shift due to 
an increase in oxidative radical production which is reversed by EPO. Image 
downloaded from flow cytometry representative of n=4 experiments. 
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Figure 5.12 EPO reduces PARP-1 activation induced by cisplatin administration. 
PARP activity was measured by measurement of utilization of biotinylated NAD. 
When compared to control cells, cisplatin caused significant increase in PARP-1 
activity, which was abrogated by EPO pre-treatment (P<0.01 by ANOVA). 
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5.4.7 EPO reduces Renal dysfunction in a model of cisplatin Nephrotoxicity 
 
Cisplatin (7 mg/ Kg) IP induced significant renal dysfunction in male wistar rats (n=9) on 
day 5 (creatinine 115 ± 52 umol/l). Animals pre-administered EPO (1000 U/Kg) 24 hours 
before cisplatin exposure (n=8) showed significant reduction in serum creatinine at day 5 
(creatinine 61 ± 36, P<0.05). Daily EPO administration (300 U/Kg) commenced after 
cisplatin exposure did not demonstrate any significant improvement in serum creatinine at 
day 5 (n=6), consistent with previously published observations [Variza ND, 2004], shown in 
Figure 5.13. 
 
EPO pre-administration was associated with preservation of normal kidney architecture on 
histological examination, shown in Figure 5.14, with reduced histological injury scored by 
two pathologists blinded to experimental grouping (sham animals 0; cisplatin + vehicle 145 
± 1; EPO pre-treatment + cisplatin 45 ± 4, P<0.01). 
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Figure 5.13 Serum creatinine at day 5 following Cisplatin exposure in male Wistar 
Rats. Cisplatin caused renal dysfunction with a significant increase in serum creatinine 
at day 5 (P<0.01). Pre-treatment with EPO (n=8) reduced the degree of dysfunction at 
day 5 (P<0.05, ANOVA), whereas daily administration of EPO post-cisplatin exposure 
had no effect. 
 
CO
NT
RL
CIS
PL
AT
IN
EP
O c
on
dit
ion
ing
EP
O p
os
t in
jury
0
25
50
75
100
125
150
p<0.01
se
ru
m
 
cr
ea
tin
in
e
u
m
o
l/ 
L
da
y 
5
P=ns
P<0.05
 173 
 
 
 
 
 
 
 
 
Figure 5.14 Histological assessment of Renal Injury induced by Cisplatin was 
assessed by two blinded pathologists. Histological severity scoring, described in 5.3.5, 
showed that cisplatin induced widespread changes in the kidney when compared to 
control sham animals (P<0.01), and this was reduced by pre-treatment with EPO 
(P<0.01, by ANOVA). Representative images from each group are shown. 
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5.5 Discussion 
 
The evidence presented in this chapter confirmed the findings described in chapter four, 
demonstrating that EPO significantly abrogated the induction of apoptotic cell death. EPO 
prevented cisplatin induced tubular epithelial cell toxicity through the activation of a number 
of important cell survival pathways. The reduction in apoptosis, measured by DNA 
fragmentation, was accompanied by a reduction in caspase-9 and caspase-3 activity, and 
preservation of mitochondrial membrane potential. 
 
Cisplatin induced the translocation of bax to the mitochondrial fraction, and associated with 
the down-regulation of the Bcl-2 family member Bcl-XL, promotes mitochondrial 
depolarisation. In healthy cells, bax is sequestered in the cytoplasm via an interaction with 
14-3-3 proteins, but following cellular stress, activation of the mitogen-activated protein 
kinase c-jun N-terminal kinase (JNK) phosphorylates 14-3-3 protein, leading to dissociation 
of Bax and mitochondrial depolarisation [Tsuruta F, 2004]. Cisplatin has been shown to 
cause a sustained activation of JNK and p38 in cancer cells lines and proximal tubular 
epithelial cells in culture. Inhibition of JNK activation by either kinase inhibitors or 
transfection of dominant negative MEKK1 has been shown to reduce apoptotic cell death 
after 24 hours, although there is some conflicting evidence [Krillele D, 2003; Arany I, 
2004].  
 
A major pathway for the protective effects of EPO in cisplatin induced apoptosis in these 
experiments was the preservation of anti-apoptotic molecules including XIAP and Bcl-XL.  
XIAP expression was maintained by EPO, which may be due to several mechanisms, 
including increased transcription through NF-  B activation, and AKT-dependent 
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phosphorylation of XIAP which renders it more resistant to ubiquitin-dependent degradation 
[Dan HC, 2004]. 
These studies have provided further elucidation of the molecular mechanisms by which EPO 
exerts its anti-apoptotic effects in the kidney. EPO binds to its cell surface receptor, leading 
to activation of two major signalling pathways – the non-genomic activation of the PI-3 K 
/AKT pathway, which leads to inactivation of a number of apoptotic mediators, and 
activation and nuclear translocation of the transcription factor NF-  B, which induces 
genomic expression of a wide range of anti-apoptotic mediators, particularly XIAP, which 
inhibit apoptosis at several levels through the inhibition of caspase-3, -7 and -9, and 
contributes to the down-regulation of JNK signalling. 
 
When administered as a pre-treatment, EPO exerted a significant effect on the course of 
cisplatin nephrotoxicity in a rat model. These observations were consistent with previous 
work, which demonstrated that EPO given after exposure to cisplatin did not affect the 
degree of injury seen, but induces a more rapid recovery in kidney function with tubular 
regeneration and mitosis occurring earlier than in untreated animals [Varizi ND, 2001]. 
Following on from the findings in models of ischaemia reperfusion injury in the kidney 
described in chapters three and four, these experiments confirm that EPO upregulates 
signalling pathways that alter the physiological resistance to an ischaemic or toxin insult.  
 
The beneficial effect of EPO demonstrated in these experiments has been confirmed in two 
recent studies using animal models of cisplatin nephrotoxicity [Salahudeen AK, 2008; Choi 
DE, 2009]. Salahudeen et al used an in vitro model of cisplatin induced apoptosis, and the 
protective effect was abrogated by the use of an inactive form of human EPO, and by the 
inhibition of JAK2 signalling with the inhibitor AG490. Darbopoietin (25 µg/ Kg) reduced 
apoptotic and necrotic cell death in a in vivo model of cisplatin toxicity, and this benefit was 
not reduced in control group that underwent venesection to control for changes in haemocrit. 
 176 
 
 
 
 
 
 
Chapter Six:  
Effects of Erythropoietin in the Heart 
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6.1 Introduction 
 
Cardiovascular disease is the number one cause of mortality in the developed world, and is 
fast becoming the main global health concern. In the United Kingdom, 105842 people died 
as a result of coronary artery disease in 2005, of which 36323 were attributed to acute 
myocardial infarction [Government Statistics, 2008]. Coronary atherosclerosis is a chronic 
disease with stable and unstable periods. During unstable periods with activated 
inflammation in the vascular wall, myocardial ischaemia and infarction may be a 
consequence of an arterial occlusion, reduced flow within a stenosed vessel or acute 
thrombosis related to plaque rupture. 
 
Coronary artery occlusion and resulting myocardial ischaemia can be reversed by surgical or 
pharmacological strategies to remove the obstruction and restore myocardial blood supply. 
Cell death occurs after a period of as little as twenty minutes, although it may take several 
hours before myocardial necrosis can be identified by macroscopic post-mortem 
examination. Long term outcome has been correlated with the degree of recannulation of the 
coronary artery lumen [Clements IP, 1993], and hence the degree of restoration of normal 
arterial blood flow and myocardial perfusion and oxygenation. Successful examples include 
the administration of thrombolytic agents, streptokinase and tissue plasminogen activator, 
which lyse the platelet thrombus, and percutaneous transluminal angioplasty, in which the 
artery is selectively cannulated with a wire and a balloon inflated across the occlusion to 
mechanically restore patency, which evidence has suggested is the superior primary therapy 
[Weaver WD, 1997]. Large clinical trials investigating the use of thrombolytics have shown 
reduction in infarct size and mortality, and improvement in left ventricular function, if 
carried out within 6 hours of the onset of symptoms [GISSI 1986, ISIS-2 1988]. Restoration 
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of blood flow or reperfusion is absolutely essential for the survival of the ischaemic 
myocardium. However, reperfusion is not without its own consequences, as animal models 
suggest that reperfusion injury accounts for up to 50% of the final size of a myocardial insult 
[Bolli R, 2004].  
 
Myocardial reperfusion injury was first described by Jennings et al in a canine model with 
histological features of cell swelling, contracture of myofibrils, and disruption of the 
sarcolemma [Jennings RB, 1960]. The injury to the heart during reperfusion causes several 
types of cardiac dysfunction, which are analogous to the early phases of acute kidney injury; 
initially “myocardial stunning” denotes mechanical dysfunction that persists after 
reperfusion despite the absence of irreversible damage and despite restoration of normal or 
near-normal coronary artery flow [Braunwald E, 1982]. The myocardium usually recovers 
from this reversible form of injury after several days or weeks, with ventricular remodelling 
around the area of infarction.  
 
At a cellular level, myocardial cell death occurs through mechanisms that are similar to 
those in the kidney, including changes in intracellular calcium, oxidative stress and 
mitochondrial dysfunction and interruption of normal cellular metabolic processes. Recently, 
attention has been focused on the phenomenon of ischaemic preconditioning, in which 
repeated short periods of myocardial ischaemia lead to physiological changes which limit 
the degree of injury induced by subsequent prolonged ischaemia. Ischaemic late pre-
conditioning is dependent on HIF-   signalling, and has been associated with increased 
circulating EPO produced in the kidney and reduction in infarction size [Cai Z, 2003]. 
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6.2 Aims 
 
In view of the protective effects observed with EPO in a rat model of renal ischaemia 
reperfusion, it was important to extend these observations into another organ, and the heart 
is an ideal model to study. Previous studies have suggested a role for EPO in foetal cardiac 
development [Wu H, 1999], and the receptor is present on foetal and neonatal ventricular 
myocytes [Juul SE, 1998], although the expression of the receptor in adult tissues is not 
known. However, cardiac tissue has a very large amount of endothelium which does express 
the EPO-R [Chong ZZ, 2003], which could be an important site of action of EPO during the 
physiological response to ischaemia reperfusion injury in the heart.  
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6.3  Methods  
 
6.3.1 Rat ventricular myoblast cell (H9c2) culture 
 
The H9c2 embryonal rat heart-derived cell line (Kimes and Brandt, 1976; Hescheler et al., 
1991) was obtained from the American Type Culture Collection (CRL 1446) and cultured in 
growth medium comprising DMEM (containing 1000 mg/l D-glucose and 110 mg/l sodium 
pyruvate) supplemented with 10% heat-inactivated newborn calf serum, 100 U/ml penicillin 
and 100 µg/ml streptomycin. Cells were grown in an air/CO2 (49:1) humidified incubator at 
37°C. Sub-confluent (80 %) cells were harvested and seeded into six-well tissue culture 
plates in 2 mL growth medium. The cells were allowed to adhere for 18 hours in an 
incubator at 37°C with 5% CO2 in 95% air.  
 
6.3.2 Myocardial Infarction in the anaesthetised rat 
 
Male Wistar rats (200-250 g, Tuck, Rayleigh, Essex, U.K.) were anaesthetised with 
thiopentone sodium (Intraval®, 120 mg/kg i.p.; Rhone-Merrieux, Essex, U.K.). The rats were 
tracheotomised, intubated and ventilated with a Harvard ventilator (30% inspiratory oxygen 
concentration, 70 strokes/min, tidal volume: 8-10 ml/kg). Body temperature was maintained 
at 38±1ºC. The right carotid artery was cannulated and connected to a pressure transducer 
(Spectramed, P23XL) to monitor mean arterial blood pressure (MAP). The right jugular vein 
was cannulated for the administration of drugs.  
 
Subsequently, a lateral thoracotomy was performed and the heart was suspended in a 
temporary pericardial cradle. A snare occluder was placed around the left anterior 
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descending coronary artery (LAD). After completion of the surgical procedure the animals 
were allowed to stabilise for 30 min before LAD ligation. The coronary artery was occluded 
at time 0 by tightening of the occluder. This was associated with the typical haemodynamic 
(fall in MAP) changes of myocardial ischemia. After 25 min of acute myocardial ischaemia, 
the occluder was re-opened to allow reperfusion for 2 h. Heart rate (HR) and MAP were 
continuously recorded on a 4-channel Grass 7D polygraph recorder (Grass, Mass., U.S.A.). 
 
 
6.3.3 Determination of infarction size and area of risk 
 
The coronary artery was re-occluded at the end of the reperfusion period, and Evans Blue 
dye (1 ml of 2% w/v) was injected into the left ventricle, via the right carotid artery cannula, 
to distinguish between perfused and non-perfused sections of the heart.  The Evans Blue 
solution stains the perfused myocardium, while the occluded vascular bed remains 
uncoloured, and defines the area at risk (AR).  The animals were killed with an overdose of 
anaesthetic and the heart excised.  It was sectioned into slices of 3-4 mm, the right 
ventricular wall was removed, and the AR (unstained) was separated from the non-ischaemic 
(blue) area. 
 
The identified AR tissue was cut into small pieces and incubated with p-nitroblue 
tetrazolium (NBT, 0.5mg/ml) for 40 min at 37°C.  In the presence of functioning 
dehydrogenase enzyme systems in surviving viable myocardium, NBT forms a dark blue 
formazan, whilst areas of necrosis lack dehydrogenase activity and therefore fail to stain. 
Pieces were separated according to staining and weighed to determine the amount of 
myocardial infarction as a percentage of the weight of the total AR tissue. 
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6.3.4 Experimental design for in vivo experiments 
 
The experimental groups outlined below were studied according the protocol described in 
6.2.2. 
(1) MI - control group: (n=8) Animals subjected to 15 min LAD occlusion and at 1 min prior 
to reperfusion received vehicle control (saline, 1 mg/ Kg bolus iv) 
 
(2) MI - EPO group: (n=12) Animals subjected to 15 min LAD occlusion at at 1 min prior to 
reperfusion received EPO (300 U/ Kg in saline bolus iv) 
 
(3) Sham Group: (n=6) Animals were subjected to the surgical procedure, without coronary 
artery occlusion and reperfusion, treated with vehicle control (saline 1mg/ Kg bolus iv) 
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6.4  Results 
 
6.4.1 Effect of EPO on H9C2 cell proliferation 
 
Preliminary experiments were aimed at confirming that the EPO/ EPO-R system was 
functional in H9C2 cells. After harvesting and counting, H9C2 cells were plated at a density 
of 0.5 x 106 in a clear 96-well plate with 100  L phenol-red free standard medium containing 
10% FCS. EPO was added to a final concentration of 10 U/mL – 30 U/mL. After 24 hrs 
incubation, 20  L of MTS solution was added to each well and the plate returned to the 
incubator for 30 min. Optical density was measured in the colorimeter after 30 minutes 
incubation, and results were calculated as percentage of value of control cell minus blank 
well correction. In each of 3 experiments, twelve wells were used for each experimental 
group. 
 
When compared to control cells cultured in standard medium with 10% FCS, there was a 
significant increase in cell number in response to administration of EPO (when compared to 
control cells, EPO 10U/mL 25 % ± 7, EPO 30 U/mL 33 % ± 8, P<0.001). The response to 
erythropoietin was also dose-dependent, being maximal at 30 U/ mL (Figure 6.1). 
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Figure 6.1 EPO induces proliferation above control in H9c2 cells. The MTS assay 
was used as an indirect measure of cellular proliferation. When compared to control 
cells, EPO caused an increase in cellular metabolism, consistent with an increase in cell 
number, in a dose-dependent manner (P<0.01 by ANOVA). 
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6.4.2 EPO maintains cell viability in serum deprived H9c2 cells 
 
H9C2 cells were plated at a density of 0.5 x 106 in a clear 96-well plate with 100  L phenol-
red free standard medium in the absence of FCS. EPO was added in increasing 
concentrations (1 U/mL – 10 U/mL – 30 U/mL – 100 U/mL). Cells were incubated for 24 
hours, and then 20  L MTS solution was added to each well. After 30 minutes, the plate was 
read, and cell viability calculated as a percentage of control value. 
 
H9C2 cells deprived of FCS showed significant reduction in cell number after 24 hrs (figure 
6.2). EPO significantly maintained cell viability in all doses above that observed in serum 
deprived conditions (serum free 0.37 ± 0.03, +EPO 10 U/ml 0.46 ± 0.04, +EPO 30 U/ml 
0.48 ± 0.03, +EPO 50 U/ml 0.51 ± 0.026, +EPO 100 U/ml 0.50 ± 0.026, all P<0.001). The 
protection observed with EPO increased in a dose-dependent manner, although with highest 
dose (100 U/mL) there was no appreciable increase in effect over that seen in cells treated 
with 50 U/mL EPO.  
 
The decrease in cell viability seen in serum deprived culture conditions was due to loss of 
cell numbers by apoptotic cell death, which is associated with an increase in activity of the 
serine protease caspase-3 (figure 6.3). Cell lysates were used to examine caspase-3 activity, 
as described in 2.2.4, to confirm that erythropoietin inhibits caspase-3 activation from a 
variety of insults. Serum deprivation induced a significant increase in caspases-3 activity 
(control 125 ± 83, serum deprivation 3068 ± 756, P<0.001), which was attenuated by EPO 
(30 U/ mL) pre-administration (973 ± 599, P<0.01 when compared to serum deprivation). 
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Figure 6.2 EPO preserves cell numbers in serum deprived conditions, measured 
by MTS assay. Measurement of cell viability was calculated by optical density minus 
blank well scores. EPO improved cell viability in a dose-dependent manner (P<0.01 by 
ANOVA). 
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Figure 6.3 EPO inhibits caspase-3 activation in serum deprived conditions, 
measured by a end-point caspase assay. Serum starvation caused an increase in 
caspase-3 activity when compared to control (P<0.0001), which was significantly 
reduced by treatment with EPO (P<0.001). 
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6.4.4 EPO prevents oxidative stress induced apoptosis in H9C2 cells. 
 
In order to mimic the type of injury observed during reperfusion, hydrogen peroxide was 
used as a model of oxidative stress in H9c2 cells. After harvesting and counting, H9C2 cells 
were plated at a density of 1 x 106 in a clear 6-well plate with 1 mL standard medium 
without FCS. Erythropoietin was added in final concentrations of 10 U/mL – 30 U/mL of 
medium and after 1 hr, hydrogen peroxide (final concentration 200 µM) was added, and the 
plates returned to the incubator for 24 hrs. The medium was removed and cells washed with 
1 mL ice-cold PBS. The cells were scraped with Teflon cell scraper, and centrifuged at 400 
g for 5 minutes at 4˚C. Pellets were lysed in digitonin buffer, and DNA fragmentation was 
assessed in lysates using cell death detection ELISA, described in 2.3.10. 
 
Hydrogen peroxide (200 µM) induced significant DNA fragmentation after 24 hrs in serum-
starved H9C2 cells (Figure 6.4). Pre-incubation with EPO (30 U/mL) for 1 hr prior to 
hydrogen peroxide significantly reduced DNA fragmentation (control 1.0 ± 0.18, H2O2 1.97 
± 0.6, EPO + H2O2 1.1 ± 0.4, P<0.01).  
 
The lysates from the previous experiment were subsequently used to examine caspase-3 
activation. Hydrogen peroxide (200 µM) induced a significant increase in caspases-3 activity 
(Figure 6.5), consistent with the observed increase in DNA fragmentation (Figure 6.4). Pre-
incubation with EPO (30 IU/mL) for 1hr was associated with a significant reduction of the 
increase in caspase-3 activity induced by hydrogen peroxide (control 126 ± 83, H2O2 1890 
± 304, EPO + H2O2 1333 ± 287, P<0.01).   
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Figure 6.4 EPO reduces Oxidative stress induced cell death, measured with DNA 
fragmentation ELISA. Hydrogen peroxide caused an increase in cell death, which was 
reduced by EPO treatment (P<0.01, by ANOVA). 
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Figure 6.5 Caspase-3 activity in hydrogen peroxide treated H9c2 cells was 
measured with an end-point caspase 3 assay. When compared to control cells, 
hydrogen peroxide induced caspase-3 activity (P<0.001), which was reduced by EPO 
treatment (P<0.01 by ANOVA). 
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6.4.6 Administration of EPO upon reperfusion reduces myocardial infarction size in 
the rat 
 
The mean values for area at risk (AR) were similar in all animal groups studied and ranged from 
49 ± 2 to 52 ± 2 % (P>0.05). In rats, which received vehicle alone, occlusion of the LAD for 25 
min followed by reperfusion for 2 hours resulted in an infarct size of 64 ± 3% (n=9) of the AR, 
show in Figure 6.6. 
 
When compared with vehicle, administration of EPO (300 IU/kg i.v. bolus administration at 1 
min prior to the onset of reperfusion) caused a significant reduction in myocardial infarct size 
(Figure 6.7). Sham operation alone did not result in a significant degree of infarction in any of 
the animal groups studied (< 1 % of the AR). It should be noted that coronary artery occlusion 
and reperfusion caused a progressive fall in mean arterial blood pressure (from a baseline MAP 
of 111 ± 6 mm/Hg to 77 ± 5 mm/Hg at the end of the 2 hr reperfusion period), (when compared 
with sham-operated animals). Administration of EPO had no significant effect on blood pressure. 
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Figure 6.6 There was no difference in the Area at Risk in Myocardial infarction in 
the rat between the experimental groups, confirming that ischaemia was restricted to 
myocardium perfused via a single vessel. 
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Figure 6.7 EPO reduces infarction size in a rat model of myocardial infarction. 
The area of infarction was measured by NBT staining, and the percentage of the area 
at risk stained was calculated. Treatment with EPO significantly reduced the 
percentage area of infarction (P<0.05) 
 
 
 
 194 
6.5 Discussion 
Having shown that EPO was protective in a short term model of renal ischaemia-reperfusion 
injury, shown in Chapter three, and that this protection may be mediated by direct effects on 
intrinsic kidney cells, it was important to examine whether this effect was organ-specific, or 
whether EPO would also be effective in a broader spectrum of organs, particularly the heart. 
For EPO to exert direct actions on cardiac myocytes, these cells must express the appropriate 
receptor. The EPO receptor has been demonstrated in cardiac tissues as shown in a recent 
study of adult mouse hearts [Cai Z, 2003]. The potential disadvantage of examining whole 
organ preparations is that it this does not exclude expression on non-myocytic cells of the 
heart, particularly the endothelium, and cardiac fibroblasts. These issues are partially 
addressed by immunohistochemical staining and immunoblotting of neonatal rat ventricular 
cardiac myocytes, which has shown that these cells, at least, express the EPO receptor. A 
functional assessment was used in H9c2 cells, and there was a significant dose-dependent 
increase in cell number induced by EPO administration. 
In the simplest experimental system showing cardioprotection by EPO, H9C2 cells were 
exposed to EPO and subjected to in vitro conditions that mimic the stresses experienced 
either during or following infarction. EPO reduced apoptotic cell death induced by growth 
factor withdrawal and oxidative stress. This was associated with a significant decrease in 
caspase-3 activity, demonstrating that these injury models in different cell types are 
dependent on similar signal transduction pathways. 
 In an established model of myocardial infarction, EPO administration at the time of 
reperfusion in a dose similar to that successfully utilized in the kidney injury model, 
described in chapter three, reduced the area of myocardial infarction significantly. 
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Several studies have been published, subsequent to our experiments, which confirm our 
finding that EPO protects the heart in animal models of ischaemia-reperfusion [Cai Z, 2003; 
Moon C, 2003; Calvillo L, 2003; Parsa CJ, 2004; Wright GL, 2004]. 
Parsa et al evaluated the actions of EPO (5000 units/kg body weight, intraperitoneal 
injection) in the adult rabbit heart. EPO was delivered at the time of coronary artery ligation 
and its effects studied at 3 days. Cardiac function was measured in vivo by micro-manometry 
both under basal conditions and in response to 
 
-adrenergic stimulation. Whilst EPO treated 
hearts did not completely retain global function, peak left ventricular pressures and left 
ventricular relaxation were significantly improved when compared to non-EPO-treated 
animals subjected to infarct. Closer examination of the area at risk showed that EPO 
decreased the area of infarcted tissue.  
Calvillo et al and Moon et al have also followed recovery in vivo for longer periods of time 
following EPO treatment. These studies have examined adult male rats. Calvillo et al 
delivered EPO (5000 units/kg body weight, intraperitoneal injection) in two protocols. First, 
the effects of EPO pre-treatment were evaluated by administration at 24 and 0.5 hrs prior to 
a 30 min ligation of the left anterior descending coronary artery. In the alternative protocol, 
EPO administration was initiated at the time of reperfusion when the suture was removed. In 
both protocols, animals subsequently received repeat doses of EPO every 24 hrs for the 
following 7 days, then haemodynamic measurements were made of cardiac function, and the 
hearts were examined histologically. Cell death was measured together with cardiac 
myocyte cross-sectional area as an estimate of the hypertrophic response following increased 
workload.  
These studies showed less cardiac myocyte loss and a smaller increase in myocyte size in 
those animals treated with EPO prior to ischaemia reperfusion. These differences appeared 
sufficient to normalise haemodynamic function, specifically with ventricular wall stress 
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remaining normal. In all of these studies, it would appear that the initial actions of EPO to 
reduce the degree of apoptotic cell death was the major contributor to the reduction in initial 
infarct areas and would therefore the decrease in left ventricular dilatation.  
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Chapter Seven: 
 
Summary 
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7.1 General Summary 
 
 
The haematopoietic growth hormone EPO plays an essential but tightly regulated role in 
maintaining basal erythropoiesis, with the ability to increase production many times over in 
response to stress stimuli. The EPO gene is exquisitely controlled by the hypoxia inducible 
factor HIF in response to oxygen tension in the renal interstitium. Originally it was thought 
that EPO had a sole function in the survival, maturation and differentiation of erthyroid 
progenitors. It has now been established that EPO is also present in many sites outside the 
bone marrow, including the vasculature, brain, and kidney and plays an important 
physiological role in the response of different tissues to ischaemia. 
 
This thesis attempts to provide evidence to extend the effect of EPO to the response of the 
kidney and the heart to ischaemic injury, which is mediated by the interaction between EPO 
and its cell surface receptor, and the signalling pathways activated. The series of 
experiments described in these chapters show that EPO reduces apoptotic cell death and 
organ dysfunction in several models of kidney injury. Several approaches were made in an 
attempt to elucidate the mediators of this survival signal, and how this applies to organ 
systems in vivo. Whilst this thesis does not provide a complete picture of these mechanisms, 
it demonstrates that the growth hormone EPO is a potential therapeutic tool to lessen the 
degree of organ damage caused by ischaemia and other toxic insults.  
 
The major findings of this thesis are: 
 
• EPO administered either before the onset of ischaemia, or at the point of 
reperfusion, significantly reduced the degree of renal dysfunction observed in a 
standard model of severe ischaemia reperfusion in the rat by (i) biochemical 
analysis, (ii) preservation of urine volume and (iii) creatinine clearance. 
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• The reduction of functional injury was mirrored by preservation of (i) normal renal 
tubular architecture and (ii) tubular function and (iii) reduced markers of tubular and 
reperfusion injury. 
 
• EPO reduced the activity of multiple caspases, and the quantity of apoptotic tubular 
cell death. Apoptosis was measured by the presence of classic histological changes 
of nuclear blebbing and condensation, and was accurately quantified by the use of 
immunohistochemistry with an antibody specific to the cleaved active fragment of 
the executioner caspase-3. 
 
• The EPO-receptor was shown to be expressed on human proximal tubular epithelial 
cells by immunoblotting, and ligand binding and receptor activation was associated 
with a proliferative response and a dose-dependent increase in cell numbers. This 
response was dependent on the presence of the known EPO-receptor and its 
associated JAK2 kinase, as inhibition of expression by RNA interference completely 
abrogated the observed cellular responses.  
 
• EPO activates several signalling pathways that contribute to the observed inhibition 
of apoptosis, including STATs and AKT. EPO was effective in preventing cell death 
in a number of injury models. In particular, cisplatin-induced apoptosis was utilized 
to show that EPO altered the development of oxidative stress and prevented PARP-1 
activation. The effect on cisplatin induced injury was also confirmed in an animal 
model with improvements in biochemical and histological parameters at day five 
after a single dose of erythropoietin was administered as a pre-conditioning therapy. 
 
• The final chapter of this thesis showed that EPO also had signalling effects and 
prevented cell death in cardiac cells in culture, and, importantly, significantly 
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reduced myocardial infarction size in a rat model of coronary artery occlusion. This 
demonstrated that EPO is functional in a number of cell types and organ systems. 
 
 
These findings are important and act as compelling evidence to consider the extension of 
studies in clinical practice to the use of EPO in trials of acute kidney injury. Translation of 
early successes in animal studies to positive outcomes in human clinical trials in AKI has 
proven difficult, but EPO is an attractive agent, particularly as it is widely established as a 
highly effective therapeutic tool in the management of anaemia.  
 
It is important to further elucidate the mechanism by which EPO exerts these observed 
effects. The development of EPO related peptides, and modified EPO molecules such as 
carbamylated EPO (CEPO), which appear to have similar effects to EPO on cell death in 
ischaemia reperfusion injury in several organ systems, have suggested that these effects are 
mediated by a different cell surface receptor. Future work to continue the work described in 
this thesis would include: 
 
• Receptor interaction studies using fluorescent-labelled EPO receptor and CD131 to 
determine whether ligand binding with EPO and CEPO cause direct proximity and 
interaction of these receptor chains. 
 
• Dose ranging studies to determine the optimum dose of EPO that is effective in 
animal models. This would allow for planning of human clinical trials with the 
smallest effective dose. 
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• Investigation of the regulation of EPO-receptor expression in health and post-injury. 
There is some evidence that EPO-receptor expression is upregulated early following 
ischaemia that might act to amplify the anti-apoptotic signal. 
 
• Clinical studies in specific clinical areas with predictable degrees of renal injury, 
such as kidney transplantation, renal injury following cardiac surgery or contrast 
nephropathy. 
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